University of Kentucky

UKnowledge
Theses and Dissertations--Pharmacology and
Nutritional Sciences

Pharmacology and Nutritional Sciences

2019

AZITHROMYCIN THERAPY REDUCES CARDIAC INFLAMMATION
AND MITIGATES ADVERSE CARDIAC REMODELING AFTER
MYOCARDIAL INFARCTION
Ahmed Hamish Neamah Al-Darraji
University of Kentucky, ahmedhamish313@gmail.com
Author ORCID Identifier:

https://orcid.org/0000-0002-0163-0368

Digital Object Identifier: https://doi.org/10.13023/etd.2019.102

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Recommended Citation
Al-Darraji, Ahmed Hamish Neamah, "AZITHROMYCIN THERAPY REDUCES CARDIAC INFLAMMATION AND
MITIGATES ADVERSE CARDIAC REMODELING AFTER MYOCARDIAL INFARCTION" (2019). Theses and
Dissertations--Pharmacology and Nutritional Sciences. 30.
https://uknowledge.uky.edu/pharmacol_etds/30

This Doctoral Dissertation is brought to you for free and open access by the Pharmacology and Nutritional
Sciences at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Pharmacology and
Nutritional Sciences by an authorized administrator of UKnowledge. For more information, please contact
UKnowledge@lsv.uky.edu.

STUDENT AGREEMENT:
I represent that my thesis or dissertation and abstract are my original work. Proper attribution
has been given to all outside sources. I understand that I am solely responsible for obtaining
any needed copyright permissions. I have obtained needed written permission statement(s)
from the owner(s) of each third-party copyrighted matter to be included in my work, allowing
electronic distribution (if such use is not permitted by the fair use doctrine) which will be
submitted to UKnowledge as Additional File.
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and
royalty-free license to archive and make accessible my work in whole or in part in all forms of
media, now or hereafter known. I agree that the document mentioned above may be made
available immediately for worldwide access unless an embargo applies.
I retain all other ownership rights to the copyright of my work. I also retain the right to use in
future works (such as articles or books) all or part of my work. I understand that I am free to
register the copyright to my work.
REVIEW, APPROVAL AND ACCEPTANCE
The document mentioned above has been reviewed and accepted by the student’s advisor, on
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of
the program; we verify that this is the final, approved version of the student’s thesis including all
changes required by the advisory committee. The undersigned agree to abide by the statements
above.
Ahmed Hamish Neamah Al-Darraji, Student
Dr. Ahmed Abdel-Latif, Major Professor
Dr. Rolf Craven, Director of Graduate Studies

AZITHROMYCIN THERAPY REDUCES CARDIAC INFLAMMATION AND
MITIGATES ADVERSE CARDIAC REMODELING AFTER MYOCARDIAL
INFARCTION

DISSERTATION
A dissertation submitted in partial fulfillment of
the requirements for the degree of Doctor of
Philosophy in the College of Medicine at the
University of Kentucky
By
Ahmed Al-Darraji
Lexington, Kentucky
Director: Dr. Ahmed Abdel-Latif
Associate Professor of Internal Medicine - Cardiology
Lexington, Kentucky
2019
Copyright © Ahmed Al-Darraji 2019
https://orcid.org/0000-0002-0163-0368

ABSTRACT OF DISSERTATION
AZITHROMYCIN THERAPY REDUCES CARDIAC INFLAMMATION AND
MITIGATES ADVERSE CARDIAC REMODELING AFTER MYOCARDIAL
INFARCTION
Introduction: Myocardial infarction (MI) remains the leading cause of morbidity and
mortality worldwide. Induced by cardiomyocyte death, MI initiates a prolonged and
uncontrolled inflammatory response which impairs the healing process. Immune
cells, such as macrophages, play a central role in organizing the early post-MI
inflammatory response and the subsequent repair phase. Two activation states of
macrophages have been identified with distinct and complementary functions
(inflammatory vs. reparatory). This bimodal pattern of macrophage activation is an
attractive therapeutic target to favorably resolve post-MI inflammation and
enhance recovery. It has been demonstrated that azithromycin (AZM), a commonly
used antibiotic with immunomodulatory effects, polarizes macrophages towards
the reparatory phenotype. AZM has an excellent safety profile and has been
approved for human use. We hypothesize that AZM reduces inflammation and
improves heart function in MI.
Methods and results: In our initial studies, we demonstrated that oral free AZM
(160 mg/kg daily for 7 days), initiated 3 days prior to MI, enhances post-MI cardiac
recovery as a result of shifting macrophages to the reparatory state. We observed
a significant reduction in mortality with AZM therapy. AZM-treated mice showed a
significant decrease in pro-inflammatory and an increase in reparative
macrophages, decreasing the pro-inflammatory/reparative macrophage ratio.
Macrophage changes were associated with a significant decline in pro- and an
increase in anti-inflammatory cytokines. Additionally, AZM treatment was
correlated with a distinct decrease in neutrophil count due to apoptosis, a known
signal for shifting macrophages towards the reparative phenotype. Finally, AZM
treatment improved cardiac recovery, scar size, and angiogenesis. We designed
this proof of concept study using pre-MI AZM therapy to achieve steady state levels
prior to injury. Therefore, in our follow-up studies we targeted inflammatory
macrophages using a non-Pegylated liposomal formulation of AZM (Lazm) which
has been shown in multiple studies to promote drug efficacy and minimize offtarget effects. To test the hypothesis that Lazm is more effective and safer than
free AZM, low doses of free/liposomal AZM (10 or 40 mg/kg, administered
intravenously) were initiated immediately after MI. We observed that Lazm induces
early resolution of the post-MI inflammatory response as evidenced by switching

of the activation state of monocytes/macrophages towards the reparatory
phenotype. Neutrophils were substantially decreased, particularly proinflammatory neutrophils. Cytokine profiles were also shifted to the antiinflammatory status with Lazm therapy. Taken together, AZM treatment resulted
in a significant shift in macrophage activation towards the reparatory state. The
shift in inflammatory state was accompanied by a decrease in apoptosis and infarct
size in the injured heart, as well as enhanced angiogenesis and LV functional
recovery in our long-term studies. In addition, Lazm was protective against offtarget effects of AZM on the heart.
Conclusion: This is the first evidence of a novel and clinically-relevant therapeutic
strategy to modulate post-MI inflammation. We found that AZM reduces cardiac
inflammation and improves adverse cardiac remodeling after infarction via
promoting a shift of macrophage activation state. The overarching significance of
this work is the modulation of sterile inflammation, which can be a viable
therapeutic target in many conditions including stroke and heart attack.
Additionally, this is the first study to demonstrate the immune modulation
properties of liposomal AZM, which has wide potential therapeutic applications
beyond the cardiovascular field. Importantly, liposomal formulation of AZM is
protective from its cardiac off-target effects. Our findings strongly support clinical
trials using AZM as a novel and clinically relevant therapeutic target to improve
cardiac recovery and reduce heart failure post-MI in humans.

Keywords: Myocardial infarction, Post-myocardial infarction inflammation,
Macrophage, Macrophage polarization, Azithromycin, liposomal azithromycin.
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Chapter I. Introduction
1.1 Background
1.1.1 Myocardial infarction

Myocardial infarction (MI) and its common complication, heart failure, are
leading causes of morbidity and mortality worldwide (Spatz, Beckman et al. 2016).
Although the hospitalization rate for MI has significantly decreased in the last 15
years (~1238 vs ~ 750/ 100000 individual per year) (Spatz, Beckman et al. 2016),
the five-year post-MI mortality rate remains high (~50%) (Lindsey, Saucerman et
al. 2016). Cardiac death is mainly related to heart failure, induced by adverse postinfarction cardiac remodeling (Lindsey, Saucerman et al. 2016). Moreover, heart
failure in the USA contributed to more than $20 billion in medical expenses in 2012
(Writing Group, Mozaffarian et al. 2016). This cost is expected to increase to more
than $53 billion by 2030 due to increasing prevalence (Heidenreich, Albert et al.
2013).
MI refers to a clinical condition characterized by full or partial epicardial
coronary artery occlusion due to rupture or erosion of vulnerable plaques (White
and Chew 2008), which leads to myocardial injury and/or death from inadequate
oxygen supply (Spatz, Beckman et al. 2016). Insufficient blood and nutrient supply
may lead to coronary artery constriction and thrombus micro-embolisation,
producing a more severe form of MI attack. When the occlusion persists for more
than 30 minutes, irreversible injury occurs to the myocardium. Beyond 6 hours of
arterial occlusion, the entire jeopardized myocardial region becomes necrotic and
the infarct size massively increases. Necrotic areas expand from the central zone
of the blocked artery, through the severely damaged endocardial layers, towards
the borders, the less ischemic subepicardium, and eventually lead to transmural
cardiac injury. Factors such as size and location of the injured zone supplied by
the occluded artery, severity of the ischemia, temperature, and systemic
hemodynamic status determine the ultimate infarct size (Skyschally, Schulz et al.
2008). Variability in resistance to ischemic injury and collateral circulation also
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contribute to the progression of MI and, ultimately, its expansion (Heusch and
Gersh 2017).
MI animal models show that the infarct size influences long-term survival
and ventricular function (Pfeffer, Pfeffer et al. 1979, Pfeffer, Pfeffer et al. 1985).
From a clinical standpoint, the likelihood of getting congestive heart failure, cardiac
aneurysm formation, and/or

myocardial rupture significantly increases if the

patient experiences infarct expansion (Jugdutt and Michorowski 1987). During the
resorption of dead tissue, the tensile strength of the injured area temporarily
declines and the non-contractile wall becomes highly susceptible to structural
deformation (Pfeffer 1995). Necrotic cardiomyocytes are replaced by fibrous
connective tissue, leading to histological changes in the myocardium (Fishbein,
Maclean et al. 1978). Fibroblast proliferation and collagen deposition progress
simultaneously, leading to scar formation, leaving the living cardiomyocytes in the
infarct zone to align to form a compressed collagen matrix. Heart dimensions begin
to change and the damaged zone becomes thin and elongated (Pfeffer and
Braunwald 1990). As a result, the ischemic insult induces serious and tangled
modifications to the cellular and extracellular components of the heart muscle,
producing alteration in cardiac capacity, architecture and function in a process
called left ventricular (LV) remodeling. These changes begin immediately post-MI
and progress for weeks to months at the site of injury, as well as in the surviving
uninjured zones (Anversa, Olivetti et al. 1991, Beltrami, Finato et al. 1994).
Of note, peri-infarct border of the injured myocardium is also affected by the
ischemic insult but contains viable myocardium contiguous with evolving infarction.
At this zone, viable cardiomyocytes experience remarkable changes in cell-cell
and cell-extracellular matrix interactions due to the death of neighboring
cardiomyocytes and formation of scar tissue (Matsushita, Oyamada et al. 1999).
In the past, peri-infarct zone was denoted exclusively by location as a part of
myocardium adjacent to the infarcted zone. However, recent research suggests
that this region is distinguished by its location and function. An increment in wall
stress is observed in the peri-infarct border, causing a decrease in cardiac muscle
contractility (Bogen, Rabinowitz et al. 1980). Studies also show that the activity of
2

Gqα, a protein contributing to myocardial hypertrophy, and phospholipase C
elevate in this zone compared to more remote areas (LaMorte, Thorburn et al.
1994). In addition, cardiomyocytes in the peri-infarct zone play an essential role in
initiating post-MI inflammation through production of pro-inflammatory mediators
such as IL-6 and TNF-α (Frangogiannis 2014).
Immediately after cardiomyocyte death, an over-exaggerated inflammatory
response is activated in the infarct/peri-infarct zones (Frangogiannis, Smith et al.
2002). Post-MI inflammation is initiated by necrotic cardiomyocytes to facilitate
cellular debris removal (Frangogiannis, Smith et al. 2002). However, this response,
characterized by leukocyte penetration into the infarcted myocardium, leads to
exacerbated cardiac damage and infarct expansion (Frangogiannis, Smith et al.
2002). In addition to central necrosis, the myocardial injury is further exacerbated
by the recruitment of inflammatory cells and their products such as extracellular
matrix metalloproteinases (MMPs). Multiple lines of evidence in animal and human
studies suggest that a more controlled inflammatory response, and thus, a
significantly reduced cardiac injury, can be achieved by limiting polymorphonuclear
leukocyte (PMN) recruitment and activation at the site of injured tissue (Hill and
Ward 1971, Crawford, Grover et al. 1988). Furthermore, post-MI inflammation is
important for proper cardiac healing and scar formation (Entman and Smith 1994,
Frangogiannis, Youker et al. 1998, Mehta and Li 1999) .
Reperfusion of the ischemic myocardium precipitates ischemia-reperfusion
(I/R) injury, leading to further damage of the infarcted myocardium (Frangogiannis,
Smith et al. 2002). I/R injury has a complicated multifaceted myocardial pathology
and is mainly influenced by the magnitude/duration of the blockage and the
following reperfusion injury. In ischemia, Intracellular pH and ATP concentrations
plummet due to anaerobic metabolism and lactate accumulation. As a result,
ATPase-dependent ion transport pathways become inactive, leading to increased
intracellular and mitochondrial calcium concentrations (calcium overload), cell
swelling and rupture, and cell death by necrosis, apoptosis, necroptosis, and
autophagy (Kalogeris, Baines et al. 2012). In the reperfusion state, oxygen supply
returns to normal levels, however; there is a massive production of Reactive
3

Oxygen Species (ROS) and intense recruitment of pro-inflammatory neutrophils to
the site of injury, exacerbating ischemic damage. The most likely mechanisms
driving I/R cell dysfunction, injury, and/or death include: a) resupply of molecular
oxygen during the reperfusion phase induces large amounts of ROS, b) intense
neutrophil infiltration induces a potent inflammatory response, c) calcium overload,
d) deterioration of endothelial function, e) mitochondrial permeability transition
(MPT) pore opening, and f) thrombosis (Yellon and Hausenloy 2007, Kalogeris,
Baines et al. 2012).
Cardiomyocyte death and extracellular matrix (ECM) deterioration in the
injured myocardium produce alarming molecules, known as danger-associated
molecular patterns (DAMPs), which initiate and exaggerate the inflammatory
response (Timmers, Pasterkamp et al. 2012). Additional initiation of inflammation
occurs via the nuclear chromatin-binding protein, High-mobility group box-1
(HMGB1), through activated Toll-Like Receptor (TLR) and Receptor for Advanced
Glycation End products (RAGE) (Andrassy, Volz et al. 2008). Molecules,
generated from ECM fragments, such as low molecular weight hyaluronan and
fibronectin fragments, ATP, and Heat Shock Proteins (HSPs) induce inflammation
post-MI as well (Huebener, Abou-Khamis et al. 2008, Dobaczewski, GonzalezQuesada et al. 2010, Arslan, de Kleijn et al. 2011, Timmers, Pasterkamp et al.
2012). DAMPs stimulate the complement cascade system, leading to the
recruitment and local infiltration of immune cells (Hill and Ward 1971). DAMPs,
through TLRs, activate the immune response to remove dead tissues but they also
start the healing process (Frangogiannis, Smith et al. 2002). The post-MI
inflammatory response is a complicated process controlled by various
inflammatory mediators. The most important players in this response are:
1.1.1.1 Complement activation
Necrotic cardiomyocytes release subcellular membrane components
enriched in mitochondria, which activate the classical complement cascade
components (C1, C2, C3, and C4) (Pinckard, Olson et al. 1975). These
components trigger the inflammatory response in the injured myocardium through
4

a complement-mediated inflammatory response. Protein and mRNA levels of
members of the classical complement pathway are elevated at the site of
myocardial injury (Vakeva, Agah et al. 1998, Yasojima, Kilgore et al. 1998) .
Complement pathway activation contributes to the recruitment of neutrophils and
monocytes (Dreyer, Michael et al. 1992). Some studies show that monocyte
chemotactic activity in the heart lymphatic drainage in the early phase of the I/R
injury is mainly attributed to C5a, a product of complement cascade activation
(Birdsall, Green et al. 1997). Research also shows that some agents like cobra
venom factor, antibody-induced inhibition of individual complement components,
and soluble form of complement receptor type 1, could have some benefits in
reducing infarct size and myocardial necrosis through inhibition of the classical
complement cascade activity (Weisman, Bartow et al. 1990, Kilgore, Friedrichs et
al. 1994, Lucchesi and Kilgore 1997, Czermak, Lentsch et al. 1998, Griselli,
Herbert et al. 1999).
1.1.1.2 Reactive oxygen species
Reactive oxygen species (ROS) damage myocardial and vascular tissues
through stimulation of cytokine production in the injured myocardium (Dhalla,
Elmoselhi et al. 2000, Lefer and Granger 2000). Studies show that ROS are key
players in the chemotaxis of leukocytes (Granger 1988) through induction of
complementary cascades, upregulation of P-selectin expression, pro-inflammatory
chemokine levels increase and potentiation of the capacity of neutrophil interaction
with the endothelial Intercellular Adhesion Molecule 1 (ICAM-1) (Patel,
Zimmerman et al. 1991, Sellak, Franzini et al. 1994, Lakshminarayanan, Beno et
al. 1997, Lakshminarayanan, Drab-Weiss et al. 1998, Akgur, Brown et al. 2000).
ROS destroy ECM molecules, degrade phospholipids in the membrane, and thus,
induce cell damage and death (Fridovich 1978, Del Maestro, Thaw et al. 1980).
Free radical scavengers such as enzymes, superoxide dismutase and catalase,
have proven beneficial in reducing scar size in an experimental canine MI model,
through inhibition of ROS signaling (Jolly, Kane et al. 1984). Mice that overexpress
copper, zinc superoxide dismutase (SOD1) show a significant protection against
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ischemic cardiac injury (Wang, Chen et al. 1998). SOD1 is a cytosolic enzyme that
efficiently limits intracellular O2 levels during oxidative stress situations such as
I/R, in which multiple cellular oxidases become active (Zweier 1988). Superoxide
and the protonated form, ⋅OOH, denature cellular enzymes like aconitase and
fumarase, causing a marked change in O2 levels (Gardner and Fridovich 1992). O2
interacts with the metal-catalyzed Haber Weiss reaction to produce ROS (Hess
and Kukreja 1995). Moreover, O2 interaction with nitric oxide produces oxidant
peroxynitrite, which causes cellular damage via protein nitration (Xia, Dawson et
al. 1996). However, some studies including human trials do not show significant
recovery in LV function with antioxidants (Gallagher, Buda et al. 1986, Uraizee,
Reimer et al. 1987, Richard, Murry et al. 1988, Maxwell and Lip 1997).
1.1.1.3 Extracellular matrix (ECM)
Besides their structural support of the injured myocardium, ECM proteins
are important regulators of post-MI inflammation (Frangogiannis 2012). Dynamic
changes in ECM components contribute to the inflammatory response through
modulation of adjacent fibroblast, endothelial cell, and inflammatory cell activity
(Frangogiannis 2012). ECM fragments induce cytokine and chemokine synthesis,
plasma-derived matrix accumulation, immune cell extravasation, and initiate the
pro-inflammatory response in the early phases post-MI (Frangogiannis 2012,
Timmers, Pasterkamp et al. 2012). Indeed, clearance of ECM fragments from the
ischemic area is important in resolving inflammation and initiating antiinflammatory pathways. Moreover, hyaluronan fragments, which are generated via
ECM network disruption, may also resolve inflammation via CD44 pathway
signaling (Frangogiannis 2012). Additional ECM-related mechanisms controlling
post-MI inflammation include a matricellular protein which is significantly increased
in the damaged zone, Thrombospondin (TSP)-1, TSP-1 can regulate inflammation
through stimulation of TGF-β and activation of anti-inflammatory pathways
(Frangogiannis and Entman 2005, Frangogiannis 2012).
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1.1.1.4 Pro-inflammatory Chemokines and cytokines
Expression of cytokines and adhesion molecules is simultaneously
upregulated after MI injury, and is primarily induced by nuclear factor kappa-lightchain-enhancer of activated B cells (NF-κB) and nuclear factor of kappa light
polypeptide gene enhancer in B-cells inhibitor (IKKβ) (Lenardo and Baltimore
1989). Multiple mediators such as cytokines and ROS stimulate NF-κB. NF-kB
induces expression of genes that contribute to inflammation, cell adhesion, and
growth (Stancovski and Baltimore 1997). Additionally, activation of NF-kB by TLRs,
which are stimulated by complement cascade and ROS, induces production of
adhesion molecules in the endothelial cells and pro-inflammatory cytokines and
chemokines in fibroblasts, white blood cells, and vascular cells (Nian, Lee et al.
2004, Gordon, Shaw et al. 2011). Suppression of post-MI inflammation and
reduction of infarct size are observed with in vivo transfer of NF-κB decoy
oligodeoxynucleotides via interference with the action of this transcriptional factor
(Morishita, Sugimoto et al. 1997).
Various chemokines are quickly upregulated after infarction, leading to
accumulation of inflammatory cells in the ischemic myocardium (Frangogiannis
2007). Neutrophils are attracted to the injured area through CC chemokines, while
glutamic acid-leucine-arginine motif (ELR)-negative CXC chemokines attract
lymphocytes and may play anti-fibrotic and angiostatic (stopping angiogenesis)
roles (Frangogiannis 2014). Leukocytes bind with chemokines on the surface of
activated endothelial cells and the matrix through adhesive film interaction
(Frangogiannis 2014). Leukocytes express different chemokine receptors, so that
certain chemokine/chemokine receptor pairs stimulate and interact to control
infiltration of a specific leukocyte subpopulation (Proudfoot, Handel et al. 2003,
Nahrendorf, Swirski et al. 2007, Dobaczewski, Xia et al. 2010).
Pro-inflammatory cytokines, such as interleukin 1-beta (IL-1β), are
upregulated and activated in the injured myocardium immediately after insult
(Bujak and Frangogiannis 2009). IL-1β production depends on the creation of
multiprotein oligomers, known as inflammasomes (Schroder and Tschopp 2010).
Activation of inflammasomes occurs in leukocytes and resident fibroblasts in the
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infarcted area and in cardiomyocytes in the border zone (Kawaguchi, Takahashi
et al. 2011, Mezzaroma, Toldo et al. 2011). IL-1β promotes the expression of
multiple inflammatory genes; including inflammatory cytokines, chemokines,
adhesion

molecules,

inducible

nitric

oxide

synthase

(iNOS),

type

2

cyclooxygenase, and type 2 phospholipase A2 (Bujak and Frangogiannis 2009).
As a result, IL-1β may induce more damage to myocardium via recruitment of
additional immune cells to the heart (Bujak and Frangogiannis 2009). IL-1β levels
are elevated in MI patients in the first few hours after attack (Guillen, Blanes et al.
1995). Indeed, recent evidence in patients with chronic atherosclerotic disease
suggests that targeting IL-1β with the specific monoclonal antibody, canakinumab,
significantly decreases recurrent cardiovascular events (Ridker, Everett et al.
2017).
Data from our lab and others documented the early expression of tumor
necrosis factor-alpha (TNF-α) in the myocardium after ischemic injury (Gordon and
Galli 1990). TNF-α acts upstream of IL-6, since neutralizing antibodies for TNF-α
can block the production of IL-6 (Frangogiannis, Smith et al. 2002). TNF-α acts
through multiple receptors with divergent actions (TNF-R1 and TNF-R2). TNFR1
activation mediates NF-κB activation, cardiomyocyte apoptosis and inflammation
in the infarct and peri-infarct zones (Hamid, Gu et al. 2009). On the contrary, TNFR2 is crucial for the healing process via reduction of inflammation and NF-kB
activation and enhancement of cell survival (Hamid, Gu et al. 2009). TNF-α, mainly
produced by macrophages, is a cornerstone to the initiation and maintenance of
the inflammatory response after MI. Indeed, elevated levels of TNF-α in humans
suffering MI are correlated with more rapid deterioration in heart function and
higher risk of mortality (Dunlay, Weston et al. 2008). IL-6 family members play an
important role in both cardiac inflammation and healing after infarction (Fischer
and Hilfiker-Kleiner 2008). Studies employing an anti-IL-6 receptor antibody show
significant reduction in cardiac inflammation, infarct size, and adverse cardiac
remodeling (Kobara, Noda et al. 2010). However, the role of IL-6 in post-MI is
multifaceted and studies utilizing genetic deletion of IL-6 do not yield improvement
in infarct size, LV function, or chronic adverse cardiac remodeling, suggesting a
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role for IL-6 in proper cardiac healing (Fuchs, Hilfiker et al. 2003). More information
about targeting certain cytokine/chemokine and other signaling pathways is
located in Table 1.1.
1.1.1.5 Cellular players in inflammation after ischemic cardiac injury:
Multiple populations of bone-marrow (BM) derived and cardiac cells are
involved in the inflammatory response after MI. The most important players in postMI inflammation include:
1.1.1.5.1 Cardiomyocytes
Cardiomyocyte death stimulates the inflammatory response post-MI
through release of several alarming/danger signals. Additionally, cardiomyocytes
in the border zone express the inflammasome, leading to the production of IL-1β,
which subsequently upregulates the inflammatory response (Frangogiannis 2014).
1.1.1.5.2 Platelets
Platelets actively participate in the regulation of inflammatory and
reparatory phases following cardiac injury (von Hundelshausen and Weber 2007).
They contribute to the production of chemokines, cytokines, and growth factors in
the injured myocardium (Frangogiannis 2014). Activated platelets, through
formation of a fibrin-based provisional matrix, enhance hematopoietic cell influx
into the infarct /peri-infarct zones (Dobaczewski, Xia et al. 2010).
1.1.1.5.3 Mast cells
Unlike small animals, the heart of large animals is occupied by a large
number of mast cells (Gersch, Dewald et al. 2002). A canine model of experimental
MI observed that resident mast cells in the injured zones exhibit a quick and
massive degranulation after infarction, leading to the release of high quantities of
pre-synthesized

pro-inflammatory

mediators

like

TNF-α

and

histamine

(Frangogiannis, Lindsey et al. 1998). Degranulation of mast cells was found
exclusively in the ischemic and reperfused zones of the injury. TNF-α induces IL9

6 production, leading to additional recruitment of mononuclear cells to the injured
myocardium. In addition, histamine is an important autacoid in I/R injury via
promotion of IL-6 production and leukocyte movement. However, recent work
investigating the role of mast cells after infarction in mice shows that mast cells
protect cardiomyocytes from damage post-MI and promote contractility (Ngkelo,
Richart et al. 2016).
1.1.1.5.4 Dendritic cells
Although myocardial damage activates dendritic cells, their exact role
remains unclear. Findings are contradictory; some studies show beneficial effects
via modulation of post-MI inflammation and production of IL-10 (anti-inflammatory
cytokine). Other studies show that these cells activate and prime CD+4 T cells in
the setting of MI (cardiac-specific autoreactive cells), leading to cardiac
autoimmune attack and damage (Anzai, Anzai et al. 2012, Van der Borght, Scott
et al. 2017).
1.1.1.5.5 Fibroblasts
The second most abundant population of cells in the heart is fibroblasts
(Souders, Bowers et al. 2009). After MI they are activated, stimulating the
inflammasome platform (Kawaguchi, Takahashi et al. 2011), which leads to an
increase in IL-1β production. Cardiac fibroblasts are also capable of producing
chemokines and cytokines and, therefore; they are directly involved in modulation
of the inflammatory response after MI (Frangogiannis 2014).
1.1.1.5.6 Endothelial cells
Endothelial cells are key players in inflammation after MI via production of
pro-inflammatory chemokines, such as monocyte chemoattractant protein-1
(MCP-1) and interferon gamma-induced protein 10 (IP-10), in the affected territory.
Additionally, production of cytokines in the infarcted area stimulates the expression
of adhesion molecules on the surface of endothelial cells, which causes a profound
adhesion of circulating inflammatory cells and initiates their migration into the
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injured myocardium (Frangogiannis, Mendoza et al. 2001, Bujak, Dobaczewski et
al. 2009). Hence, production of pro-inflammatory chemokines and adhesion
molecules by endothelial cells at local sites of myocardial injury is crucial to the
initiation and maintenance of the inflammatory response post-MI.
1.1.1.5.7 Vascular cells and pericytes
Angiogenesis is an essential element of the healing process (Frangogiannis
2014). Wound healing of the injured myocardium is highly correlated with the
intensity of angiogenesis since more nutrients and oxygen will be available through
a plentiful vascular network. Enhanced production of angiogenic growth factors
facilitates

the

formation

of

a

hyperpermeable

microvascular

network

(Frangogiannis 2014). Vascular endothelial growth factor (VEGF), fibroblast
growth factor (FGF), and other angiogenic growth factors are generated and
released in the first hours after cardiac insult (Li, Brown et al. 1996, Lee, Wolf et
al. 2000, Frangogiannis 2014). Inhibiting the formation of granulation tissue,
enhancing the resolution of inflammation, and stabilization of scar tissue are
processes regulated by the maturation of new blood vessels at the infarct/periinfarct zones (Zymek, Bujak et al. 2006, Frangogiannis 2014). Platelet-derived
growth factor (PDGF) is important in myocardial healing post-MI. PDGF, through
activation of the PDGF receptor, stimulates mural cell recruitment through the
vasculature into the infarcted myocardium, leading to accelerated acquisition of a
mural coat by these newly formed blood vessels (Zymek, Bujak et al. 2006).
1.1.1.5.8 Lymphocytes
Multiple

lymphocyte

subpopulations

(CD4+ and

CD8+ T-cells,

Foxp3+regulatory cells (Tregs), invariant natural killer (iNK) T-cells, and γδT-cells)
infiltrate the injured heart. Regulatory T-cells (Tregs) play a key role in the
immunomodulatory changes after MI (Frangogiannis, Mendoza et al. 2000,
Hofmann and Frantz 2015). Recent evidence suggests that Tregs are involved in
the suppression of post-MI inflammation through modulation of the macrophage
and fibroblast response (Dobaczewski, Xia et al. 2010, Saxena, Dobaczewski et
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al. 2014, Weirather, Hofmann et al. 2014). Upregulation of INF-gamma by Tregs
induces anti-fibrotic changes in the heart through overexpression of IP-10 (antifibrotic chemokine CXCL10/IFN-γ) (Bujak, Dobaczewski et al. 2009, Ramjee, Li et
al. 2017). In addition, it has been observed that CD4+ T-cell-deficient mice have
higher levels of leukocytes and pro-inflammatory monocytes with more
deteriorated cardiac remodeling during follow-up (Liu, Wang et al. 2016).
Apart from Tregs, circulating cytotoxic T (CD8) lymphocytes are elevated in
the first week post-MI, suggesting a potential role in post-MI inflammation. In a rat
model of experimental MI, harvesting these cells from the heart after infarction and
culturing them with healthy neonatal cardiomyocytes induces a cytotoxic effect on
cardiomyocytes (Varda-Bloom, Leor et al. 2000). However, whether their
recruitment to the injured myocardium exacerbates injury has not been established
yet (Ong, Hernandez-Resendiz et al. 2018). Finally, B lymphocytes are also crucial
players in the pathology of MI and adverse cardiac remodeling. Mature B
lymphocytes secrete large amounts of CCL7 and stimulate Ly6Chi monocyte
migration and infiltration to the injured myocardium, leading to progression of
cardiac injury and poor recovery (Zouggari, Ait-Oufella et al. 2013).
1.1.1.5.9 Neutrophils
The first population of inflammatory cells that infiltrates the injured
myocardium is neutrophils (Figure 1.1) (Reimer, Murry et al. 1989). This influx is
dependent on the complement cascade, ROS synthesis, and ELR/CXC
chemokines (Frangogiannis 2014). Neutrophils are attracted to the MI zone
through complement C5a, which is an important mediator in the stimulation and
chemoattraction of neutrophils (Reimer, Murry et al. 1989). Research shows that
depletion

of

complement

system

using

cobra

venom

factor

blocks

polymorphonuclear neutrophil (PMN) recruitment and activation and reduces
myocardial damage after I/R injury (Hill and Ward 1971, Crawford, Grover et al.
1988). These outcomes are likely related to the effects of C3a, C4a, and C5a on
vessels, to the increased vascular permeability, to the altered vessels tone, and to
the production of cytolytic membrane attack complex (C5b-9). C5b-9 induces
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formation of transmembrane channels, promotes calcium influx to the cell, and
interferes with cardiomyocyte function.
Conversely, other studies show that endothelial cells may be a primary
source for certain neutrophil chemotactic factors (Strieter, Kunkel et al. 1988). For
instance, TNF-α and/or IL-1β treatment activates endothelial cells to produce a
neutrophil chemotactic factor, with a similar structure to the human monocytederived neutrophil activating factor (NAF) (Thelen, Peveri et al. 1988).
Hypoxia/reperfusion

challenge

to

endothelial

cells

stimulates

neutrophil

attachment to the surface of endothelial cells (Reimer, Murry et al. 1989), via an
interaction between neutrophil CD18 and endothelial intracellular adhesion
molecule-1 (ICAM-1)(Smith, Rothlein et al. 1988). In addition, endothelial
leukocyte adhesion molecule-1 (ELAM-1) can also facilitate adhesion between
neutrophils and endothelial cells (Bevilacqua, Pober et al. 1987, Smith, Marlin et
al. 1989). Chemoattraction of neutrophils to the injured myocardium is further
enhanced in the first 48 hours by the upregulated activity of myocardial
myeloperoxidase (Mullane, Kraemer et al. 1985).
In acute inflammation, neutrophils are essential in removing dead cells and
debris, as well as in resolving inflammation and maintaining homeostasis (OrtegaGomez, Perretti et al. 2013). Recruited neutrophils secrete products to facilitate
inflammatory cell infiltration to the infarcted zone (Frangogiannis 2012, Ma,
Yabluchanskiy et al. 2013). However, these products are toxic and may lead to
more damage to the local cardiomyocytes and endothelium (Reimer, Murry et al.
1989). Neutrophils release a wide range of products such as proteolytic enzymes
(producing liquefaction of cells), platelet-activating factor, arachidonic acid
metabolites, and ROS(Reimer, Murry et al. 1989). ROS such as superoxide anion
(O2⨪), hydrogen peroxide (H2O2), hydroxyl radical (• OH), and hypochlorous anion
(OCL-) (Reimer, Murry et al. 1989), are mainly produced by neutrophils after
infarction. ROS destroy extracellular matrix molecules, degrade phospholipids in
the membrane, and thus, induce cell damage and death (Fridovich 1978, Del
Maestro, Thaw et al. 1980). Activated neutrophils produce a positive feedback
mechanism by converting phospholipids in the cell membrane into arachidonic
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acid, which then transforms into a strong chemotactic molecule, hydroxyeicosatetraenoic acid (HETE), by the effect of certain lipoxygenases. HETEs are
important chemoattractants responsible for further neutrophil infiltration into the
injured myocardium (Snyderman and Goetzl 1981). In addition, neutrophils
generate an array of pro-inflammatory cytokines which further recruit mononuclear
cells (Frangogiannis 2014).
Prolonged neutrophil accumulation in the heart post-MI is deleterious (Chia,
Nagurney et al. 2009, Guasti, Dentali et al. 2011). Some studies show that there
is a beneficial “time window” for neutrophil infiltration into the infarcted
myocardium, beyond which persistent neutrophil accumulation leads to infarct
expansion and exacerbated heart failure (Simpson, Fantone et al. 1988). Studies
show that inhibiting neutrophil stimulation and infiltration into the injured
myocardium is effective in preventing infarct expansion and irreversible myocardial
damage (Reimer, Murry et al. 1989). Systemically, high neutrophil counts after MI
are associated with progression of atherosclerosis and comorbid complications in
murine models (Doring, Drechsler et al. 2015). Clinical data suggests that any
further delay in neutrophil apoptosis after MI contributes to this exaggerated
inflammatory response (Garlichs, Eskafi et al. 2004).
While controversial, research shows neutrophil products released post-MI
can influence the recruitment of different subsets of monocytes (Ly6Chi and Ly6Clo)
in the first week after MI in mice (Nahrendorf, Swirski et al. 2007). Neutrophils may
play a role in the migration and local activation of the predominant cardiac
monocytes, Ly6Chi (classical, pro-inflammatory), 4 days after injury (Soehnlein,
Zernecke et al. 2008, Frodermann and Nahrendorf 2017). Additionally, animal data
suggests that neutrophils negatively affect myocardial healing by selectively
recruiting pro- rather than anti-inflammatory monocytes (Nahrendorf, Swirski et al.
2007, Soehnlein, Zernecke et al. 2008). Indeed, treatment with monoclonal
antibodies against either α or β subunits of surface membrane adhesion
glycoprotein

(Mo1),

which

facilitates

neutrophil

aggregation

and

monocyte/neutrophil interaction, is protective against myocardial damage and
reduces myocardial risk area (Simpson, Todd et al. 1990).
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Although there is wide acceptance that neutrophils are important mediators
of cardiac injury after ischemia, aggressive neutrophil depletion studies following
MI have shown contradictory results (Horckmans, Ring et al. 2017). Some studies
show reduced scar size with neutrophil depletion, while others fail to demonstrate
any beneficial effects (Romson, Hook et al. 1983, Chatelain, Latour et al. 1987).
The migrated and accumulated neutrophils in the cardiac tissue may cause more
tissue damage due to dysregulated repair processes. A recent study shows that
depletion of neutrophils using anti-Ly6G antibody in a murine experimental MI
model reduces Ly6Chi monocyte (pro-inflammatory) release from the spleen and
accumulation in the injured myocardium. Moreover, there was an increase in the
proliferation of macrophages in the anti-inflammatory activation state in the injured
myocardium, and impaired heart healing (Horckmans, Ring et al. 2017). These
changes improve with resupply of the neutrophil product, neutrophil-derived
lipocalin (NGAL), which acts via myeloid-epithelial-reproductive tyrosine-protein
kinase (mertk) to enhance cardiomyocyte efferocytosis, suggesting an essential
role for neutrophils in the healing process after infarction. (Horckmans, Ring et al.
2017). Aggressive depletion of neutrophils, the first immune cells infiltrating the
injured myocardium responsible for inflammation regulation, may not be the most
practical method examining the role of these cells in healing since this strategy
may disturb the entire inflammatory response. To our knowledge, this is the first
study showing that M2 macrophages may have detrimental effects on cardiac
recovery. They identified M2 macrophages using 3 markers (arginase, YM1, and
IL-4). Further research shows that this is not sufficient analysis to determine
specific macrophage phenotype. Their view of the macrophage-neutrophil
interaction as merely dependent on activation of mertk by NGAL to resolve postMI inflammation does not take into consideration that cardiomyocytes can directly
activate mertk in macrophages through efferocytosis (Wan, Yeap et al. 2013).
Using more specific strategies, like NGAL-/- specific knock out in neutrophils or
inhibition of neutrophil adhesion, are probably better in identifying the effects of
neutrophils in the healing process.
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These contradictory results targeting neutrophils may be due to a dual role
of neutrophils in cardiac inflammation and healing. While the initial wave of
inflammatory/primed neutrophils can lead to exaggerated cardiac damage if not
cleared in a timely fashion, the activity of neutrophil clearing can reduce
inflammation and initiate the healing process. Clinical data suggests that delayed
neutrophil apoptosis after MI contributes to an exaggerated inflammatory response
(Garlichs, Eskafi et al. 2004). Additionally, a recent report shows that the
neutrophil/lymphocyte ratio positively correlates to myocardial necrosis and Creactive protein (CRP) elevation (Tahto, Jadric et al. 2017). Apoptotic neutrophils
have anti-inflammatory and angiogenic effects through production of apoptotic
factors (annexin A1 and lactoferrin) and polarization of macrophage activation
states to the anti-inflammatory phenotype which results in production of
inflammatory resolving mediators, such as IL-10 and TGF-β (Soehnlein and
Lindbom 2010).
Resolution of cardiac inflammation after MI occurs 3-7 days after the acute
event (Dewald, Ren et al. 2004). It is likely that apoptotic cell removal from the
injured myocardium is the most influential cellular mechanism in resolution of
inflammation due to production of inhibitory mediators by phagocytes (Huynh,
Fadok et al. 2002). The life-span of neutrophils is somehow increased in the
presence of TNF-α and IL-1β, in the early pro-inflammatory microenvironment
(Colotta, Re et al. 1992). Monocytes and differentiated macrophages sterilize the
site of injury through phagocytosis of dead cardiomyocytes and apoptotic
neutrophils (Frodermann and Nahrendorf 2017). The mechanisms of inflammation
resolution attributed to engulfment of apoptotic granulocytes include: a) neutrophil
death generates resolving mediators which inhibit inflammatory cell recruitment to
the heart (Bournazou, Pound et al. 2009), b) macrophage engulfment of apoptotic
neutrophils stimulates the anti-inflammatory machinery to produce inflammation
resolving cytokines (IL-10 and TGF-β) and lipid mediators and reduce proinflammatory cytokine production (Soehnlein and Lindbom 2010).
The disparate contributions of neutrophils to MI pathology may relate to
multiple activation states of a single cell type. Recent work investigating the
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temporal activation of neutrophils reports that they have two distinct activation
states in ischemic heart: pro-inflammatory (N1) (CD11b+/Ly6G+/CD206-) and antiinflammatory (N2) (CD11b+/Ly6G+/CD206+) (Ma, Yabluchanskiy et al. 2016). The
N1 phenotype is associated with LV thinning and dominates the heart after infarct.
The N2 phenotype increases in abundance over time and correlates with proper
healing (Ma, Yabluchanskiy et al. 2016). Interestingly, post-MI migrating
neutrophils are CD206- in the bloodstream, then become CD206+ in the heart,
which could suggest that the activation state is changed by microenvironment (Ma,
Yabluchanskiy et al. 2016). Accordingly, this may explain the disparate outcomes
of strategies targeting neutrophils, and at the same time, could represent an
attractive therapeutic avenue in MI treatment via reprogramming of neutrophils to
the anti-inflammatory phenotype.
1.1.1.5.10 Monocytes
Monocytes and macrophages, as members of the innate immunity system,
play crucial roles in the heart at steady state, as well as after injury (Hulsmans,
Sam et al. 2016). They are the second most prevalent immune cells in the injured
myocardium, after the early neutrophil accumulation (Zlatanova, Pinto et al. 2016).
In mice, there are two subsets of monocytes: a) Ly6Chi chemokine (C-C motif)
receptor-2 (CCR2)

hi

chemokine (C-X3-C motif) receptor-1 (CX3CR1)

lo

(classical/pro-inflammatory), which infiltrate the heart early, immediately after
neutrophils (day1), and disappear during the resolution phase of inflammation, b)
Ly-6CloCCR2loCX3CR1hi monocytes (nonclassical/anti-inflammatory), which are
recruited to the heart beginning on the third day after injury (Nahrendorf, Swirski
et al. 2007, Nahrendorf and Swirski 2013, Hulsmans, Sam et al. 2016). Monocytes
migrate to the heart from the bone marrow (BM) and spleen in two sequential
periods of monocyte movement (Nahrendorf, Swirski et al. 2007, Nahrendorf and
Swirski 2013). In humans, research has identified three subsets of monocytes
based on the expression of CD14 and CD16: a) classical/pro-inflammatory
(CD14++CD16−), b) intermediate (CD14++CD16+), and c) nonclassical/antiinflammatory (CD14+CD16++) monocytes (Hulsmans, Sam et al. 2016). It is likely
17

there are very few monocytes in the heart during steady state (Hulsmans, Sam et
al. 2016). Information about the classification and surface markers of immune cells
in the heart after MI is found in Table 1.2.
In BM, hematopoietic stem cells (HSCs) give rise to common myeloid
progenitors. These progenitors differentiate into granulocyte myeloid progenitors
that give rise to Ly6Chi monocytes (Hettinger, Richards et al. 2013). Ly6Chi
monocytes migrate from the BM to the peripheral blood, a process controlled by
the monocyte chemoattractant protein-1 (MCP1)/CCR2 signaling axis (Serbina
and Pamer 2006, Hulsmans, Sam et al. 2016). Studies show that the Ly6Clo
monocytes derive from Ly6Chi under the control of a nuclear receptor subfamily-4dependent transcriptional process (Hanna, Carlin et al. 2011). Although it is rare
for this to happen in the steady state condition, HSCs may also migrate to
extramedullary

hematopoietic

sites

such

as

the

spleen

and

initiate

monocytopoeiesis after tissue injury (Leuschner, Rauch et al. 2012, Robbins,
Chudnovskiy et al. 2012). The spleen may also host monocytes, providing an
important source of rapid response to tissue injury and inflammation, as seen in
the first 24 hours after MI (Swirski, Nahrendorf et al. 2009). Under the control of
adrenergic stimuli, bone marrow HSCs move towards the spleen and reside there.
In the first 24 hours after MI, Ly6Chi monocyte recruitment to the heart occurs,
mainly from the spleen (40%) (Leuschner, Rauch et al. 2012, Honold and
Nahrendorf 2018).
Ly6Chi monocytes differentiate into pro-inflammatory macrophages under
the effect of M-CSF. These two populations are involved in the removal of dead
cells and tissue debris via phagocytosis, resulting in production of proteolytic
enzymes, which may lead to increased tissue damage. On the other hand, Ly6Clo
monocytes participate in tissue healing via induction of angiogenesis, fibroblast
proliferation, and collagen accumulation (Dutta and Nahrendorf 2015). Ly6Clo
monocytes are the primary sources of fibronectin, which is essential in stabilizing
the infarct region and preventing cardiac rupture (Frangogiannis, Smith et al.
2002). Similar to neutrophilia, profound monocytosis disturbs healing post-MI,
while inhibition of pro-inflammatory monocyte recruitment improves cardiac
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recovery (Dutta and Nahrendorf 2015). Studies show that MCP-1 deletion, an
important regulator of monocyte recruitment to the injured myocardium, results in
a substantial decrease in monocyte infiltration into the heart. Although MCP-1
deficient mice did not differ in scar size from wild type mice, they had significant
improvement in LV function, implying the importance of monocyte repair processes
in the infarcted myocardium (Dewald, Zymek et al. 2005). In human studies, an
increased number of pro-inflammatory monocytes after MI correlates with higher
incidence of future clinical events (Han, Jing et al. 2014). Moreover, clinical studies
reveal that elevated levels of inflammatory blood monocytes CD14+CD16− in MI
patients increase the risk of poor myocardial salvage and heart failure during long
term follow-up (Maekawa, Anzai et al. 2002, Tsujioka, Imanishi et al. 2009).
1.1.1.5.11 Macrophages
At steady state, macrophages are the primary immune cells in organs such
as the liver, brain, and heart (Hulsmans, Sam et al. 2016). In the murine heart, ̴
10% of non-cardiomyocyte cells are macrophages with a comparable percentage
in the human heart (Pinto, Paolicelli et al. 2012, Heidt, Courties et al. 2014).
Macrophages have a spindle-like shape and typically exist in the interstitial space
or near endothelial cells (Nahrendorf, Swirski et al. 2007, Pinto, Paolicelli et al.
2012, Heidt, Courties et al. 2014). Macrophage numbers significantly increase
post-MI due to infiltration of monocytes and the enhanced self-renewal capacity of
resident macrophages (Heidt, Courties et al. 2014). As illustrated in lineage tracing
studies, there are two major macrophage populations in the adult heart, classified
according to their origin. The first population is embryonically-derived cardiac
resident macrophages; these cells are present at birth and are maintained largely
by local proliferation. The second subset is Ly6Chi-differentiated bone BM-derived
macrophages (Ginhoux, Greter et al. 2010, Schulz, Gomez Perdiguero et al.
2012). Of note, intestinal and dermal macrophages derive mostly from Ly6Chi cells
in peripheral blood, originated from the BM, due to the fast-turnover rate (Zigmond,
Varol et al. 2012, Tamoutounour, Guilliams et al. 2013). A recent study shows that
the self-renewal capacity of embryonically derived macrophages substantially
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decreases with age and BM-derived monocytes become the major source of
macrophages, even under physiological conditions (Molawi, Wolf et al. 2014).
Under normal physiological status, most cardiac macrophages are
embryonically derived. These cells classify into multiple subsets based on the
expression of histocompatibility-2 (MHC-II) and CCR2 (Epelman, Lavine et al.
2014). Embryonically derived macrophages primarily originate from embryonic
yolk-sac progenitors and from local proliferation of cardiac macrophages, without
major

contribution

from

BM-derived

monocytes.

Most

cardiac

resident

macrophages are MHC-IIlo CCR2− (Epelman, Lavine et al. 2014, Leid, Carrelha et
al. 2016). The second largest population of macrophages is MHC-IIhi CCR2−,
arising from MHC-IIlo CCR2− macrophages (Epelman, Lavine et al. 2014). The third
and most rare population is CCR2+ cells, which generate from hematopoiesis in
the fetal liver and migrate during embryonic development to the heart (Epelman,
Lavine et al. 2014, Leid, Carrelha et al. 2016, Honold and Nahrendorf 2018).
Embryonically-derived CCR2- macrophages are primarily located in the
myocardial wall and play crucial developmental roles in the formation of blood
vessels and development of the heart conduction system (adult atrioventricular
and sinus nodes) (Honold and Nahrendorf 2018). Research shows that
macrophages communicate with cardiomyocytes through Cx43 (connexin 43) gap
junctions and depolarize simultaneously with attached cardiomyocytes (Pinto,
Paolicelli et al. 2012, Honold and Nahrendorf 2018). Conversely, CCR2+
macrophages reside in the trabecular projections of the endocardium and have a
limited role in heart development (Honold and Nahrendorf 2018). Cardiac resident
macrophages can also contribute to early neutrophil extravasation after infarction
by production of CXCL (C-X-C motif chemokine ligand) 2 and CXCL5, facilitating
transendothelial leukocyte migration into ischemic myocardium (Hulsmans, Clauss
et al. 2017, Honold and Nahrendorf 2018).
Although it remains highly controversial, the belief is that Ly6Chi monocytes
differentiate into Ly6Clo macrophages shortly after migration to the heart. Research
shows that Ly6Clo macrophages infiltrate the injured myocardium directly from the
blood in the reparative phase. They reside in the heart for many weeks in low
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numbers with unclear function and limited capacity to renew locally (Leuschner,
Rauch et al. 2012, Courties, Heidt et al. 2014, Hilgendorf, Gerhardt et al. 2014).
Another controversial finding is that cardiac macrophages with embryonic origin
die locally soon after infarction, therefore; they are not involved in post-MI
inflammatory events (Leuschner, Rauch et al. 2012).
Macrophage function is primarily dependent on the surrounding
environment. Adoptive studies show that lung transplantation of peritoneal
macrophages leads to significant changes in the gene expression profiles and
function of macrophages, which were compatible in new environments (Lavin,
Winter et al. 2014). Steady state macrophage function is not fully understood in
the heart, however; gene-profiling studies suggest they are vital for angiogenesis
(Pinto, Paolicelli et al. 2012, Honold and Nahrendorf 2018). In addition,
macrophages perform immunological cardiac functions such as regulation of
infection defense and removal of dead cells (Ma, Mouton et al. 2018).
Following MI, Infiltrated monocytes/macrophages phagocytize dead
cardiomyocytes and neutrophils, thereby removing cellular and tissue debris from
the injured myocardium (Figure 1.1). These cells produce inflammatory cytokines,
proteases, and ROS (Frodermann and Nahrendorf 2017). It has been observed
that macrophage depletion strategies in an experimental MI model cause
progressive impairments in post-MI inflammation and, ultimately, cardiac recovery
(van Amerongen, Harmsen et al. 2007, Leblond, Klinkert et al. 2015). Besides that,
a more severe form of cardiac remodeling occurs with increased macrophage
numbers, as reported in ApoE−/− (apolipoprotein E)( exhibiting a prolonged postMI inflammation)-deficient or chemokine Decoy Receptor D6 (resolving CC
chemokine–driven inflammatory responses )-deficient mice (Panizzi, Swirski et al.
2010, Cochain, Auvynet et al. 2012). While these observations may appear
contradictory at face value, careful teasing apart of the used strategies in these
studies can elucidate. Macrophages are very heterogenous and plastic
populations of cells with various and rather complimentary functions. Interventions
that specifically target a certain category or function of macrophages could be
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more useful for better understanding the immunopathology of MI, unlike general
suppression or enhancement of post-MI inflammation.
In addition to their primary function (phagocytosis and efferocytosis),
macrophages produce large amounts of chemokines/cytokines/lipid signaling
molecules after injury (Swirski and Nahrendorf 2013, Ma, Mouton et al. 2018),
which enable them to communicate with other cells in the heart and other tissues
(Honold and Nahrendorf 2018). Macrophages secret MMPs and proteolytic
enzymes, which degrade ECM and accelerate tissue remodeling and scar
formation (Honold and Nahrendorf 2018). Additionally, macrophages produce
copious amounts of anti-inflammatory cytokines, such as TGF-β, an essential
player in cardiac healing and scar stabilization (Frangogiannis, Smith et al. 2002,
Honold and Nahrendorf 2018). Macrophages induce angiogenesis through
secretion of Vascular Endothelial Growth Factor (VEGF) (Nahrendorf, Swirski et
al. 2007). The multiple polarization and activation states of macrophages govern
their diversity in function (Ma, Mouton et al. 2018). Macrophage activation states
are reflected by different gene expression profiles and functions, and are
influenced by different microenvironments, time after injury, macrophage origin,
and age (Nahrendorf and Swirski 2016, Ma, Mouton et al. 2018). Post-MI,
macrophages

are

generally

classified

into

pro-inflammatory/classically

activated/M1-like or anti-inflammatory/alternatively activated/reparative/M2-like
based on genetic and cytokine profiles and functions (Nahrendorf and Swirski
2016, Ma, Mouton et al. 2018).
Of note, macrophage classification into pro- and anti-inflammatory
phenotypes is oversimplified and is mainly derived from in vitro systems and
artificial stimulation strategies (Nahrendorf and Swirski 2016). In vivo, the
activation state of macrophages more realistically represents a spectrum between
pro- and anti-inflammatory phenotypes, which is highly influenced by surrounding
microenvironment. Removing macrophages from these highly complex conditions
may affect their activation state, as seen in microglia after 7 days in culture
(Gosselin, Link et al. 2014, Nahrendorf and Swirski 2016). Secondly, M1 and M2
may represent two extremes of activation state, leading one to ignore important
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transitionally activated macrophages (Gosselin, Link et al. 2014). Activation of
human monocytes with M-CSF or G-CSF followed by various stimuli generates
macrophages with distinctly different profiles from the traditional M1/M2
classifications, which may be relevant to cardiovascular disease (Xue, Schmidt et
al. 2014, Nahrendorf and Swirski 2016). Despite the limitations in the M1/M2
paradigm, it remains a helpful tool in examining changes in macrophage
phenotype and respective function in response to various stimuli, environmental
changes, therapeutic interventions, etc. Below, we summarize the main
characteristics of pro- and anti-inflammatory macrophages.
1.1.1.5.11.1 Classically activated macrophages (M1; pro-inflammatory)
Activated T-helper 1 lymphocytes (Th-1), which secrete large amounts of
IFN-γ and other pro-inflammatory mediators like lipopolysaccharide (LPS) and
cytokines (TNF-α, GM-CSF) interact with and classically activate macrophages
(Mantovani, Sica et al. 2004, Gombozhapova, Rogovskaya et al. 2017). Further
classification of M1 macrophages subdivides them into M1a if they are activated
through TLRs or M1b if they are activated through high mobility box group protein
1 (HMBG1), with lower phagocytic capability than M1a macrophages (BenMordechai, Palevski et al. 2015, Ma, Mouton et al. 2018). M1 macrophages are
the dominant myocardial macrophages in the first 3 days after MI (Ma, Mouton et
al. 2018). Activated M1 macrophages phagocytize cellular debris, inducing
changes in MHCII configuration and other cell surface markers (Bauersachs,
Galuppo et al. 2001, Murray, Allen et al. 2014). This process also stimulates
production of pro-inflammatory cytokines (IL12, IL-23, IL-27, TNF) and
chemokines (CXCL9, CXCL10, CXCL11) and expression of cell surface markers
(CD40, CD80, CD86) (Bauersachs, Galuppo et al. 2001). In addition, classically
activated macrophages release high quantities of nitric oxide, ROS, and proteolytic
enzymes (MMP-1, MMP-2, MMP-7, MMP-9, MMP-12), which break down
fibronectin, collagen, elastin and other extracellular components (Mantovani,
Biswas et al. 2013, Mulder, Banete et al. 2014, Ma, Mouton et al. 2018). While
these mechanisms are essential for clearing damaged cardiac tissue after MI, if
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left unchecked they can exacerbate the ischemic damage, expand the infarct
region, and delay inflammation resolution (Ma, Mouton et al. 2018). More
information about pro-inflammatory macrophages is found in Table 1.3. More
information about markers of different subsets of immune cells is present in Table
1.4.
1.1.1.5.11.2 Alternatively activated macrophages (M2; reparative)
Macrophages alternatively activate in response to anti-inflammatory
mediators such as IL-4 and IL-13, produced by T-helper lymphocytes (Th-2)
(Gombozhapova, Rogovskaya et al. 2017). Additional mediators, such as IL-12,
IL-33, and IL-34, also cause M2 activation (Martinez, Gordon et al. 2006, Pesce,
Kaviratne et al. 2006, Hazlett, McClellan et al. 2010). Moreover, M1 macrophages
may be repolarized into M2 through treatment with pro-M2 factors, as detailed here
(Pelegrin and Surprenant 2009).
M2 macrophages are further subdivided into M2a, M2b, and M2c subsets
(Nahrendorf and Swirski 2013) based on mechanism of activation, function, and
gene profile. For example, M2a and M2c macrophages are important players in
the adaptive immune response, while M2b macrophages are crucial for regulation
and

suppression

of

inflammation

(Lindsey,

Saucerman

et

al.

2016,

Gombozhapova, Rogovskaya et al. 2017). Phenotypes can shift from one state to
another as shown in both in vivo and in vitro experiments (Gombozhapova,
Rogovskaya et al. 2017, Ma, Mouton et al. 2018). Recent evidence indicates a
new M2 macrophage subset, M4, identified in response to monocyte activation
with CXCL4 (Gleissner, Shaked et al. 2010). This phenotype expresses both M1
(CD86 and major histocompatibity complex II) and M2 ( mannose receptor and
fibrinogen-like protein 2) genes and their corresponding cytokines, while
phagocytic function is almost entirely lost (Gleissner, Shaked et al. 2010).
M2 is the most dominant macrophage phenotype in the myocardium 5-7
days after injury (Yan, Anzai et al. 2013, Ma, Mouton et al. 2018). These cells
phagocytize necrotic cells to accelerate inflammation resolution, forming scar
tissue (Ma, Mouton et al. 2018). These macrophages characteristically produce
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large amounts of IL-10, IL-1ra, and decoy type II receptors. Receptors such as
mannose (e.g. CD206), scavenger, galactose-type, and CD163 are also highly
expressed by this phenotype (Bauersachs, Galuppo et al. 2001, Dinarello 2005,
Gombozhapova, Rogovskaya et al. 2017). Furthermore, M2 macrophages secrete
CCL17, CCL22, CCL24 and TGF-β, which mediate inflammation resolution and
demonstrate anti-inflammatory effects (Kzhyshkowska, Gratchev et al. 2006,
Mantovani 2008, Medzhitov and Horng 2009). TGF-β stimulates fibroblast
generate of extracellular matrix components, as well as induction of myofibroblast
differentiation (Gombozhapova, Rogovskaya et al. 2017). M2 macrophages
secrete TGF-β, insulin like growth factor, and platelet-derived growth factor, which
and promote angiogenesis and cell proliferation (Gombozhapova, Rogovskaya et
al. 2017).
After infarct, the macrophage life-span is approximately 20 hours. They are
continuously replenished by infiltrating monocytes and the phenotypic changes of
infiltrated macrophages (Lindsey, Saucerman et al. 2016). In humans,
macrophages are recruited to the heart in a similar pattern but with a delayed
kinetic due to age-related changes in the immune system (Ma, Mouton et al. 2018).
Reperfusion strategies inhibit cardiac immune cell infiltration, resulting in an
accelerated timeline of innate immune activation and reduced adaptive immune
response (Yan, Anzai et al. 2013, Ma, Mouton et al. 2018). More information about
anti-inflammatory macrophages is found in Table 1.3. More information about
markers of different subsets of immune cells is present in Table 1.4.
1.1.1.6 Inflammation resolution after cardiac ischemia
Timely resolution of post-MI inflammation is important to prevent adverse
cardiac remodeling and subsequent heart failure (Ma, Mouton et al. 2018). This
response peaks in the first five days and decreases gradually (Ma, Mouton et al.
2018). This process is related to neutrophil recruitment inhibition, apoptotic cell
(neutrophils, myocytes) and matrix debris removal, and stimulation of fibroblast
formation and collagen deposition (Frangogiannis 2012). Resolution of post-MI
inflammation is primarily dependent on engulfment of apoptotic cardiomyocytes
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and neutrophils which release high quantities of inhibitory mediators (Huynh,
Fadok et al. 2002). Interruptions to this process negatively affect the following
healing process (Wan, Yeap et al. 2013). More information about interfering with
the immune response post-MI is found in Table 1.5.
Macrophages are key players in the post-MI healing phase (Ma, Mouton et
al. 2018), as evidenced by a decrease in recovery and exaggeration of adverse
cardiac remodeling with total macrophage depletion and by the significant
improvement in cardiac functional recovery with adoptive transfer of activated
macrophage strategies (Leor, Rozen et al. 2006, van Amerongen, Harmsen et al.
2007). Macrophages phagocytize apoptotic cells, inducing potent

anti-

inflammatory and immune resolution activities. This process induces production of
anti-inflammatory cytokines such as TGF-β and IL-10, actively participating in
resolution of post-MI inflammation (will discuss later in Cytokines responsible for
resolution of inflammation post-MI). Moreover, macrophages primarily contribute
to fibrotic and angiogenic events post-MI.
In addition, certain pathways may resolve post-MI inflammation. Expression
of Interleukin Receptor Associated Kinase (IRAK)-M, an endogenous suppressor
of innate immune response, has been shown to upregulate in macrophages and
fibroblasts in the injured myocardium. Accordingly, this results in suppression of
macrophage-derived cytokine expression and enhancement of a matrix-preserving
myofibroblast phenotype in the heart (Chen, Saxena et al. 2012). Activation of
mertk in macrophages is crucial for efficient removal of dead cardiomyocytes and
initiation of the anti-inflammatory phase. Mertk deficiency is associated with more
accumulation of apoptotic cardiomyocytes and unresolved inflammation, leading
to decreased myocardial salvage (Wan, Yeap et al. 2013). Lipid pro-resolving
mediators (resolvins, lipoxins, protectins, and maresins), potent anti-inflammatory
compounds activated during phagocytosis, may have an essential role in resolving
post-MI inflammation (Prabhu and Frangogiannis 2016). Studies show that
exogenous administration of resolvin E1 or resolvin D1 enhances inflammation
resolution and prevents adverse cardiac remodeling after infarction (Keyes, Ye et
al. 2010, Kain, Ingle et al. 2015). There may be other pathways (TLR signaling,
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Janus activated kinases (JAKs), and Pentraxin-3) that are potential mediators in
resolution of post-MI inflammation, however their contribution remains unclear and
needs further investigation (Frangogiannis 2012).
1.1.1.6.1 Cytokines involve in inflammation resolution post-MI
1.1.1.6.1.1 IL-10
IL-10 is a potent anti-inflammatory cytokine, mainly expressed by stimulated
Th2 lymphocytes and alternatively activated macrophages (Mosmann 1994,
Frangogiannis 2012). IL-10 modifies monocyte/macrophage function, morphology,
and phenotype. Secretion of IL-1α, IL-1β, TNF-α, IL-6, and IL-8 is inhibited by IL10 in macrophages (Frangogiannis 2012). Furthermore, IL-10 may participate in
matrix remodeling via enhancement of TIMP-1 synthesis, leading to stabilization
of ECM and scar, and thus, reduction of cardiac rupture risk (Lacraz, Nicod et al.
1995, Frangogiannis 2012). IL-10 mRNA and protein levels are both increased in
experimental I/R injury models (Frangogiannis 2012). On one hand, some studies
show that depletion of IL-10 in mice is associated with exaggerated inflammation,
excessive neutrophil recruitment, more advanced cardiac remodeling, and
increased mortality (Yang, Zingarelli et al. 2000). Conversely, other studies reveal
that IL-10-/- mice have comparable mortality rate and resolution of inflammation to
wild type mice, but higher levels of TNF-α and MCP-1 in the damaged myocardium
(Zymek, Nah et al. 2007). In addition, these studies show that deposition of fibrous
tissue and scar formation are not affected by IL-10 deletion (Aoki and Kao 1999).
These contradictory results may be explained by redundant and overlapping
pathways responsible for inflammation resolution that are simultaneously activated
and rescued in IL-10-/- mice after MI.
1.1.1.6.1.2 TGF-β
TGF-β is an essential element in the transition from inflammation to healing
and fibrosis induced by its pleiotropic properties (Bujak and Frangogiannis 2007).
Via activation of endothelial mononuclear cells, TGF-β inhibits the production of
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pro-inflammatory cytokines and chemokines (Frangogiannis 2012). TGF-β
stimulates fibroblast production of ECM proteins (collagen, fibronectin, tenascin,
and proteoglycans) (Bassols and Massague 1988). Moreover, TGF-β reduces the
expression of proteinases (plasminogen activator and collagenase) and enhances
the production of proteinase inhibitors (plasminogen activator inhibitor and TIMP1), leading to an inhibition in matrix breakdown (Laiho, Saksela et al. 1986,
Frangogiannis 2012). As a result, TGF-β plays a dual role post-MI; 1) reducing
production of pro-inflammatory cytokines and chemokines, and 2) increase of the
deposition of ECM (Frangogiannis 2012). Research shows that post-MI TGF-β
administration decreases myocardial injury, an effect that is associated with TNFα inhibition (Lefer, Tsao et al. 1990). Other studies suggest that inhibiting the TGFβ signaling pathway using a TGF-β type II receptor antagonist modulates fibrotic
tissue accumulation at the injured myocardium and attenuates adverse cardiac
remodeling (Ikeuchi, Tsutsui et al. 2004, Okada, Takemura et al. 2005). However,
research also shows that earlier suppression of TGF-β decreases survival rate and
accentuates LV dilatation and heart failure, suggesting a potential role for TGF-β
signaling in the inhibition of post-MI inflammatory pathways (Ikeuchi, Tsutsui et al.
2004, Frangogiannis 2012). These different observations most likely relate to the
pleiotropic effects of TGF-β on the inflammatory and healing phase post-MI. TGFβ can activate both Smad-dependent and-independent pathways. In the
inflammatory phase, Smad3 actively participates in post-MI inflammation
resolution and fibrosis. While this signaling cascade does not seem to play a role
in inflammation resolution in the healing phase, it facilitates interstitial fibrosis in
the injured myocardium (Frangogiannis 2012).
1.1.1.7 Targeting macrophage phenotypes
The presence of pro-inflammatory monocytes/macrophages over a
prolonged period in the myocardium induces infarct expansion (Courties, Heidt et
al. 2014). Animal studies reveal that shifting macrophages to the reparative
phenotype induces timely resolution of inflammation and enhances cardiac
recovery (Weirather, Hofmann et al. 2014). Here, it is important to mention that
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macrophage polarization is a multifactorial process dependent on interaction with
other inflammatory cells, age, microenvironment, and time after injury. The balance
between macrophage phenotypes is reversible (Ben-Mordechai, Palevski et al.
2015) and can be therapeutically harnessed to enhance cardiac healing after
ischemic injury. Research shows that early intervention aimed at altering
macrophage activation state or shifting the balance towards the reparative state
substantially reduces the risk of developing heart failure (de Couto, Liu et al. 2015,
Kain, Liu et al. 2017). However, studies in alternative macrophage activation in MI
have had limited safety in humans. In the next sections, we will critically evaluate
the different anti-inflammatory approaches previously tested following MI.
1.1.2 Anti-inflammatory treatments in MI
A balanced inflammatory response fundamentally regulate healing and
remodeling after MI. However, therapeutic interventions targeting the systemic
inflammatory pathways have yielded limited success in pre-clinical and clinical
studies. Modulating the post-MI inflammatory response is an elusive target as
studies have shown that the complete inhibition of inflammation is rather harmful
(Frangogiannis 2014). Animal studies using non-steroidal anti-inflammatory drugs
(NSAIDs) yielded contradictory results regarding protection against myocardial
injury (Jugdutt, Hutchins et al. 1980, Romson, Hook et al. 1982, Flynn, Becker et
al. 1984, Mullane, Read et al. 1984). Some studies revealed that NSAIDs were
able to protect the heart from ischemic injury, albeit with limited success. These
studies suggest that these protective effects are not related to the inhibition of the
cyclo-oxygenase pathway in the myocardial tissue (Jugdutt, Hutchins et al. 1980,
Romson, Hook et al. 1982). It was also observed that ibuprofen, a member of the
non-steroidal family, inhibits PMN activation by the complement cascade and
generation of ROS species (Flynn, Becker et al. 1984). Other parts of research
show no effect of NSAIDs on neutrophil infiltration and no beneficial effect on
cardiovascular inflammation, remodeling, or development of heart failure (Mullane,
Read et al. 1984). In clinical trials, NSAID use in coronary artery disease patients
correlated with higher mortality and recurrent MI (Schjerning Olsen, Fosbol et al.
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2011). Another anti-inflammatory class of therapeutic agents, glucocorticosteroids,
were found to delay wound healing and are associated with higher incidence of
ventricular aneurysm development in MI patients and therefore their use should be
avoided (Bulkley and Roberts 1974). With modern anti-inflammatory therapies,
observations from animal experimental studies suggest that suppression of IL-1,
IL-6, MCP-1, CC chemokines, CXC chemokines, or TNF-α improves the cardiac
recovery and function post-MI. Research demonstrates that targeting integrin
signaling (CD11/CD18) reduces neutrophil recruitment after MI and is effective in
minimizing scar size (Arai, Lefer et al. 1996). Unfortunately, data from clinical trials
after acute ischemic injury were disappointing (Faxon, Gibbons et al. 2002).
Deletion of IL-1 and MCP-1 significantly decreased adverse cardiac remodeling
without noticeable reduction in scar size, which suggests that the inflammatory
response contributes to reduced cardiac function post-MI without necessarily
altering cardiomyocyte death (Bujak and Frangogiannis 2009, Frangogiannis
2014). On the other hand, selective targeting of potential inflammatory mediators
in MI such as IL-1β using selective monoclonal antibodies demonstrate some
success in clinical studies, albeit with high cost and modest benefit (Seropian,
Toldo et al. 2014). Based on the above data, strategies aimed at modulating the
inflammatory response rather than profoundly suppressing this response may
represent promising therapeutic avenues to improve post-MI outcomes.
1.1.3 Macrolides as immunomodulatory drugs
Macrolides are antibiotic agents with a common structure that contain a
macrolide ring (Zarogoulidis, Papanas et al. 2012). Macrolides include multiple
FDA-approved members such as azithromycin, clarithromycin, erythromycin,
roxithromycin, telithromycin, and dirithromycin, as well as non-FDA-approved
agents such as carbomycin and josamycin (Zarogoulidis, Papanas et al. 2012). Of
note, azithromycin (AZM) is an azalide derivative of macrolides, is not an inhibitor
of CYP3A4, and has a lower potential to interact with food or other drugs, unlike
other members. Macrolides have wider spectrum of coverage in comparison with
penicillins and have lower risk of allergic reaction (Zarogoulidis, Papanas et al.
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2012). The mechanism of action of macrolides as antibiotics is through inhibition
of protein synthesis in microorganisms, caused by suppression of ribosomal
translocation and inhibition of peptidyl-transferase action (Ungureanu 2010,
Zarogoulidis, Papanas et al. 2012). They reversibly bind to the P site on the 50s
subunit of the bacterial ribosome (Zarogoulidis, Papanas et al. 2012). Macrolides
are bacteriostatic antibiotics, however; they become bactericidal at higher doses.
Importantly, macrolides are highly concentrated in leukocytes, and thus, achieve
high levels at sites of infection (Zarogoulidis, Papanas et al. 2012).
In

addition

to

antimicrobial

activity,

macrolides

also

have

immunomodulatory and anti-inflammatory properties, as recently demonstrated in
a large number of studies (Rubin and Henke 2004, Feola, Garvy et al. 2010,
Zarogoulidis, Papanas et al. 2012). These non-antimicrobial activities are dosetime-dependent, and the underlying molecular mechanisms remain poorly defined
(Kanoh and Rubin 2010, Zarogoulidis, Papanas et al. 2012). Macrolides are able
to reduce the time of inflammation and modulate immune system activation
(Zarogoulidis,

Papanas

et

al.

2012).

Moreover,

macrolides

display

immunomodulatory actions through polarization of immune cells to the antiinflammatory activation state (Feola, Garvy et al. 2010), modifying the production
of cytokines (Shinkai, Foster et al. 2006), reducing the generation of ROS,
preventing neutrophil activation and migration, inducing neutrophil apoptosis, and
inhibiting nuclear transcription factors (Kanoh and Rubin 2010, Zarogoulidis,
Papanas et al. 2012). Hence, macrolides are immunomodulatory rather than
immunosuppressive drugs as they exhibit a non-linear time-dependent inhibition
of pro-inflammatory mediators (Kanoh and Rubin 2010).
1.1.3.1 Molecular mechanisms of immunomodulatory effects of macrolides
The mode of action of macrolides as immunomodulatory agents seems
multifaceted (Kanoh and Rubin 2010). These mechanisms may include: a)
normalization of the Ca+2 response and maintenance of normal intracellular Ca+2
concentration (Kanoh and Rubin 2010), b) inhibition of the mitogen-activated
protein kinase (MAPK) pathway, specifically ERK1/2 (Kaneko, Yanagihara et al.
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2003, Imamura, Yanagihara et al. 2004, Tsai, Rodriguez et al. 2004, Kanoh and
Rubin 2010), and c) inhibition of NF-kB and activator protein 1 (AP-1) signaling
through inhibition of nuclear translocation and signaling (Aoki and Kao 1999,
Desaki, Takizawa et al. 2000, Kanoh and Rubin 2010). The proposed modes of
action of immunomodulatory effects of macrolides are summarized in Figure 1.2.
The following will focus on the immunomodulatory and anti-inflammatory
properties of AZM as it is the agent of choice in this project.
1.1.4 Azithromycin
AZM is highly concentrated in leukocytes, macrophages and neutrophils,
where it reaches 5 to 100-fold higher concentrations than in serum (Foulds,
Shepard et al. 1990, Zimmermann, Ziesenitz et al. 2018). The AZM modulation of
macrophage activation state towards the anti-inflammatory phenotype and the
cytokine profile to the anti-inflammatory state is well documented (Zarogoulidis,
Papanas et al. 2012). AZM therapy also reduces glutathione S-transferases
(GSTs), specifically GST theta 1 (GSTT1) and GST Mu 1 (GSTM1) levels in cystic
fibrosis cell lines (Jiang, Finkbeiner et al. 1999, McGrath-Morrow and Stahl 2000,
Leme, Raposo et al. 2010), implying that AZM may have novel antioxidant activity
(Zarogoulidis, Papanas et al. 2012). Interestingly, IL-10 levels also decline with
GST, suggesting a relationship between immunomodulatory effects and
suppression of GST. AZM suppresses H292 cell line stimulation by N-3oxododecanoyl homoserine lactone (3-oxo-C12-HSL), a sensory signaling
molecule produced by P. aeruginosa, due to inhibition of ERK1/2 phosphorylation
(Imamura, Yanagihara et al. 2004, Kanoh and Rubin 2010).
Studies reveal that AZM reduces the expression of mRNA and protein levels
of TNF-α, which may be attributed to inhibition of NF-kB and AP-1 translocation to
the nucleus and binding to DNA (Ivetic Tkalcevic, Bosnjak et al. 2006, Cigana,
Assael et al. 2007, Zarogoulidis, Papanas et al. 2012). LPS-stimulated models also
show reduction of TNF-α with AZM treatment (Ivetic Tkalcevic, Bosnjak et al. 2006,
Zarogoulidis, Papanas et al. 2012). Research reports that AZM inhibits both TNFα secretion and neutrophil recruitment to the lung in a murine model (Tsai,
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Rodriguez et al. 2004, Feola, Garvy et al. 2010). Following neutrophil mobilization
and activation to the site of injury, they undergo apoptosis, initiating inflammation
resolution (Kanoh and Rubin 2010). AZM enhances neutrophil apoptosis (Koch,
Esteban et al. 2000, Kanoh and Rubin 2010), and promotes macrophage
phagocytosis of apoptotic neutrophils, resulting in inflammation resolution. This
resolution is related to the alternatively activated macrophage state (Yamaryo,
Oishi et al. 2003, Hodge, Hodge et al. 2006).
1.1.4.1 Immunomodulatory and anti-inflammatory effects of AZM in sterile
inflammatory diseases
AZM

modulates

the

inflammatory

response

through

macrophage

repolarization towards the reparative state (Murphy, Sundareshan et al. 2008,
Cory, Birket et al. 2014), as demonstrated in models of inflammation and tissue
injury such as spinal cord injury (Zhang, Bailey et al. 2015), lung inflammation
(Feola, Garvy et al. 2010), and stroke (Amantea, Certo et al. 2016). In a model of
lung inflammation, AZM reduces the production of pro-inflammatory cytokines (IL6 and IL-12) while increasing IL-10. Additionally, AZM significantly decreases the
expression of iNOS and pro-inflammatory macrophage receptor (CCR7) while
increasing arginase activity and anti-inflammatory macrophage receptor (MR and
CD23) expression (Murphy, Sundareshan et al. 2008). In an ischemic stroke
model, which induces a sterile inflammatory response similar to MI, AZM shifts
macrophages towards the reparative phenotype, leading to a limited blood brain
barrier injury and improved neurological recovery (Amantea, Certo et al. 2016).
Likewise, in an experimental retinal ischemia/reperfusion model, AZM is protective
against neuronal injury. This protection is attributable to the anti-inflammatory
properties of the drug, as evidenced by reduced MMP-9/2 expression and activity
(Varano, Parisi et al. 2017). Research in a spinal cord injury model finds that preinjury AZM treatment induces macrophage repolarization to the reparative
phenotype as demonstrated by increased M2 macrophage (CD206, Arginase 1)
and reduced M1 macrophage (CD86) marker expression (Zhang, Bailey et al.
2015). Accompanying the immunomodulatory effects of AZM is an increase in
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tissue sparing and functional recovery (Zhang, Bailey et al. 2015). In this report, in
vitro experiments confirm a well-defined shift in cytokine profile towards the antiinflammatory state (IL-12 downregulation and IL-10 upregulation), indicating a
more prominent M2 macrophage phenotype with AZM therapy. Subsequent work
by the same group shows that post-injury AZM treatment significantly shifts
macrophage state to the reparative phenotype (Gensel, Kopper et al. 2017) in
macrophages isolated from spinal cord as well as in in vitro stimulated
macrophages using a gene-array approach to provide a comprehensive and
unbiased profiling of macrophage phenotype. Importantly, this work shows that
AZM doses (10, 40, 160 mg/kg) suppress the expression of pro-inflammatory (M1)
genes in macrophages, while two doses (10, 160 mg/kg) induce anti-inflammatory
(M2) gene expression (Gensel, Kopper et al. 2017). These effects strongly suggest
that AZM exerts its immunomodulatory effects in both high and low doses similarly,
without causing off-target effects at higher doses.
1.1.5 Liposomes
Various therapeutic agents have attempted to alleviate cardiac remodeling
post-MI through systemic administration, however; they achieved limited efficacy
due to a lack of bioavailable cardiac tissue (Dasa, Suzuki et al. 2015). Furthermore,
most drug delivery systems do not achieve sufficient accumulation in the damaged
myocardium or in the cells of interest, which may increase potential off-target
effects. Although local delivery may be an option in the setting of MI, it may require
repeated catheterization, which is not an applicable and cost-effective procedure
(Dasa, Suzuki et al. 2015). To avoid off-target effects and enhance efficacy, an
encapsulated dosage form has been utilized successfully (Bornmann, Graeser et
al. 2008, Dasa, Suzuki et al. 2015).
Liposomal dosage form, an FDA approved drug delivery platform, is a selfclosed spherical structure made of one or more phospholipid bilayers surrounded
by an aqueous core. Since they can hold both lipophilic and hydrophilic
compounds, liposomes represent an attractive drug delivery system to achieve
targeted drug delivery (Levchenko, Hartner et al. 2012).
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They improve drug

pharmacokinetics, minimize systemic side effects, decrease required dose,
prolong circulation half-life, and reduce time to reach steady state (Oh, Nix et al.
1995). In addition, encapsulated therapeutic agents slowly release from the
liposomes, providing continuous exposure to the targeted site and enhanced drug
efficacy (Cheraghi, Negahdari et al. 2017). Non-cardiac applications show that
liposomal delivery platforms can reduce doxorubicin drug toxicity by reducing the
administered dose while keeping or enhancing antitumor effectiveness (Rose
2005). In this study, liposomal doxorubicin reaches steady state level faster and
with fewer doses due to promoted accumulation in the targeted organs (Charrois
and Allen 2003). After infarct, cellular and vascular permeability increase in the
injured myocardium, facilitating the accumulation of nanoparticles such as
liposomes in the damaged zones (Takahama, Minamino et al. 2009). Liposomes
are a proven potent drug delivery system that can serve as a carrier to achieve
higher drug concentration at sites of cardiac injury (Mueller, Marcus et al. 1981).
Liposomes can also augment the local distribution of tracers in the infarcted
myocardium (Caride, Twickler et al. 1984).
The post-infarction myocardium contains a large variety of diverse cells
such as inflammatory phagocytes that may be successfully targeted,
hypothetically,

by liposomal delivery platforms (Oh, Nix et al. 1995). After

parenteral administration, mononuclear phagocytes naturally take up liposomes.
Liposomes can harness the physiological function of these cells to mediate
targeted delivery, therefore promoting therapeutic agent efficacy (Kelly, Jefferies
et al. 2011). Stroke research shows that parentally administered gene therapy
localizes in infiltrated macrophages in the infarcted brain (Tanaka, Kitagawa et al.
2004). These observations replicate with macrophages in several studies (Scott,
Rosano et al. 2009, Harel-Adar, Ben Mordechai et al. 2011, Cheraghi, Negahdari
et al. 2017). Mononuclear phagocytes (neutrophils, monocytes, macrophages)
play pivotal roles in the immunopathology of MI, and thus, represent an attractive
target for liposomal drug delivery (Kelly, Jefferies et al. 2011), as demonstrated
with liposomal celecoxib therapy (Margulis, Neofytou et al. 2015, Cheraghi,
Negahdari et al. 2017).
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In targeting cardiac macrophages with liposomes, research shows that
parenteral administration of phosphatidylserine-presenting liposomes (PSliposomes) shifts cardiac macrophage phenotype to the reparatory state (HarelAdar, Ben Mordechai et al. 2011). These liposomes are taken up by macrophages
both in vivo and in vitro, activating them to produce large amounts of antiinflammatory cytokines (TGF-β and IL-10) and reduce production of proinflammatory cytokines (TNF-α). Moreover, mannose receptor, CD206, is
upregulated,

while

pro-inflammatory

macrophage

marker,

CD86,

is

downregulated, implicating a marked shift in the function from pro-inflammatory
towards reparative state. This strategy is associated with significant improvement
in scar size, angiogenesis, LV function, and cardiac remodeling in the PS-liposome
treated group (Harel-Adar, Ben Mordechai et al. 2011).
1.1.5.1 Liposomal AZM
AZM precipitates in aqueous solution due to poor solubility, which has
detrimental effects on drug efficacy (Peters, Friedel et al. 1992, Oh, Nix et al.
1995). To prevent AZM hydrolysis during storage and to achieve easier
administration without co-solvents, a lyophilized drug-phospholipid dosage
formulation may be used. Hydrophobic drugs such as AZM reside in the acyl
hydrocarbon chain of liposomes, while hydrophilic drugs locate mostly in the
aqueous interior. Therefore, liposomal formulations may be effective in increasing
solubility, extending half-life, and improving the therapeutic index and stability of
AZM (Cheraghi, Negahdari et al. 2017). Consequently, liposomes alter the
biodistribution and the clearance rate of encapsulated drugs (Gabizon, Shmeeda
et al. 2003, Cheraghi, Negahdari et al. 2017). Our research indicates that
liposomes increase AZM solubility 75 times, suggesting superior potency due to
higher drug availability. In agreement with this strategy, studies show that the
antibacterial effects of liposomal AZM against intracellular M. avium growth in
macrophages is 41-fold higher than free AZM (Oh, Nix et al. 1995). This may
explain the success of liposomal preparation in promoting the pharmacodynamic
effects of the drug. Although lack of efficient assays to precisely determine the
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intracellular concentration of AZM limits our ability to test this hypothesis, this
strategy successfully enhances the intracellular deposition of other antibiotics
(ciprofloxacine) (Oh, Nix et al. 1995). Additionally, AZM substantially spreads
throughout the body due to the large volume of distribution (27 liters/kg) (Oh, Nix
et al. 1995), and as such, developing a strategy that constrains it to target cells
may improve efficacy and prevent non-specific distribution and accumulation. In
conclusion, liposomes are valuable tools in enhancing the pharmacokinetics,
reducing off target side effects, and achieving targeted delivery of drugs post-MI.
Furthermore, these liposomes decrease the exposure of other systems to the drug
and thus reduce the potential microbial resistance for AZM.
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1.2. STATEMENT OF THE PROBLEM
Myocardial infarction (MI) is a severe ischemic disease, causing sudden
death and heart failure with prevalence rates promptly rising worldwide. Despite
significant advances in medical care, mortality rate and comorbid complications
remain high in MI patients. Heart failure is one of the most expensive chronic
illnesses with medical costs constituting 1-2% of overall healthcare spending. PostMI inflammatory changes in the heart play a critical role in the pathophysiology of
MI and its related complications. Likewise, these inflammatory pathways regulated
healing and remodeling after MI. Accordingly, targeting suppression of post-MI
inflammation is a potential therapeutic approach in MI treatment. However, multiple
clinical trials fail to demonstrate the effectiveness of traditional anti-inflammatory
drugs such as corticosteroids, cyclosporine, and non-steroidal anti-inflammatory
drugs in treating patients with MI. Additionally, studies that selectively target one
signaling pathway (cytokine and/or receptor) fail to demonstrate robust clinical
benefits.
A growing body of evidence suggests that modulation of post-MI
inflammation via selective targeting of potential inflammatory mediators may hold
the key in protecting the heart from adverse cardiac remodeling and chronic heart
failure. However, the development of such therapies is a challenge as they must
act as immunomodulatory rather than immunosuppressive agents since
immunosuppressive agents have proven harmful in MI patients. Macrophages are
key players in acute inflammation and chronic recovery, which present in MI in two
activation states: pro-inflammatory and reparative. Pro-inflammatory macrophages
contribute to adverse cardiac remodeling and heart failure while reparative
macrophages

enhance

tissue

healing.

Recent

research

reveals

that

immunomodulation of the inflammatory response post-MI via macrophage
repolarization towards the reparative state counterbalances pathophysiological
mechanisms of adverse cardiac remodeling and prevents heart failure. However,
translational approaches to harness this benefit are not clinically available.
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In this work, we represent an approach to achieve this goal by using a small
molecule drug. Research demonstrates that azithromycin (AZM) alters the
inflammatory response and polarizes macrophages to the alternatively activated
state in various inflammatory pathologies. AZM has an excellent safety profile and
is approved for human use. We hypothesize that AZM therapy modulates the
excessive inflammatory response post-MI, and thus, improves cardiac recovery.
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1.3 Hypothesis
Azithromycin is a potential immunotherapy to improve inflammation and adverse
cardiac remodeling after MI. To test this hypothesis, we performed the following
studies:
1: Examine the immunomodulatory and cardioprotective effects of azithromycin
post-MI (a proof-of-concept study).
Hypothesis: AZM therapy modulates the potent inflammatory response, and thus,
improves cardiac recovery after infarction.
2: Determine the immunotherapeutic effects of low dose liposomal AZM delivered
after infarction (clinically-relevant study).
Hypothesis: Low dose liposomal AZM (Lazm) treatment, started immediately after
MI, yields an enhanced immunomodulatory potential and cardiac recovery with low
risk of adverse effects
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Table 1.1: Innate immune mechanisms in MI: contribution of studies using
transgenic mice (Liaudet and Rosenblatt-Velin 2013)
Transgenic
Model
strain
of MI
TNF alpha
pathway
TNF alpha KO I/R (30'120')
TNF alpha KO P.O. (up
to 7 D)
TNFR1-R2 KO P.O. (24
h)
TNFR1 (p55) P.O. 7KO 28 D
TNFR2 (p75) P.O. 7KO 28 D
IL-1 beta pathway
IL-1R KO I/R (1
h/6 h to
7 D)
gp-130 mutant P.O. (up
to 2 W)
IL-10 pathway
IL-10 KO I/R (30'2-24 h)
IL-10 KO I/R (1
h/6 h to
7 D)
TGF beta
pathway
Smad3 KO I/R (1
h/6 h to
D)
TSP-1 KO I/R (1
h/3 h to
7 D)
CXCR4 KO P.O. (3
W)
IP-10 KO I/R (1
h/6 h to
7 D)
MCP-1 KO I/R (1
h/6 h to
7 D)

Main findings

Reduced infarct size and contractile dysfunction.
Reduced NF-kappaB activation, chemokine expression,
PMN infiltration.
Improved cardiac function. Reduced myocardial ICAM-1
expression.
Increased infarct size, increased apoptosis of cardiac
myocytes.
Reduced mortality, improved functional recovery.
Increased mortality, increased LV dysfunction.
Reduced chemokine, cytokine and MMP expression.
Reduced PMN infiltration, LV dilation and LV fibrosis.
Persistent myocardial STAT3 activation, increased
myocardial inflammation, LV dysfunction and LV rupture.
Increased PMN infiltration, ICAM-1/TNF expression and
infarct size.
Increased expression of TNF and CCL2. No effect on LV
dysfunction and remodeling.

Reduced PMN infiltration and chemokine expression.
Reduced dilative LV remodeling and diastolic
dysfunction.
Increased and prolonged expression of IL-1, IL-6 and
TGF-beta. Enhanced LV adverse remodeling with
increased fibrosis.
No influence on LV systolic dysfunction and adverse
remodeling
Expansion of fibrosis, increased remodeling and systolic
dysfunction
Increased PMN (after 24 and 72 h) and macrophages
(after 3 to 7 D).
Delayed macrophage recruitment and myofibroblast
accumulation. Reduced cytokine expression. Reduced
LV remodeling.
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Table 1.1 (Continued)
CCR2 KO P.O. (up
to 28 D)
CCR1 KO P.O. (up
to 21 D)
ICAM-1 KO I/R
(30'/2 h3 W)
ICAM-1/P-sel I/R (30'KO 1 h/3-24
h)
CD-18 KO I/R
(30'/2 h)
Cardiac P.O. (4
restricted W)
mutated
IkappaB
Cardiac- P.O. (24
restricted h)
mutated
IkappaB
p50 KO I/R
(30'/24
h)
p50 KO P.O. (up
to 8 W)
p50 KO P.O. (4
W)
TLR2 KO I/R
(30'/60')
(isolated
hearts)
TLR2 KO P.O. (1
to 4 W)
TLR2 KO I/R
(30'/60')
TLR4 deficient P.O. (up
to 4 W)
(C3H/HeJ mice)
TLR4 KO P.O. (14 W)

Reduced macrophage infiltration, MMP expression and
collagen deposition. Reduced LV systolic dysfunction
and LV remodeling.
Reduced PMN infiltration, decreased apoptosis,
increased proliferation of myofibroblasts in the infracted
tissue. Reduced LV remodeling.
Reduced reperfusion injury at 2 h.
Reduced PMN infiltration at 24 h, but no change in infarct
size.
Reduced PMN infiltration and smaller infarct size (at 2 h
reperfusion)
Diminished NF-kB p65 activation and cytokine
expression. Reduced LV remodeling, fibrosis and systolic
function.
Increased infarct size and apoptosis. Reduced
expression of anti-apoptotic proteins (Bcl-2 and c-IAP1).

Reduced PMN infiltration, decreased infarct size
Reduced mortality, LV remodeling and systolic
dysfunction
Increased expression of cytokines, chemokines and
MMPs. Enhanced remodeling, fibrosis, hypertrophy and
systolic dysfunction.
Improved post-ischemic functional recovery. Blunted
myocardial expression of TNF alpha and IL-1 beta.

Reduced TGF beta expression and fibrosis. Reduced LV
remodeling and systolic dysfunction.
Reduced myocardial PMN accumulation, ROS formation
and IL-1 beta expression. Suppressed coronary
endothelial dysfunction.
Reduced remodeling and preserved systolic function.
Reduced fibrosis and expression of cytokines.
Reduced systolic dysfunction and remodeling.
Decreased TGF beta expression. Reduced lymphocyte
infiltration and apoptosis.
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Table 1.1 (Continued)
TLR4 KO I/R (1
h/24 h)
MyD88 KO I/R (1
h/up to
7 D)
RAGE KO I/R
(30'/48
h)
Inflammasome
pathway
Caspase-1 KO
P.O. (up
to 9 D)
ASC KO I/R
(30'/up
to 2 W)

Reduced infarct size, myocardial PMN infiltration and
oxidative stress.
Reduced infarct size, reduced LV dysfunction, reduced
myocardial PMN infiltration, MCP-1 and ICAM-1
expression.
Reduced infarct size, myocardial inflammation and
dysfunction.

Reduced LV remodeling, MMP-3 and IL-18 expression
and apoptosis.
Reduced infarct size at 48 h. Reduced LV fibrosis,
remodeling and systolic dysfunction. Reduced
myocardial cytokine expression.

ASC: apoptosis-associated speck-like protein containing a caspase recruitment
domain; Bcl-2: B-cell CLL/lymphoma 2;c-IAP-1: inhibitor of apoptosis protein-1;
CCL: chemokine (C-C motif) ligand ; CCR: chemokine (C-C motif) receptor;
CXCR: chemokine (C-X-C motif) receptor; D: Day; H: hour;ICAM-1: inter-cellular
adhesion moelcule-1; IkappaB: inhibitor of KappaB; IL: interleukin; IL-1R: IL-1
beta receptor; IP-10: Interferon-inducing protein 10; I/R: Ischemia/Reperfusion;
KO: Knockout; LV: left ventricle; MCP-1: monocyte chemoattractant protein-1;
MMP: matrix metalloproteinase; MyD88: myeloid
differentiation primary response gene 88; NF-kappaB: nuclear factor kappaB;
PMN: ploymorphonuclear cell; P.O.: permanent occlusion; P-sel: P-selectin;
RAGE: receptor for advanced glycation end-products; ROS: reactive oxygen
species; SDF-1: stromal cell-derived factor-1; STAT: signal transducer and
activator of transcription; TGF beta: transforming growth factor beta; TLR: toll-like
receptor; TNF alpha: tumor necrosis factor alpha; TNFR1: TNF receptor 1;
TNFR2: TNF receptor 2; TSP-1: Thrombospondin-1; W: week.
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Table 1.2: Gating strategies for immune cells (Ma, Mouton et al. 2018)
Cells labeled
Species
Gating strategy
Monocytes
Ly6ChighCCR2highCX3CR1lowCD62 L+
Classical monocytes Mouse
low
low
high
−
Ly6C CCR2 CX3CR1 CD62L
Nonclassical
Mouse
monocytes
CCR2+Ly6Chigh
Inflammatory blood
Mouse
monocytes
CD14+CD16−, CD14+CD16+
Blood monocytes
Human
B220−F4/80+CD115+Ly6C−,
Blood monocytes
Mouse
B220−F4/80+CD115+Ly6C+
MHCIIlowCCR2+
Cardiac monocytes Mouse
+
−
−
high
CD11 b F4/80 Ly6G Ly6C ,
Monocytes
Mouse
CD11 b+F4/80−Ly6G−Ly6Clow
Lineage−CD11 b+F4/80lowLy6C+
Cardiac monocytes Mouse
+
−
−
−
low
Blood and cardiac
Mouse
CD11 b CD11C MHCII CD68 Ly6C ,
monocytes
CD11 b+CD11C−MHCII−CD68−Ly6Chigh
Macrophages
CD45+CD11 b+F4/80+CD206−
M1 macrophages
Mouse
+
+
+
+
CD45 CD11 b F4/80 CD206
M2 macrophages
Mouse
Mouse
CD45+CD11 b+F4/80+Ly6Clow
Resident cardiac
macrophages
CD11 b+F4/80+CD206+
Alternatively
Mouse
activated
macrophages
+
+
+
+
+/−
Mouse
CD11 b F4/80 CD64 Ly6C MHCII
M1 like
macrophages
CD11 b+F4/80+CD64+Ly6C−MHCII+/−
M2 like
Mouse
macrophages
F4/80+CD86+
M1 macrophages
Mouse
F4/80+CD206+
M2 macrophages
Mouse
+
−
F4/80 CD206
M1 macrophages
Mouse
+
+
CD45 CD68
Cardiac, blood, and Rat
spleen
macrophages
+
+
+
low
CD11 b F4/80 CD68 Ly6C , CD11
Monocyte-derived
Mouse
b+F4/80+CD68+Ly6Chigh
cardiac
macrophages
CD14+CD64+MERTK+F4/80+CX3CR1+MHCII−, Resident cardiac
Mouse
+
+
+
+
+
+
CD14 CD64 MERTK F4/80 CX3CR1 MHCII , macrophages
CD14+CD64+MERTK+F4/80+CX3CR1−MHCII−,
CD14+CD64+MERTK+F4/80+CX3CR1−MHCII+
F4/80+CD11 b+Ly6Clow, F4/80+CD11
Alternatively
Mouse
+
medium
+
+
lhigh
b Ly6C
, F4/80 CD11 b Ly6C
activated
macrophages
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Table 1.2 (Continued)
CD45+CD11 b+F4/80+Ly6C−MHCIIhigh,
CD45+CD11 b+F4/80+Ly6C−MHCIIlow, CD45+
CD11 b+F4/80+Ly6C+MERTK+CD206+, CD45+
CD11 b+F4/80+Ly6C+MERTK−CD206−
CD45+F4/80+MHC-IIlowCCR2−,
CD45+F4/80+MHC-IIhighCCR2−
CD45+F4/80+MHCIIhighCCR2+
CD14+CD16+CD163+CD204+CD206+CD209−

45

Cardiac resident
macrophages

Mouse

Cardiac resident
macrophages
Monocyte-derived
cardiac
macrophages
Anti-inflammatory
M2c macrophages

Mouse
Mouse
Human

Table 1.3: Properties of M1 and M2 macrophages post-MI (Ma, Mouton et al.
2018)
Stimuli
Transcription
factors
Markers

Cell
physiology

Pro-inflammatory
GM-CSF, IFN-γ, TNF-α, IL-1β

Anti-inflammatory
Hydrogen sulfide, IL-4, IL-10,
IL-13, IL-33, TGF-β1, M-CSF
AP-1, HIF-1α, IRF3, IRF5, NF- c-Maf, c-Myc, IRF4, JMJD3,
κB, STAT1
KLF4, PPAR-γ, STAT3,
STAT6
CCL2 (MCP1), CCL3 (MIP1a), Arg1, CCL1, CCL16, CCL17,
CCL4 (MIP1b), CCL5
CCL18, CCL22, CCL24,
(RANTES), CCL7, CCL8,
CXCL13, CXCL17, CXCL22,
CCR2, CD80, CD86, CXCL1,
CXCL24, CXCR1, CXCR2,
CXCL2, CXCL6, CXCL8 (IL-8), CD163, CD206 (MRC1),
CXCL9, CXCL10, CXCL11,
CD280 (MRC2), Cd301a
CXCL16, IL-1β, IL-6, IL-12, IL- (Clec10a, Mgl1), Cd301 b
23, iNOS, MHCII, RNS, ROS,
(Mgl2), Dectin-1, Fizz1
S100a8, S100a9, TNF-α
(Retnla, Relmα), IL-10,
PGE2, Spp1 (osteopontin),
Stabilin1, TGF-β1, VEGF,
Ym1 (Chi3l3)
Pro-inflammation; proteolysis; Anti-inflammation and
phagocytosis of debris;
resolution of inflammation;
antigen presentation to
phagocytosis of apoptotic
lymphocytes
cells; pro-angiogenesis;
ECM production and scar
formation
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Tabl1 1.4: Summary of markers of immune cells in humans and rodents
(Ma, Mouton et al. 2018)
Marker
CCR2/CD192

CD11 b/ITGAM

CD14

CD16/FCGR3

CD64/FcγR1

CD68/macrosialin

CD163
CX3CR1

F4/80/EMR1

Location

Expressed by Cell physiological
function
Cell surface Monocytes,
Mediates Ly6Chigh
macrophages monocytes
recruitment and
migration
Cell surface Monocytes,
Couples with CD18 to
macrophages, form integrin αMβ2
neutrophils,
(also named Mac1 or
NK cells
complement receptor
3) to initiate immune
response
Cell surface Human
Mediates toll-like
monocytes
receptor 4 activation
and production of IFNβ
Cell surface Human
Binds to the Fc portion
monocytes
of IgG antibodies,
antigen presentation,
anti-inflammatory
cytokine production
Cell surface Monocytes,
Antibody-dependent
macrophages phagocytosis,
recognizes the Fc
region of IgG
Endosomal/l Monocytes,
Antigen processing
ysosomal
macrophages and presentation,
compartment
binds to oxidized low, cell surface
density lipoprotein
Cell surface, Macrophages, Hemoglobin/haptoglob
neutrophils
in scavenger receptor,
secreted
(soluble)
anti-inflammatory
Cell surface Monocytes,
Mediates Ly6Clo
macrophages monocyte recruitment,
inhibits proliferation of
local macrophages
Cell surface Macrophages Promotes proinflammatory factor
production, induces
antigen-specific
efferent Treg cells

47

Table 1.4 (Continued)
Galectin 3/Mac2

Cell surface,
secreted

Macrophages

Ly6C/Gr-1

Cell surface

Monocytes

Mac3
MERTK

Cell surface
Cell surface

Macrophages
Macrophages,
phagocytes

MHCII

Cell surface

Macrophages,
dendritic cells,
B cells
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Induces monocytemacrophage
differentiation,
interferes with
dendritic cell fate
decision, regulates T
cell apoptosis, inhibits
B-lymphocyte
differentiation into
plasma cells
A specific marker for
pro-inflammatory
monocytes
A glycoprotein
Mediates
phagocytosis,
increases migration
Mediates antigen
presentation

Table 1.5: Post-MI effect of perturbing inflammation components (Mouton,
Rivera et al. 2018)
Perturbation Effect
Reducing
↑LV physiology
inflammation:
IL-1α null
↓LV remodeling
TREM1 null
NF-κB null
TLR4 null
TRPV2 null
PSpresenting
liposomes
Total
neutrophil
depletion
Total
macrophage
depletion
M2-specific
depletion
Macrophage
modulation:
Wntless null
Macrophage
EP3R null
Macrophage
EP3R
transgenic
CD5L null

↓LV physiology
↑Fibrosis

Mechanism
IL-1α null: ↓innate immune response in
cardiac fibroblasts
TREM1 null: ↓myeloid cell recruitment
from the spleen and bone marrow;
↓CCR2+
Pro-inflammatory but not pro-reparative
X3CR1+ monocyte infiltrationTLR4 null:
↓neutrophil infiltration/activation TRPV2
null: ↓macrophage migration PSliposomes: ↑macrophage secretion of IL10 and TGF-β
↓Necrotic myocyte removal
↑Macrophage inflammatory response
↑Myofibroblast activation
Total: ↓necrotic/apoptotic cell removal
↓Fibroblast and endothelial cell activation

↓LV physiology
↓Collagen
deposition
↓Neovascularization M2: prolonged N1 neutrophil/M1
macrophage activation
↑LV physiology
Wntless: ↑reparative M2 macrophages,
neovascularization
↓LV remodeling
EP3R null: monocyte TGF-β
signaling/↓CX3CR1 and VEGF signaling,
↓Ly6Clo reparative monocyte activation
EP3R transgenic: ↑angiogenesis CD5L
null: ↓neutrophils, ↓collagen
accumulation, ↓IL-1 receptor-associated
kinase 4, NF-κB, myeloperoxidase, and
inducible nitric oxide synthase

MI, myocardial infarction; LV, left ventricular; ↑, increase; ↓, decrease.
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Table 1.6: Summary of clinical outcomes with anti-inflammatory agents
post-MI (Seropian, Toldo et al. 2014)
Therapy

Outcome

Glucocorticoids

conflicting results, associated with impaired
healing, scar thinning, ventricular aneurysm,
and increased risk of ventricular rupture
worse clinical outcome and ventricular rupture
after AMI
failed to improve coronary reperfusion on
angiography, ST-segment resolution, increased
infections and bleeding complications
failed to reduce infarct size or reduce major
adverse cardiac events
conflicting and inconclusive results regarding
the role IL-6 in ventricular remodeling

NSAIDs
rhuMAb CD18 (humanized
monoclonal antibody against
CD18)
Pexelizumab (humanized
antibody against C5)
Tocilizumab (humanized
monoclonal antibody against
the IL-6 receptor )
Anakinra (competitive
inhibitor of IL-1)
Etanercept and infliximab
(TNF-α blockers )
PI3K inhibitor

a favorable effect on C-reactive protein (CRP)
levels and trend toward more favorable left
ventricular remodeling and reduced incidence
of HF at 3 months
a dose-dependent increase in adverse cardiac
events, significantly lowered the interest in
these drugs for heart disease
no protective effect in ischemia-reperfusion
model
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Figure 1.1: Primary immune cells at the site of infarction.
Neutrophil and macrophage responses after infarction. Shifting the response of
M2 macrophage to the left by using AZM is beneficial in MI (Hypothesis).
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Figure 1.2: The likely underlying molecular mechanisms for the
immunomodulatory effects of macrolides.
AP-1, activator protein 1; CaMK, calmodulin kinase; DAG, diacylglycerol; EGFR,
epidermal growth factor receptor; ER, endoplasmic reticulum; ERK, extracellular
signal-regulated kinase; GFR, cytokine receptor/growth factor receptor; GPCR,
G-protein-coupled receptor; IKK, IκB kinase; IP3R, inositol triphosphate receptor;
IRAK, IL-1 receptor-associated kinase; MEK, MAPK/ERK kinase; PKC, protein
kinase C; TAK1, transforming growth factor-activated protein kinase 1; TLR, Tolllike receptor. Big arrows, major pathways influenced by macrolides; dashed
arrows, sub-pathways or cross-talk pathways; red lines, inhibition by macrolides;
red arrows, levels are increased by AZM; AZM, azithromycin (Kanoh and Rubin
2010).
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CHAPTER II. SPECIFIC AIM 1
Azithromycin
therapy
reduces
mitigates
adverse
cardiac remodeling

cardiac inflammation
and
after myocardial infarction:

Potential therapeutic targets in ischemic heart disease
Ahmed Al-Darraji, Dalia Haydar, Lakshman Chelvarajan, Himi Tripathi, Bryana
Levitan, Erhe Gao, Vincent J. Venditto, John C. Gensel, David J. Feola, Ahmed
Abdel-Latif
Published: July 12, 2018
https://doi.org/10.1371/journal.pone.0200474
2.1 Summary
Introduction: Acute myocardial infarction (MI) is a primary cause of worldwide
morbidity and mortality. Macrophages are fundamental components of post-MI
inflammation. Pro-inflammatory macrophages can lead to adverse cardiac
remodeling and heart failure while anti-inflammatory/reparative macrophages
enhance tissue healing. Shifting the balance between pro-inflammatory and
reparative macrophages post-MI is a novel therapeutic strategy. Azithromycin
(AZM), a commonly used macrolide antibiotic, polarizes macrophages towards the
anti-inflammatory phenotype, as shown in animal and human studies. We
hypothesized that AZM modulates post-MI inflammation and improves cardiac
recovery.
Methods and results: Male WT mice (C57BL/6, 6–8 weeks old) were treated with
either oral AZM (160 mg/kg/day) or vehicle (control) starting 3 days prior to MI
and continued through day 7 post-MI. We observed a significant reduction in
mortality with AZM therapy. AZM-treated mice showed a significant
decrease in pro-inflammatory (CD45+/Ly6G-/F4-80+/CD86+) and increase in
anti-inflammatory
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(CD45+/Ly6G-/F4-80+/CD206+)

macrophages,

decreasing

the

pro-

inflammatory/anti-inflammatory macrophage ratio in the heart and peripheral blood
as assessed by flow cytometry and immunohistochemistry. Macrophage changes
were associated with a significant decline in pro- and increase in anti-inflammatory
cytokines. Mechanistic studies confirmed the ability of AZM to shift macrophage
response towards an anti-inflammatory state under hypoxia/reperfusion stress.
Additionally, AZM treatment was associated with a distinct decrease in neutrophil
count due to apoptosis, a known signal for shifting macrophages towards the antiinflammatory phenotype. Finally, AZM treatment improved cardiac recovery, scar
size, and angiogenesis.
Conclusion: Azithromycin plays a cardioprotective role in the early phase post-MI
through attenuating inflammation and enhancing cardiac recovery. Post-MI
treatment and human translational studies are warranted to examine the
therapeutic applications of AZM.
2.2 Introduction
Acute myocardial infarction (MI) is a leading cause of mortality and
morbidity in the western world(van der Laan, Nahrendorf et al. 2012). MI provokes
a profound coordinated inflammatory response, a process mediated by
inflammatory bone marrow (BM) and peripheral blood (PB) cells, which has been
linked to the development of end stage heart failure (HF), a highly frequent
complication post-MI (van der Laan, Nahrendorf et al. 2012). The peri-infarct zone
demonstrates dynamic cellular changes with the infiltration of various inflammatory
cells including neutrophils, monocytes, and macrophages (Epelman, Liu et al.
2015).

Monocytes

infiltrate

the

peri-infarct

zone

and

differentiate

into

macrophages, which play an important role in the initial inflammatory as well as
the following reparatory phases (Dutta and Nahrendorf 2015). Two dominant
patterns of macrophage activation are found: pro-inflammatory/classically
activated

macrophages

(M1-like)

and

anti-inflammatory/alternatively

activated/reparative macrophages (M2-like), with different cell markers and gene
expression profiles (Epelman, Liu et al. 2015). In mice, the initial exaggerated
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inflammatory response may actually confer long-term harm because reductions in
the initial recruitment of inflammatory monocytes reduce infarct size and prevent
adverse cardiac remodeling (de Couto, Liu et al. 2015, Protti, Mongue-Din et al.
2016). Pro-inflammatory macrophages trigger inflammation, damage of extra
cellular matrix (ECM)(Gibbs, Shanley et al. 1999), production of reactive oxygen/
nitrogen species and pro-inflammatory cytokines (IL-6, TNF-α, and IL-1β)
(Martinez, Sica et al. 2008). In contrast, anti-inflammatory macrophages promote
ECM repair, angiogenesis, and production of anti-inflammatory cytokines (IL-4, IL10, and IL-13) (Sunderkotter, Goebeler et al. 1991).
Azithromycin (AZM), a clinically approved macrolide antimicrobial agent,
has an excellent safety profile in humans. AZM modulates the inflammatory
response through macrophage polarization towards the reparative state (Murphy,
Sundareshan et al. 2008, Cory, Birket et al. 2014), as demonstrated in models of
inflammation and tissue injury such as spinal cord injury (Gensel, Kopper et al.
2017), lung infection (Feola, Garvy et al. 2010), and stroke (Amantea, Certo et al.
2016). In these clinically relevant scenarios, AZM reduces the production of proinflammatory cytokines (IL-6 and IL-12) and increases that of anti-inflammatory
cytokines (IL-10)(Murphy, Sundareshan et al. 2008). Additionally, AZM
significantly decreased the expression of iNOS and pro-inflammatory macrophage
receptor (CCR7) while increasing arginase activity and anti-inflammatory
macrophage receptors (MR and CD23) (Murphy, Sundareshan et al. 2008). In an
ischemic stroke model, which induces a similar sterile inflammatory response to
MI, AZM shifted macrophages from the pro-inflammatory to the reparative state
leading to inhibition of blood brain barrier injury and improvement in neurological
recovery (Amantea, Certo et al. 2016). Likewise, in a retinal ischemia/reperfusion
experimental model, AZM was protective against neuronal injury. This protection
was attributed to the anti-inflammatory properties of AZM, as evidenced by the
reduction in MMP-9/2 expression and activity (Varano, Parisi et al. 2017). In
addition to its immunomodulatory properties, AZM is well tolerated, achieves a
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wide therapeutic index, and has well characterized pharmacokinetic and
pharmacodynamic properties(Koch, Esteban et al. 2000).
Here, we provide the first evidence that AZM reduces the inflammatory
response and mediates cardioprotection against adverse cardiac remodeling and
HF post-MI. AZM produces its positive effects through increasing neutrophil
apoptosis and switching macrophage activation towards an anti-inflammatory
phenotype. Our findings present an important step towards designing clinically
relevant strategies to reduce the risk of cardiac remodeling and HF after MI.
2.3 Materials and methods
Study Design. 8–10 week old male C57BL/6 mice (Jackson Laboratory,
BarHarbor, ME) were treated with either AZM (Azithromycin tablets, USP,
Sandoze, NDC0781194133, Princeton, NJ), (crushed tablets suspended in 2%
methylcellulose), orally using gastric gavage at 160 mg/kg/day or vehicle (2%
methylcellulose), starting 3 days prior to MI or sham surgery through day 7 postMI (Fig 1A). Timing of AZM therapy was selected to ensure appropriate steadystate levels at the time of injury (Feola, Garvy et al. 2010). AZM administration
continued for 7 days after surgery to cover the entire duration of post-MI
inflammatory response (Heidt, Courties et al. 2014, Ramirez, Iyer et al. 2014). AZM
treatment was not associated with changes in liver or kidney function throughout
the period of administration (S1 Fig). All procedures were conducted under the
approval of the University of Kentucky IACUC in accordance with the NIH Guide
for the Care and Use of Laboratory Animals (DHHS publication No. [NIH] 85–23,
rev. 1996).
2.3.1 Murine model of myocardial infarction
Mice were anesthetized with 1–3% isoflurane using a small animal
vaporizer system. Pain reflexes were examined to make sure that the mouse was
adequately anaesthetized prior to surgery. Following a left thoracotomy between
the fourth and fifth ribs and removal of pericardial sac, the heart was exposed and
pushed out of the thorax under direct visualization. The left anterior descending
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coronary artery (LAD) was identified under a surgical microscope and permanently
ligated 3 mm below its origin using a 6–0 silk suture as previously described (Gao,
Lei et al. 2010, Klyachkin, Nagareddy et al. 2015). The sham group underwent the
same surgical procedure except the suture was passed under the LAD but not tied.
Following LAD ligation, the heart was placed back into the intrathoracic space and
the pneumothorax was manually evacuated. After muscle closure, the skin was
sutured using 4–0 Prolene running sutures.
2.3.2 Humane endpoints
Animals were treated with pain medications for 24–48 hours after surgery.
This duration may be prolonged if animals showed signs of pain, discomfort or
reduced food or water intake. Animals were followed every 8 hours for 24 hours
followed by daily for 1 week, for any signs of clinical deterioration or overt heart
failure. Their water and food consumption is monitored carefully. Any animals that
show signs of decompensation were resuscitated and if this is unsuccessful, they
were humanly euthanized. We also monitored mice for additional signs of distress
or weight loss >15–20% from baseline weight; hunched posture; ruffled coat; etc.
If the mice exhibited any of these signs, they were euthanized without any
subsequent experimental procedures. Most of the mortality in our MI group
occurred in the first week after surgery. Necropsy showed blood filled thoracic
cavity suggesting myocardial rupture as the cause of death.
The appearance of the surgical site is checked for signs of infection, undue
sutures, and seroma formation. When possible, infection, sutures, or seroma
formation is treated medically (antibiotics, if indicated) or surgically (replacing
sutures or percutaneous drainage, respectively). In rare cases in which infection
appears to have occurred, we consulted with DLAR veterinary for advise,
treatment and management. In cases where complications are felt to be causing
the animal significant distress, the animal is euthanized.
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2.3.3 Method of euthanasia
Mice were euthanized using high dose isoflurane followed by cervical
dislocation to confirm their euthanasia.
2.3.4 Flow cytometry
Peripheral

blood

diaminetetraaceticacid

tubes

containing

1:5

ratios

of

ethylene

(EDTA)/citrate-theophylline-adenosinedipyridamole

(CTAD) were used to collect blood samples at 1, 3 and 7 days after MI (4 MI mice
and 3 sham mice /treatment group). Whole blood was centrifuged at 700g for 5
minutes, and plasma layer was collected in separated tubes and kept at -80°C.
The remaining cell pack was incubated with 0.5 ml of 1X of red blood lysing buffer
(BD pharm lyse) for 10 minutes with gentle agitation for RBC lysis followed by
dilution using 0.5 ml of staining buffer (5% goat serum, 0.05% sodium azide in
phosphate-buffered saline) to stop the reaction. The suspension was centrifuged
at 400g for 5 minutes, and supernatant was discarded. This step was repeated if
we observed residual red blood cells. The white blood cell pellet was resuspended
in staining buffer, washed to remove any remaining lysis buffer, and centrifuged at
400g for 5 minutes. Cells from individual blood samples were split into two portions
for flow cytometry and reverse transcription-polymerase chain reaction (RT-PCR)
based on cell counts so that each sample contained ∼106 live (trypan bluenegative) cells. Cells for rtPCR were lysed using cell lysis buffer (Life technologies)
for 10 minutes with strong agitation and kept at -80°C for gene analyses. Cells for
staining were immediately incubated on ice for 30 minutes with conjugated primary
antibodies against FITC-conjugated Ly6G/C (BD Pharmingen), APC-CY7conjugated CD45 (Biolegend), PE-conjugated CD115 (Biolegend) for the
monocyte panel. After incubation, cells were washed twice using flow buffer and
analyzed using an LSR II (Becton Dickinson) in the University of Kentucky Flow
Cytometry

Core.

Monocytes

(CD45+/CD115hi/Ly6-Chi)

and

were

classified

anti-inflammaory

Neutrophils were identified as CD45+/CD115lo/Ly6G/Clo.
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as

pro-inflammatory

(CD45+/CD115hi/Ly6-Clo).

Heart tissue collected at the same time points was rapidly removed and
placed in ice cold PBS (VWR International). The heart was manually minced using
razor blades. Minced heart tissue was transferred into 15 ml tube with Collagenase
B (Roche, Indianapolis, IN) and Dispase II (Roche, Indianapolis, IN) solution for 30
minutes in 37°C water bath, with manual agitation every 5–10 minutes. Then, the
digestion reaction was terminated using cold staining buffer, and tubes were
placed in ice. The digestion mixture was filtered through 70 μm cell strainers and
centrifuged at 400g for 5 min at 4 0C, then the supernatant was aspirated and cells
were resuspended in 0.5 ml of staining buffer. Cells from individual hearts were
split into approximately three portions based on cell counting so that each sample
contained ∼106 live (trypan blue-negative) cells for flow cytometry and RT-PCR as
detailed above. Cells were incubated directly on ice for 30 minutes with conjugated
primary antibodies against FITC-conjugated Ly6G (BD Pharmingen), PEconjugated CD206 (Biolegend), PerCP-CY5.5-conjugated CD86 (Biolegend),
PECY7-conjugated

F4/80

(Biolegend),

and

APC-CY7-conjugated

CD45

(Biolegend) for the macrophage panel, or the monocyte panel detailed above. After
incubation, cells were washed twice using flow buffer and analyzed using an LSR
II (Becton Dickinson). Macrophages were classified into pro-inflammatory
(CD45+/Ly6G-/F4-80+/CD86+ cells) and ant-inflammatory (CD45+/Ly6G-/F480+/CD206+ cells). Laser calibration and compensation were carried out for every
experiment utilizing unstained and single fluorescent controls.
Using the same protocols mentioned earlier, cells isolated from hearts and
peripheral blood were incubated with APC-CY7-conjugated CD45 (Biolegend),
FITC-conjugated Ly6G (BD Pharmingen), APC-conjugated Annexin 5 (Biolegend)
and PE-conjugated propidium iodide (PI) (Biolegend) to identify apoptosis in
neutrophils. Cells were considered apoptotic if they were PIlo/Annexin Vhi. For flow
analyses in all experiments we utilized FlowJo (version 7) software to generate dot
plots and analyze the data.
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2.3.5 Histology
Mice (N = 12-15/treatment group) were sacrificed 30 days after MI and
hearts were collected in diastole by using saturated KCl and CdCl2 (100 mM) given
through the apex into the left ventricular (LV) cavity. Then we cannulated the
ascending aorta and perfused the heart with PBS (VWR International) followed by
10% buffered formalin (VWR International) at 75 mmHg. Hearts were placed in 5
ml of 10% neutral buffered formalin (VWR) and fixed overnight at room
temperature. Hearts were then sectioned into 2-mm cross-sectional slices followed
by paraffin embedding. Tissue was transferred to 70% ethanol for overnight
followed by sectioning into 4-μm sections starting at the level of LAD ligation.
Sections were then stained with Masson’s trichrome to evaluate scar size. Digital
images were taken, and areas were evaluated using NIH ImageJ (version 7). We
measured the LV area, LV cavity area, and infarct area in stained sections, as
previously described (Klyachkin, Nagareddy et al. 2015). The scar size was
presented as a percentage of LV myocardial volume.
2.3.6 Immunohistochemistry
Mice (N = 4/treatment group) were sacrificed 3 days after MI and hearts
were collected. Immunohistochemical assessments were carried out on
deparaffinized and rehydrated sections as previously described (Klyachkin,
Nagareddy et al. 2015). After deparaffinization and washing, slides were incubated
with primary antibodies: rat anti-mouse CD86 (1:100, BD Biosciences), goat antimouse CD206 (1:1000, R and D Systems), rabbit anti-mouse YM1 (1:25, Stem
Cell technologies), and goat anti-mouse IL-1β (1:200 R & D System) overnight at
4°C. After washing, sections were incubated with secondary antibodies conjugated
to Alexa Fluor 594,647 (1:500, Invitrogen, Carlsbad, CA), then incubated with
Sudan Black B (Sigma Aldrich, St. Louis, MO) for 30 minutes. and subsequently
incubated with DAPI nuclear counterstain. 10–15 adjacent areas in the pre-infarct
and remote zones per section were analyzed (1–2 sections/animal) at 40x
magnification using Nikon Confocal Microscope A1 in the University of Kentucky
Confocal Microscopy facility. Only nucleated antibody positive cells were counted.
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Calculations were performed using the Cell Counter plugin for ImageJ (version
1.51d). Data were presented as total positive cells per high power field in the region
of interest.
A similar protocol was used to prepare heart sections from mice on day 30
for angiogenesis assessment using FITC- isolectin B4 (FL1201, Vector Labs,
Burlingame, CA). 10–15 adjacent areas in the pre-infarct per section were
examined (1–2 sections/animal) at 40x magnification using Nikon Confocal
Microscope A1 in the University of Kentucky Confocal Microscopy facility. Data
were presented as total capillary density per mm2 in the peri-infarct region. All
measurements were analyzed by blinded observers.
To examine apoptosis in heart tissue, we used a TdT dUDP Nick-End
Labeling (TUNEL) Assay and Caspase-3 staining. Caspase 3 staining was done
in deparaffinized and rehydrated sections using antibody against cleaved caspase
3 as previously described (Klyachkin, Nagareddy et al. 2015). TUNEL staining was
performed in Biospecimen Procurement and Translational Pathology Shared
Resource Facility (BPTP SRF) at the University of Kentucky. Only nucleated
positive cells were counted in the peri-infarcted and infarcted areas. Calculations
were done using the Cell Counter plugin for ImageJ (version 1.51d). Data were
presented as total positive cells per high power field in the region of interest. All
measurements were analyzed by blinded observers.
2.3.7 Real-time polymerase chain reaction
We utilized PureLink RNA Mini Kit (ThermoFisher Scientific) to collect total
RNA from heart and blood cells according to the manufacturer’s protocol. The
extracted RNA was quantified using NanoDrop 8000 spectrophotometer
(Thermofisher). Then, cDNA was synthesized using SuperScript VILO cDNA
synthesis kit (Invitrogen). Quantitative RT-PCR was performed using a
QuantaStudio 7 Flex real-time thermocycler (Applied Biosystems by life
technology) to quantify the mRNA expression of markers identifying: inducible
nitric oxide synthases (iNOS), tumor necrosis factor alpha (TNF-α), monocyte
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chemotactic protein-1 (MCP-1), transforming growth factor beta (TGF-β),
interleukin-1 beta (IL-1β), interleukin-6 (IL-6), interleukin-4 (IL-4), chitinase-like3
Chil3 (YM1), Peroxisome proliferator-activated receptor gamma (PPARg). We
used the comparative Ct method for relative estimation of mRNA expression which
was normalized to 18s (a housekeeping gene). To overcome the possible errors
due to augmentation of contaminated DNA: (a) we used primers adjusted to bridge
an intron for specific cDNA augmentation; (b) we used proper negative control
reactions (template free controls); (c) we reassessed the consistency of product
augmentation through examination of the melting curve of augmented products
(dissociation graphs); and (d) the melting temperature (Tm) was 57°C–60°C, and
the probe Tm was at least 10°C more than the primer Tm. The primer sequences
are listed in S1 Table.
2.3.8 Echocardiography
We used a Vevo 3100 system supplied with a 15-7-MHz linear broadband
transducer and a 12-5-MHz phased array transducer to acquire Echocardiograms.
We assessed cardiac function at baseline (before cardiac surgery) then at 48 hours
after MI, and immediately before sacrifice at 30 days after MI. We utilized a heating
pad to keep the body temperature at 37°C during the experiment; the temperature
was measured using a rectal temperature probe. To determine the left ventricular
function and volume in M-mode, two-dimensional and Doppler echocardiography
modes we utilized modified parasternal long-axis and short-axis. We also used Mmode tracings at the mid-papillary level to estimate the systolic and diastolic
parameters, and Teichholz formula at end-systole and end-diastole to measure the
LV volumes. All mice were anaesthetized using 1%–3% isoflurane during
Echocardiography to maintain a heart rate of 450–500 BPM for all
echocardiographic acquisitions. Echocardiography imaging and analysis was
performed by a blinded investigator.
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2.3.9 Cell culture and hypoxic exposure
The murine macrophage cell line J774 (ATCC, Manassas, VA) was used
for the in vitro studies on the anti-inflammatory effects of AZM. Cells were plated
in 6 well plates at concentration 0.3×106 cells/well in media consisting of DMEM,
10% FBS, 1% penicillin/streptomycin, 1% sodium pyruvate, L-Glutamine, and
Glucose. Following cell adhesion (4–6 hours) cells were treated with AZM (SigmaAldrich, St. Louis, MO) at concentration 30 μM or DMSO (SIGMA-ALDRICH, St.
Louis, MO) as control and incubated over night at 37 C with 5% CO2. To induce
hypoxia-reperfusion injury, cultured cells were established in a gas-tight modular
chamber (STEMCELL Technologies Inc., Seattle, WA) containing 1% O2, 5%
CO2, 94% N2, or in normal oxygen tension with 20% O2, 5% CO2 as control for
24 hours at 37°C followed by reperfusion with 21% O2, 5% CO2 for 24 or 48 hours.
Supernatants were collected at the end of these time points to assess the
cytokines level and their ratio (TNF-α and IL-10).
2.3.10 ELISA assays
Protein concentrations of TNF-α and IL-10 are measured using standard
ELISA kits (BD Biosciences, San Deigo, CA) according to the manufacturer
protocol. Data are presented as individual cytokine values and their ratio.
2.3.11 Luminex assay
Plasma was collected according to the above mentioned protocols at days
3, and 7 post-MI. Inflammatory biomarkers (IL-12, IL-1β, IL-1α, IL-6, TNF-α, MCP1, MIP-1a and MIP-1b) were assayed using the Milliplex mouse cytokine magnetic
kit (MILLIPLEX MAP for Luminex xMap Technology, Millipore, USA) according to
the manufacturer’s protocol.
2.3.12 Liver and kidney function tests
Plasma was collected according to the above mentioned protocols at days
1, 3, and 7 post-MI. Samples were sent to ANTEC diagnostic to assay blood urea
nitrogen, alanine aminotransferase (ALT), albumin, and albumin/globulin ratio.
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2.3.13 Statistical analysis
Values are expressed as mean ± standard error of mean (SEM). We used
unpaired Student t test or analysis of variance (one-way or multiple comparisons)
to estimate differences, as appropriate. We utilized two-sided Dunnett or Dunn
tests for post hoc multiple comparison procedures, with control samples as the
control category. Throughout the analyses, a P value less than 0.05 was
considered statistically significant. All statistical analyses were performed using
the Prism 7 software package (GraphPad, La Jolla, CA).
2.4 Results
2.4.1 AZM shifts macrophages away from the pro-inflammatory towards the
reparative state post-MI
Macrophages are the predominant inflammatory cells type in cardiac tissue
after cardiac injury, regulating its healing at multiple phases. It is well established
that AZM can modulate inflammation through shifting macrophages towards the
reparative phenotype (Murphy, Sundareshan et al. 2008, Feola, Garvy et al. 2010,
Cory, Birket et al. 2014, Gensel, Kopper et al. 2017). To date, the effect of AZM on
the inflammatory response after MI at the level of macrophages has not been
characterized. We analyzed the phenotype of macrophages in cardiac tissue at
several time points following induction of MI using flow cytometry (Figure 2.1A).
We detected a significant reduction in the pro-inflammatory macrophages
(CD45+/Ly6G-/F4-80+/CD86+) at 1 day following MI with AZM treatment (Figure
2.1B). This effect was associated with a significant increase in the reparative
macrophages (CD45+/Ly6G-/F4-80+/CD206+) at day 1 and 3 after MI (Figure
2.1C). Overall, the ratio between pro- and anti-inflammatory macrophages was
reversed towards an anti-inflammatory state with AZM treatment, particularly in the
early phase after MI (Figure 2.1D).
Under physiological conditions, resident macrophages maintain tissue
homeostasis (Epelman, Liu et al. 2015). However, after injury such as MI,
monocytes infiltrate the heart and differentiate into macrophages. Monocytes
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contribute to tissue healing and repair through coordinated activities of different
monocyte subpopulations (Ly6Chi vs. Ly6Clo) (Nahrendorf, Swirski et al. 2007,
Swirski, Nahrendorf et al. 2009). We assessed monocyte subpopulations (Ly6Chi
vs. Ly6Clo) after MI in the PB and heart (Figure 2.2A). While we did not notice
significant differences between blood monocyte subsets in AZM vs. vehicle treated
mice, we detected a significant reduction in the Ly6Chi (pro-inflammatory)
monocytes (CD45+/Ly6C/Ghi/CD115hi) in cardiac tissue after MI with AZM
treatment (Figure 2.2B). There was no significant difference in the Ly6Clo (antiinflammatory) monocytes in cardiac tissue with AZM treatment. This suggests a
reduction in pro-inflammatory monocyte infiltration to the heart or a reduction in
their polarization in the myocardium. Since maintained Ly6Chi monocytes impair
healing after MI (Swirski, Nahrendorf et al. 2009), these results imply that AZM
treatment reduces detrimental inflammatory response following myocardial
ischemia.
2.4.2 AZM downregulates pro-inflammatory cytokines while upregulating
anti-inflammatory cytokines following cardiac injury
Macrophages have distinctive cytokine profiles based on their inflammatory
status. Pro-inflammatory macrophages are potent generators of toxic effector
molecules (reactive oxygen species, nitric oxide) and pro-inflammatory cytokines
(IL-1β, TNF-α, IL-6)(Martinez, Sica et al. 2008). Conversely, reparative
macrophages produce anti-inflammatory molecules (TGF-β and IL-10) and
express scavenger, mannose, and galactose-type receptors (Cynamon, Klemens
et al. 1992, Song, Ouyang et al. 2000). We conducted in vitro studies to examine
the effect of hypoxia/reperfusion injury on the phenotype of J774 macrophages in
the presence or absence of AZM. Following 24 hours hypoxia and reperfusion, we
noted significant shift in macrophage cytokine production towards a proinflammatory phenotype with higher TNF-α levels compared to IL-10 levels. AZM
treatment shifted the cytokine production towards an anti-inflammatory pattern with
significant increase in IL-10/TNF-α ratio (Figure 2.3). We also examined the effect
of AZM on cytokine expression following MI in the in vivo studies. Our data confirm
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the change towards the anti-inflammatory state with AZM treatment. In heart
tissue, AZM treatment was associated with significant reductions in the gene
expression of iNOS and inflammatory cytokines (MCP-1, TNF-α, IL-6, and IL-1β)
while the anti-inflammatory cytokines/macrophage modulatory factors (TGF-β and
IL-4, PPARγ and YM1) were increased (Figure 2.4A).
A similar trend was noted in the gene expression of pro- and antiinflammatory cytokines in PB cells at the same time points (Figure 2.4B). These
gene expression results are corroborated by IHC and ELISA studies of the heart
and plasma, respectively. Three days after MI, we quantified IL-1β and YM1 levels
in the peri-infarct zone. IL-1β was remarkably downregulated with a concomitant
elevation in YM1 in AZM treated mice compared to the control group (S2.2 Figure).
In plasma, levels of inflammatory cytokines (IL-12, IL-1β, IL-1α, IL-6, TNF-α, MCP1, MIP-1a and MIP-1b) were suppressed on days 3 and 7 post-MI as assessed by
the Luminex assay (S2.3 Figure). Overall, these results imply that AZM treatment
modulates the inflammatory response following myocardial ischemia by
attenuating

the

pro-inflammatory

changes

and

enhancing

anti-

inflammatory/reparative cytokine production.
2.4.3 AZM treatment is associated with alternative macrophages activation
in the peri-infarct region
The balance between pro- and anti-inflammatory macrophages in the periinfarct region plays an important role in infarct expansion and adverse cardiac
remodeling (Harel-Adar, Ben Mordechai et al. 2011, Ben-Mordechai, Palevski et
al. 2015, de Couto, Liu et al. 2015, Epelman, Liu et al. 2015). To evaluate the
impact of AZM on the activation state of macrophages in the peri-infarct region, we
quantified

pro-inflammatory

(CD86+)

and

anti-inflammatory

(CD206+)

macrophages 3 days post-MI using immunohistochemistry. Our results confirmed
the shift towards an anti-inflammatory state with AZM treatment. AZM-treated mice
had significantly lower numbers of CD86+ cells and higher numbers of CD206+
cells (Figure 2.5). Importantly, the pro-inflammatory/reparative macrophage ratio
was decreased robustly in the AZM treated compared to the vehicle group. Of note,
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macrophage inflammatory state is a spectrum from the pro- to the antiinflammatory phenotypes. Nonetheless, we used the same strategy for assessing
each population quantitatively to avoid any bias. We counted CD86 and CD206
separately and this could have led to double counting of cells in each category.
These findings are in agreement with our flow cytometry data and implicate a
potential therapeutic role for AZM in reducing post-MI cardiac inflammatory
changes.
2.4.4 AZM reduces neutrophil counts after cardiac ischemia through
enhancing apoptosis
In acute inflammation, neutrophils are key players in removing pathogens
and debris, thus contributing to the return of normal tissue homeostasis (Carbone,
Nencioni et al. 2013). Evolutionary mechanisms have developed to limit the initial
inflammatory response after MI. These pathways include a robust switch of
macrophages towards anti-inflammatory phenotype following ingestion of
apoptotic neutrophils (Serhan and Savill 2005). Indeed, prior studies have
implicated the ingestion of apoptotic cells as a mechanism for the antiinflammatory changes observed with AZM (Hodge, Hodge et al. 2006). While our
data as well as others have shown that AZM induces alternative polarization of
macrophages towards the anti-inflammatory state, the mechanism of these
changes is not entirely clear. We hypothesized that AZM promotes neutrophil
apoptosis which likely initiates the anti-inflammatory changes. In support of this
hypothesis, prior reports have confirmed the pro-apoptotic effects of macrolides on
neutrophils (Aoshiba, Nagai et al. 1995, Rapp 1998). We therefore analyzed
neutrophil numbers (CD45+/CD115lo/Ly6G/Clo) using the gating strategy outlined
in Fig 2A in the heart and PB via flow cytometry. Treatment with AZM resulted in
significant reductions of neutrophil counts in cardiac tissue and PB in the early
phase after MI (Figure 2.6A). To further investigate the mechanism associated
with neutrophil count reduction, we examined neutrophil apoptosis using Annexin
V and PI staining in cardiac tissue using flow cytometry. AZM treatment was
associated with a significant increase in the percentage of apoptotic neutrophils in
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the early inflammatory phase after MI compared to vehicle-treated mice (Figure
2.6B and 2.6C). Our findings indicate that AZM treatment reduces neutrophil
numbers after cardiac injury through pro-apoptotic effects, which could account for
its post-MI immunomodulatory effect.
2.4.5 AZM diminishes cardiac cell death and scar size while promoting
angiogenesis following cardiac ischemic injury
Alternatively activated macrophages are master regulators of the healing
process after MI by regulating cardiomyocyte apoptosis, collagen deposition, and
angiogenesis in the peri-infarct regions (Aurora, Porrello et al. 2014). To determine
the effect of AZM effects on programmed cell death in the heart post-MI, we
investigated cleaved caspase-3 positive staining of cells in the infarct zone, periinfarct border, and remote (normal) zones 3 days post-MI. We found that apoptosis
was significantly reduced within the infarct and border regions in the AZM-treated
group compared to vehicle-treated group (Figure 2.7). In order to confirm our
caspase 3 staining results, we performed TUNEL assay in the peri-infarct region.
The results were consistent with the caspase 3 assay (S2.4 Fig), suggesting
enhanced survival of cardiac cells, likely driven by AZM. These data corroborate
the immunohistochemistry and real-time PCR results, demonstrating significant
reduction in pro-apoptotic cytokines such as TNF-α. We then assessed the effect
of AZM therapy on the infarct size using morphometric assessments on Masson’s
trichrome-stained cross-sections from the hearts (30 days post-MI). We observed
significantly smaller scar size in mice treated with AZM compared to those treated
with vehicle (Figure 2.8A and 2.8B). These data indicate that AZM protects the
infarcted heart from the adverse cardiac remodeling that occurs chronically after
ischemia. Alternatively activated macrophages produce multiple cytokines
(including pro-angiogenic factors) that can enhance regeneration (Sunderkotter,
Goebeler et al. 1991, Song, Ouyang et al. 2000). Angiogenesis is regarded as a
major stimulator of tissue recovery in the heart after ischemic injury. To examine
the vessels density in the peri-infarcted areas between groups, we assessed
quantified isolectin (a marker of endothelial cells in blood vessels) 30 days
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following MI. Mice treated with AZM had significantly higher capillary density in the
peri-infarct region compared to vehicle-treated mice (Figure 2.8C and 2.8D).
Taken together with the results detailed in Fig 7, AZM treatment reduces scar size
after MI, which could be explained by the reduction in cellular apoptosis and
enhanced angiogenesis in the ischemic heart.
2.4.6 AZM preserves cardiac function, reduces adverse remodeling and
improves survival post-MI
Loss of balance between inflammatory and reparative phases post-MI can
result in adverse cardiac remodeling and eventually systolic HF (de Couto, Liu et
al. 2015). Our data suggest an immunomodulatory role for AZM on the heart postMI. To examine the translation of these cellular effects on cardiac function,
echocardiography was carried out on AZM and vehicle treated mice at baseline,
and 2 and 30 days after MI. We observed preservation of LV ejection fraction as
well as fractional shortening in AZM treated compared to vehicle mice (Figure
2.9A-9C). We also observed similar effects on parameters of LV remodeling such
as LV end-systolic and end-diastolic diameters (Figure 2.9D-9E). In agreement
with the noted reduction in scar size, we observed significantly less deterioration
in infarct wall thickness in AZM treated group compared to controls (Figure 2.9F).
Therefore, the beneficial effect of AZM extends beyond the enhancements in the
inflammatory balance after MI to a favorable recovery of LV functional and
remodeling parameters as summarized in S2.2 Table. Additionally, survival rates
reflect these AZM-mediated functional improvements with a marked reduction in
mortality in AZM-treated mice (Figure 2.9G).
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2.5. Discussion
Cardiac inflammation is a crucial component of the recovery phase after MI.
However, a tug-of-war between pro- and anti-inflammatory forces in the ischemic
myocardium impacts cardiac recovery. Reversing the pro-inflammatory forces
after MI can enhance cardiac recovery and survival. In this study, we provide first
evidence that the macrolide, AZM, exerts immunomodulatory effects on
macrophages after MI shifting them towards anti-inflammatory phenotype. This is
demonstrated by significant reduction in pro-/anti-inflammatory macrophage ratio
and pro-inflammatory genes expression in parallel with significant elevation in antiinflammatory gene expression. These immunomodulatory effects resulted in
reduced apoptosis and scar size, enhanced cardiac functional recovery, and
improved survival. Taken together, AZM represents a novel and clinically available
target for reducing cardiac inflammation and damage following MI.
The immunomodulatory effects of AZM after MI appear to be multifactorial
including direct effects on macrophages as well as pro-apoptotic effects on
neutrophils. It is well accepted that neutrophils play a critical role in tissue healing
following MI through debris clearance from the injury site (Ortega-Gomez, Perretti
et al. 2013). However, prolonged neutrophil accumulation in the heart post-MI is
considered deleterious (Chia, Nagurney et al. 2009, Guasti, Dentali et al. 2011).
On the other hand, aggressive neutrophil depletion following MI can disturb the
healing process, leading to impaired functional recovery (Horckmans, Ring et al.
2017). Clinical data suggest that a delay in neutrophil apoptosis after MI
contributes to the exaggerated inflammatory response (Garlichs, Eskafi et al.
2004). Here, we show that AZM enhances neutrophil apoptosis in cardiac tissue
after MI, which could explain the reduction in neutrophil counts in our studies. This
is in agreement with other reports in the literature that suggest a pro-apoptotic
effect of macrolides on neutrophils (Aoshiba, Nagai et al. 1995, Inamura, Ohta et
al. 2000). The pro-apoptotic effect of AZM is most noticeable on the first day after
MI. Importantly, studies have shown that AZM is more concentrated in
polymorphonuclear leukocytes, which will induce apoptosis in these cells through
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arresting cell cycle in G2/M (Ribeiro, Hurd et al. 2009). Engulfing apoptotic
neutrophils by macrophages stimulates the anti-inflammatory response through
blocking pro-inflammatory cytokines and enhancing anti-inflammatory cytokines
(IL-10 and TGF-β) and pro-resolving lipid mediators(Soehnlein and Lindbom
2010).
In addition to its effects on neutrophil apoptosis, AZM can have direct effects
on macrophages. Our in vitro results indicate that AZM therapy attenuates the
inflammatory changes seen in macrophages subjected to hypoxia/reperfusion
injury. In addition, induction of programmed cell death in neutrophils results in
decrease in the production of inflammatory cytokines and chemokines (Soehnlein,
Zernecke et al. 2008), as demonstrated in our study. Indeed, our experiments
show that AZM treatment decreased the expression of MCP-1 which promotes
Ly6Chi cells recruitment to the infarcted tissue. Ly6Chi monocytes differentiate into
pro-inflammatory macro phages in the peri-infarct border which eventually
contribute to adverse cardiac remodeling (Panizzi, Swirski et al. 2010).
Furthermore, through the reduction in neutrophil count and modulation of
macrophage phenotype, the production and deleterious effects of proinflammatory cytokines such as TNF-α, IL-1β, and IL-6 were diminished (Saini, Xu
et al. 2005). In parallel to the decreased pro-inflammatory cytokines, we observed
significant increase in anti-inflammatory cytokines such as TGF-β and IL-4 which
have been linked to favorable cardiac remodeling and functional recovery after MI
(Lambert, Lopez et al. 2008).
The immunomodulatory effects of AZM have been demonstrated in various
inflammatory and tissue injury scenarios (Zhang, Bailey et al. 2015, Gensel,
Kopper et al. 2017). Among them, acute stroke and spinal cord injury have close
resemblance to the inflammatory reactions (biphasic macrophage response and
chemokine profile) happening post-cardiac injury (Gensel and Zhang 2015,
Amantea, Certo et al. 2016). AZM treatment after spinal cord injury led to
significant decrease in pro-inflammatory macrophages and increase in antiinflammatory macrophages (Zhang, Bailey et al. 2015, Gensel, Kopper et al.
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2017). Interestingly, and in accordance with our data, the shift in macrophage
phenotype was associated with marked functional improvements in mice. The
exact molecular mechanisms through which AZM exerts its immunomodulatory
effects are not fully understood. However, transcription factors such as NF-kB and
AP-1 are likely targets (Kanoh and Rubin 2010) Our unpublished data suggest that
AZM reduces NF-kB activation through decreasing the translocation of phosphop65 to the nucleus. Furthermore, there is a simultaneous increase in IKKβ and
IκBα with AZM therapy. This does not exclude immunomodulatory actions
mediated through other intracellular signaling pathways (Kanoh and Rubin 2010).
Macrophages are essential players in the myocardial environment post-MI
and their role extends beyond the inflammatory phase to tissue regeneration and
healing (Godwin, Pinto et al. 2013, Petrie, Strand et al. 2014). The heart possesses
a remarkable regenerative capacity in the early stages of postnatal life, an ability
lost by day 7 after birth (Porrello, Mahmoud et al. 2011, Porrello, Mahmoud et al.
2013). It has been postulated that this regenerative capacity is related to the
naivety of the immune system in which macrophage modulation plays a central
role (Song, Ouyang et al. 2000). Indeed, anti-inflammatory macrophages have
been shown to interact with stem cells following cardiac injury leading to enhance
cardiac recovery (de Couto, Liu et al. 2015). Overall, AZM therapy is associated
with higher numbers of anti-inflammatory macrophages (CD206+ cells) after MI
with the majority of changes occurring in the peri-infarct region as shown in our
immunohistochemistry data. This phenotypic shift is associated with smaller scar,
better cardiac function, and enhanced angiogenesis after MI. Additionally, we
observed a significant reduction in apoptotic heart cells in both infarct and periinfarct areas at day 3 post-MI, which could be attributed to the survival factors
released from reparative macrophages (Lambert, Lopez et al. 2008, Murray, Allen
et al. 2014) . In summary, the early shift in macrophages towards the reparative
phenotype by AZM treatment can limit acute ischemic damage and promote
chronic cardiac recovery.
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The balance between macrophage phenotypes is reversible (BenMordechai, Palevski et al. 2015) and can be therapeutically harnessed to enhance
cardiac healing after ischemic injury. Animal studies show that early interventions
aimed at altering macrophage activation state or shifting the balance towards the
anti-inflammatory phenotype can substantially reduce the risk of HF development
(de Couto, Liu et al. 2015, Kain, Liu et al. 2017). Kain et al initiated a phenotypic
switch in macrophages after myocardial injury by using either free or encapsulated
15-epi-Lipoxin

A4.

They

demonstrated

upregulation

of

the

reparative

macrophages as well as the anti-inflammatory/macrophage modulatory genes
(Mrc-1, Ym-1, Arg-1). Moreover, cardiac function was improved in 15-epi-Lipoxin
A4 treated mice compared to controls (Kain, Liu et al. 2017). These findings were
confirmed in multiple studies using different therapeutic approaches, including
formyl peptide receptor 2 (Heo, Kwon et al. 2017), cardiosphere-derived cells(de
Couto, Liu et al. 2015), and endogenous Annexin-A1(Qin, Finlayson et al. 2017).
However, studies on alternative macrophage activation in MI utilized experimental
therapeutics with limited safety data in humans. Conversely, our strategy of using
AZM is more clinically relevant and can be safely translated to human studies.
Healing and remodeling after MI are fundamentally regulated by the
inflammatory pathways. Modulating the inflammatory response post-MI is an
elusive target as studies have shown that complete inhibition of inflammation is
rather harmful (Frangogiannis 2014). Indeed, therapeutic interventions targeting
the systemic inflammatory pathways have yielded limited success in pre-clinical
and clinical studies (Frangogiannis 2014). Delayed healing and development of
ventricular aneurysm were reported with glucocorticosteroids, and their uses
should be avoided post-MI (Bulkley and Roberts 1974). On the other hand,
NSAIDs use in coronary artery disease patients has been correlated with higher
mortality and recurrent myocardial infarction (Schjerning Olsen, Fosbol et al.
2011). Selective targeting of inflammatory mediators such as IL-1β using selective
monoclonal antibodies demonstrated success in clinical studies, albeit with high
cost and modest benefit (Seropian, Toldo et al. 2014). Therefore, strategies aimed
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at modulating the inflammatory response rather than its suppression provides
promising therapeutic modalities. In this study, we show that AZM as a small
immunoregulatory molecule provides more specific modulation to the post-MI
inflammation through increasing the abundance of anti-inflammatory macrophages
without completely blunting the pro-inflammatory mediators.
In this study, we initiated AZM 3 days prior to MI to ensure appropriate
steady-state levels at the time of injury (Feola, Garvy et al. 2010). Based on
published literature(Kanoh and Rubin 2010), we anticipate rapid accumulation of
AZM in macrophages and fast immunomodulatory actions. Hence, initiating AZM
following MI could be beneficial as well and this is currently being studied in our
lab. Another limitation in our study is the use of relatively higher dose of AZM
(160mg/kg/day) than the clinically prescribed dose (10-45mg/kg)(Zhang, Bailey et
al. 2015). As a proof of concept, we aimed to achieve a dose consistent with our
in vitro studies. However, multiple human studies have demonstrated AZM safety
at higher doses and its wide therapeutic window. Given the allometric scaling on
AZM, lower doses than those used in our study may be effective in humans (Rapp
1998, Petrie, Strand et al. 2014). Finally, we sought to examine the extremes of
macrophage polarization by quantifying the pro- and anti-inflammatory
macrophages based on gene expression and surface markers. While this is a
helpful approach for examining the effects of AZM, we acknowledge that it
oversimplifies the macrophage landscape and categorizes them into only two main
groups (pro- and anti-inflammatory) which may lead to overestimating either of the
categories(Nahrendorf and Swirski 2016). Future studies are warranted to provide
a comprehensive examination of the effect of AZM on the various macrophage
subtypes after MI.
Conclusions
Cardiac inflammatory changes following MI are mediated, at least in part,
by pro-inflammatory macrophages, which have detrimental effects on cardiac
function and survival. This is the first study to demonstrate the efficacy of AZM as
an immunomodulatory pharmacological agent for macrophages after MI. Our
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results indicate that the anti-inflammatory effects of AZM are related to its direct
effects on macrophages and its pro-apoptotic effects on neutrophils. Systematic
assessment of cardiac and systemic changes demonstrates that the beneficial
effects of AZM result in significant reduction in scar size, adverse cardiac
remodeling, cardiac function, and survival post cardiac ischemia. AZM has a wide
therapeutic window, can be administered orally, has low side effect profile and has
been approved for human use. These criteria make it an ideal agent for novel and
effective therapeutic interventions to improve survival and reduce HF following MI
in humans.
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Figure 2.1. AZM therapy shifts macrophages towards the anti-inflammatory
phenotype in the heart after myocardial infarction.
Experimental design for the in vivo study (Panel A). Representative FACS plots
demonstrating the gating strategy for pro-inflammatory (CD45+/Ly6G+/F4-80+/CD86+) and
anti-inflammatory (CD45+/Ly6G+/F4-80+/CD206+) macrophages (Panel B). Quantitative
analyses of pro-inflammatory subpopulations (CD86+) and anti-inflammatory
subpopulations (CD206+) are presented in Panels C and D, respectively, at different time
points following MI in AZM and vehicle treated groups. There is a significant reduction in
the inflammatory macrophages in the first day after MI in AZM-treated mice, which is
associated with a significant increase in anti-inflammatory ones. These changes translate
into a significant reduction in the pro-/anti-inflammatory (CD86+/ CD206+) ratio at days 1
and 3 after MI (Panel E) (n = 4 MI and 3 sham mice/group/time point, *P<0.05, **P<0.01
and ****P<0.001 compared to vehicle controls). Data presented as mean ± SEM. AZM,
azithromycin; IHC, immunohistochemistry; LAD, left anterior descending coronary artery;
rtPCR, real-time Polymerase Chain Reaction.
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Figure 2.2. AZM therapy reduces cardiac inflammatory monocytes after MI.
Representative
FACS
plots
demonstrating
the
gating
strategy
for
hi
+
hi
hi
lo
+
hi
lo
Ly6C (CD45 /CD115 /Ly6-C ) and Ly6C (CD45 /CD115 /Ly6-C ) monocytes (Panel
A). Quantitative analyses of monocyte subpopulations in PB and heart tissue
demonstrating no significant changes in PB monocyte subpopulations but significant
reduction in cardiac Ly6Chi population throughout the different time points after MI in AZM
treated mice (Panel B) (n = 4 MI and 3 sham mice/group/time point, *P<0.05 and **P<0.01
compared to vehicle controls). Data presented as mean ± SEM. AZM, azithromycin; PB,
peripheral blood.
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Figure 2.3. AZM therapy reduces the production of inflammatory cytokines in
macrophages subjected to ischemia/reperfusion injury.
Quantitative analyses of pro-inflammatory cytokine, TNF-α, and the anti-inflammatory
cytokine, IL-10, production from J774 macrophages subjected to 24 hypoxia followed by
24 and 48 hours of reperfusion. The analysis demonstrates reduction of TNF- α compared
to vehicle both at 24 and 48 hours. No significant changes were noted in IL-10 production.
Overall, the IL-10/TNF-α ratio was significantly higher in macrophages treated with AZM
(Panel B) (two independent experiments and 4 replicates/time point, *P<0.05, ***P<0.001
and **** P<0.0001 compared to vehicle controls). Data presented as mean ± SEM. AZM,
azithromycin; IL-10, interleukin 10; TNF-α, tumor necrosis factor-alpha.
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Figure 2.4. AZM treatment exerts immunomodulatory effects on cytokines
expression following MI.
mRNA expression of pro-inflammatory cytokines in HT (Panel A) and PB (Panel B),
demonstrate significant reduction in gene expression of these cytokines in the early
inflammatory phase following injury with AZM therapy compared to vehicle controls (red
line demarcates the level of gene expression in sham operated mice). The mRNA
expression of anti-inflammatory cytokines is augmented with AZM therapy compared to
vehicle control (n = 4 mice/group/time point, *P<0.05, **P<0.01, ***P<0.001 and ****
P<0.0001 compared to vehicle controls). Data presented as mean ± SEM. AZM,
azithromycin; HT, heart; IL-1β, interleukin 1 beta; IL-6, interleukin 6; IL-4, interleukin 4;
iNOS, inducible nitric oxide synthase; MCP-1, monocyte chemoattractant protein-1; PB,
peripheral blood; PPARγ, peroxisome proliferator-activated receptor gamma; TGF-1β,
tissue growth factor 1 beta; TNF-α, tumor necrosis factor-alpha; YM1 (Chil3), chitinaselike 3.
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Figure 2.5. AZM treatment enhances alternative macrophage activation in the periinfarct border of the injured heart.
Immunohistochemical assessment of the content of pro-inflammatory (CD86+) and
reparative macrophages (CD206+) markers 3 days post-MI. Panel A shows representative
images from vehicle- and AZM-treated mice demonstrating higher density of CD86+
compared to CD206+ cells in the peri-infarct border in vehicle-treated mice. White line
demarcates the infarct border. Panel B shows quantitative assessment of CD86+, CD206+
and the markers ratio 3 days post-MI. The difference in pro-inflammatory and antiinflammatory macrophages lead to a significant shift towards an anti-inflammatory state
and the reduction in their ratio in AZM-treated mice (n = 4 animals/group, *P<0.05 and
****P<0.0001 compared to vehicle controls). Scale bars represent 50 μm. Data presented
as mean ± SEM. AZM, azithromycin; HPF, high power field.
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Figure 2.6. Cardiac neutrophils are reduced with AZM treatment due to apoptosis.
Panel A summarizes the quantitative assessment of neutrophil (CD45 +/CD115lo/
Ly6G-Clo) numbers and demonstrates significant reduction in the AZM-treated group
relative to controls in the heart and peripheral blood during the early inflammatory
stage post-MI. Panel B illustrates the flow cytometry analyses of neutrophil populations
stained against annexin V and PI showing higher percentage of early apoptotic
neutrophils in AZM-treated mice. Panel C summarizes the quantitative assessment of
early apoptotic neutrophils and demonstrates significantly higher percentage in the heart
in the AZM-treated group during the early stage following MI (n = 4 mice/group/time
point, *P<0.05 compared to vehicle controls). Data presented as mean ± SEM. AZM,
azithromycin; HT, heart; PB, peripheral blood; PI, propodium Iodide.
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Figure 2.7. AZM reduces apoptosis post-infarction.
Panel A shows representative light microscope images of cleaved caspase-3 staining for
infarcted and border regions in AZM- and vehicle-treated mice 3 days after MI.
Quantitative analyses (Panel B) of apoptosis reveal a remarkable reduction in caspase-3
activation in the infarct and border regions of AZM-treated group compared to the control
group (n = 4 animals/group, **P<0.01 compared to vehicle controls). Scale bars represent
100 μm. Data presented as mean ± SEM. AZM, azithromycin; HPF, high power field.
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Figure 2.8. AZM treatment reduces scar size and enhances angiogenesis after
myocardial injury.
Representative Masson's trichrome staining at 30 days after myocardial injury in vehicleand AZM-treated groups (Panel A). Quantitative analysis of scars as percentage of LV
area shows significant reduction in AZM group relative to the control group (Panel B)
(vehicle-treated, n = 15 vs. AZM-treated, n = 12, **P<0.01 compared to vehicle controls).
Representative isolectin staining (Green) for capillary density in the peri-infarct region in
AZM- and vehicle-treated animals demonstrates higher capillary density in AZM group
compared to control (Panel C). Quantitative analysis of capillary density confirms the
higher angiogenesis rate and capillary density in AZM-treated group (Panel D) (n = 4
animals/group, **P<0.01 compared to vehicle controls). Scale bars represent 50 μm. Data
presented as mean ± SEM. AZM, azithromycin; MI, acute myocardial infarction; LV, left
ventricular.
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Figure 2.9. AZM treatment improves chronic cardiac remodeling and survival postMI.
30 day following MI, transthoracic echocardiography using M-Mode (Panel A) and 2D
echocardiography was performed on AZM- and vehicle-treated animals to evaluate left
ventricular function and remodeling parameters. Quantitative analyses demonstrate
significant recovery in LV function as assessed by ejection fraction (LVEF) (Panel B) and
fractional shortening (FS) (Panel C). Data also shows significant improvements in LV
adverse remodeling parameters such as end-systolic diameter (LVESD) (Panel D) and
end-diastolic diameter (LVEDD) (Panel E). Additionally, we observed significantly thicker
infarct walls suggesting of enhanced recovery and regeneration (Panel F). Survival curves
of AZM and vehicle-treated mice 30 days post-MI demonstrate a significant improvement
in survival with AZM treatment (Panel G). (Echo data: vehicle-treated, n = 15 vs. AZMtreated, n = 12; survival data: vehicle-treated, n = 48 and AZM-treated, n = 53; *P<0.05,
**P<0.01 and ****P<0.001 compared to vehicle control). Data presented as mean ± SEM.
AZM, azithromycin; MI, acute myocardial infarction.
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Supplemental Figure 2.1. AZM does not alter kidney or liver function with prolonged
use after myocardial infarction. The levels of plasma Albumin, Albumin/Globulin,
Blood Urea Nitrogen or ALT all these parameters were not significantly different between
vehicle and AZM-treated groups. (n=4/group/time point). ALT, alanine aminotransferase;
AZM, azithromycin.

85

Supplemental Figure 2.2. AZM treatment reduces IL-1β and increases YM1
expression in the peri-infarct border of the injured heart. Immunohistochemical
assessment of cells expressing IL-1β and YM1 3 days post-MI. Panel A shows
representative images from vehicle and AZM-treated mice demonstrating higher density
of IL-1β compared to YM1 in the peri-infarct border in vehicle-treated mice. Yellow arrows
point to positive cells. Panel B shows quantitative assessment of IL-1β and YM1 3-days
post-MI, which indicate significant reduction in IL-1β and elevation in YM1 positive cells.
(n=4 animals/group/time point, ****P<0.0001 compared to vehicle controls). Scale bars
represent 50 m. Data presented as mean ± SEM. AZM, azithromycin; HPF, high power
field; IL-1β, interleukin 1 beta; YM1 (Chil3), chitinase-like 3.
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Supplemental Figure 2.3. AZM therapy reduces the secreted inflammatory
cytokines. Quantitative analyses of cytokines (IL-12, IL-1β, IL-1α, IL-6, TNF-α, MCP-1,
MIP-1a and MIP-1b) in vehicle and AZM-treated mice. The analysis demonstrates
reduction of pro-inflammatory cytokines on days 3 and 7 post MI compared to vehicle.
(n=4 mice/group/time point, *P<0.05 and **P<0.01 compared to vehicle controls). Data
presented as mean ± SEM. AZM, azithromycin; IL-1, interleukin 1; IL-12, interleukin 12;
MCP-1, monocyte chemoattractant protein-1; MIP, Macrophage Inflammatory Proteins;
N.D., non-detectable; TNF-α, tumor necrosis factor-alpha.
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Supplemental Figure 2.4. AZM reduces apoptosis in the infarcted heart. Panel A
shows representative light microscope images of a TdT dUDP Nick-End Labeling Assay
(TUNEL) for the border regions in AZM and vehicle-treated mice 3 days after MI.
Quantitative analyses (Panel B) of apoptosis reveal a reduction in TUNEL positive cells
in the border regions of AZM-treated group compared to the control group (n=4 animals/
group, ****P<0.0001 compared to vehicle control). Scale bars represent 100 m. Data
presented as mean ± SEM. AZM, azithromycin.
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S2.1 Table. Forward and reverse primer sequence used in the experiments.

Prime
r

Forward

Reverse

18S

CCAGTGGTCTTGGTGTGCTG

GGAGAACTCACGGAGGACGA

i-NOS

CAGCTGGGCTGTACAAACCTT

CATTGGAAGTGAAGCGTTTCG

IL-6

CTTCCATCCAGTTGCCTTCTTG

AATTAAGCCTCCGACTTGTGA
AG

MCP1

CCCAATGAGTAGGCTGGAGA

TCTGGACCCATTCCTTCTTG

TNF-

TGGAACTGGCAGAAGAGG

AGACAGAAGAGCGTGGTG

IL-1

CAACCAACAAGTGATATTCTCCA
GATCCACACTCTCCAGCTGCA
TG

TGF-

CGGAGAGCCCTGGATACCACCT GCCGCACACAGCAGTTCTTCT
A
CT

IL-4

ACAGGAGAAGGGACGCCAT

PPAR


GAAGCCCTACAGACGAGCTC
A

GCCAGTTTCGATCCGTAGAA

AATCCTTGGCCCTCTGAGAT

Chil3
(YM1)

AGGCTTTGCGGTCCTGAT

CCAGCTGGTGAAGTAGCAGA
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S2.2 Table. Echocardiographic morphometric parameters at 30 days post-MI.

Primer

Vehicle

AZM

P value

Left ventricular
ejection fraction

27.97.4

46.84.9

0.04

Fractional
shortening

14.14

23.92.6

0.049

Left ventricular endsystolic diameter

4.60.4

3.30.2

0.02

Left ventricular enddiastolic diameter

5.30.3

4.30.2

0.01

Left ventricular endsystolic volume

108.821.7

48.410.5

0.02

Left ventricular enddiastolic volume

136.217.8

84.78.7

0.01

Infarct wall
thickness

0.780.09

1.10.07

0.02
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CHAPTER III. SPECIFIC AIM2
Liposomes

Enhance

the

Immunotherapeutic Efficacy of Azithromycin

in Myocardial Infarction and Reduces the Risk of Adverse Effects

3.1 Summary
Introduction: There is a growing body of evidence showing that altering
the inflammatory response by alternative macrophage polarization towards
the reparative phenotype is protective against acute ischemic injury and
improves cardiac functional recovery. Research shows that AZM, a macrolide
antibiotic, alters inflammation and polarizes macrophages to the alternatively
activated state in inflammatory conditions. We demonstrated that free AZM
treatment (160 mg/kg/day, orally), initiated 3 days pre-MI, enhances post-MI
cardiac recovery as a result of shifting macrophages to the reparatory state. Due
to the limited clinical translational perspective (pre-MI treatment and relatively
high dose of AZM) of our initial proof-of-concept study, we planned this study
using a liposomal formulation of AZM (Lazm) to achieve rapid onset of action
via targeted accumulation in inflammatory phagocytes. Based on our
preliminary studies with Lazm, we hypothesized that Low dose of liposomal
AZM (Lazm) treatment, started after MI, yields enhanced immunomodulatory
potential and cardiac recovery with low risk of adverse effects.
Methods and results: Low dose free and liposomal AZM (40 or 10 mg/kg, IV)
were administered immediately post-MI. We observed a significant shift
favoring anti-inflammatory/reparatory macrophages with both AZM
formulations (free and liposomal). A significant decrease in cardiac
inflammatory neutrophils with AZM treatment was paralleled with significant
reduction in the infiltration of inflammatory monocytes. Modulation of the
inflammatory cell response was associated with a significant reduction in proinflammatory and an equivalent increase in anti-
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inflammatory gene expression. Taken together, AZM treatment induced a systemic
shift in post-MI inflammatory response. AZM effects resulted in reduced cardiac
cell death and scar size, and enhanced angiogenesis. These protective effects let
to improvement of the functional/structural complications usually seen post-MI.
Importantly, the liposomal formulation of AZM was protective from its cardiac offtarget effects.
Conclusion: We demonstrate that AZM is a potent immunomodulatory agent for
the detrimental post-MI inflammatory response. Moreover, our studies are the first
to demonstrate that targeted AZM delivery using liposomal formulations achieves
more effective immunomodulatory effects with less cardiac side effects. To our
knowledge, this is the first evidence of the immune modulation properties of
liposomal AZM. Our findings strongly support clinical trials using AZM as a novel
and clinically relevant therapeutic target to improve cardiac recovery and reduce
heart failure post-MI in humans.
3.2 Introduction
Myocardial infarction (MI) remains a primary cause of morbidity and
mortality globally, albeit hospitalization rates reduced in the last 15 years (Spatz,
Beckman et al. 2016). Heart failure resulting from post-infarction remodeling is a
major driver of cardiac death (Lindsey, Saucerman et al. 2016, Spatz, Beckman et
al. 2016). Cardiomyocyte death and extracellular matrix (ECM) breakdown at the
area of cardiac injury induce a potent and poorly controlled inflammatory response
(Timmers, Pasterkamp et al. 2012), interfering with healing and scar formation
processes (Entman and Smith 1994, Frangogiannis, Youker et al. 1998, Mehta
and Li 1999). Innate immune cells such as neutrophils, monocytes, and
macrophages are key players in this response (Hulsmans, Sam et al. 2016). After
infarction, neutrophils are the first inflammatory cells to infiltrate the infarcted
myocardium (Reimer, Murry et al. 1989). While neutrophils play an important role
in removing dead cells and debris, their byproducts may exacerbate cardiac
damage (Reimer, Murry et al. 1989, Ortega-Gomez, Perretti et al. 2013). A recent
study reveals that there are two activation states of neutrophils in the post-ischemic
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heart: pro-inflammatory (N1) and anti-inflammatory (N2) neutrophils (Ma,
Yabluchanskiy et al. 2016). N1 neutrophils dominate the heart immediately after
infarction and contribute to the development of adverse cardiac remodeling and
heart failure, while N2 neutrophils increase gradually after MI and have cardioprotective effects (Ma, Yabluchanskiy et al. 2016). Additionally, neutrophils can
negatively impact post-MI healing through preferential recruitment of proinflammatory (Ly6Chi) (Soehnlein, Zernecke et al. 2008), rather than antiinflammatory monocytes (Ly6Clo) (Nahrendorf, Swirski et al. 2007).
Macrophages are essential in organizing the early post-MI inflammatory
and subsequent reparative phases. General classification of macrophages is into
pro-inflammatory/classically

activated/M1

and

anti-inflammatory/alternatively

activated/reparative/M2 macrophages based on gene profile and function
(Nahrendorf and Swirski 2016, Ma, Mouton et al. 2018). Pro-inflammatory
macrophages are dominant days 1-3 post-MI (Ma, Mouton et al. 2018) and
mediate the inflammatory process (Sica, Matsushima et al. 1990, Ma, Mouton et
al. 2018). Following this early inflammatory phase, on days 5-7, reparative
macrophages are the most prevalent and are characterized by high expression
levels of IL-10, IL-1Ra, and decoy type II receptors (Dinarello 2005, Yan, Anzai et
al. 2013, Ma, Mouton et al. 2018). Due to the production of these mediators, M2
macrophages play a central role in inflammation resolution and demonstrate robust
anti-inflammatory effects, potentially involved in tissue remodeling and
angiogenesis (Gombozhapova, Rogovskaya et al. 2017). There is a growing body
of evidence showing that repolarization of macrophages to the reparative
phenotype is protective against early development of ischemic lesion and its
subsequent cardiac remodeling (Schnoor, Cullen et al. 2008, Harel-Adar, Ben
Mordechai et al. 2011, de Couto, Liu et al. 2015, Kain, Liu et al. 2017, Qin,
Finlayson et al. 2017). Previous research from our lab demonstrates that
azithromycin (AZM), a commonly used antibiotic with immunomodulatory effects,
alters post-MI inflammation through repolarization of macrophages to a reparative
phenotype, which ultimately leads to increased protection against adverse cardiac
remodeling and heart failure (Al-Darraji, Haydar et al. 2018). However, these
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findings have limited clinical translation given the pre-MI treatment and relatively
high dose, which our non-targeted delivery of AZM dictated (Al-Darraji, Haydar et
al. 2018). It remains unclear whether low dose AZM immediately after cardiac
injury is effective in shifting macrophage phenotype or enhancing cardiac recovery
post-MI. The goal of this translational study is to demonstrate pre-clinical findings
showing the efficacy of AZM as immunotherapeutic agent in a clinically translatable
model of MI therapy.
Liposomes are formed of one or more phospholipid bilayers surrounded by
an aqueous core (Levchenko, Hartner et al. 2012), which can hold both lipophilic
and hydrophilic compounds. Given their biocompatibility and ease of use, they
rapidly became an attractive drug delivery system (Levchenko, Hartner et al.
2012). Research shows that liposomes reduce the ED50 of the cytotoxic drug,
doxorubicin, in preventing drug toxicity while promoting anti-tumor efficacy (Rose
2005). Doxorubicin liposomes reach steady state faster and with fewer doses due
to intensified localization at targeted organs (Charrois and Allen 2003).
Additionally, liposomes are highly effective carriers, achieving higher drug
concentration at sites of cardiac injury (Mueller, Marcus et al. 1981). Increased
cellular and vascular permeability in the injured myocardium enhances the specific
capacity of liposomes to deliver therapeutic agents to the site of injury (Takahama,
Minamino et al. 2009). Research shows that liposomes facilitate the local
distribution of tracers in infarcted myocardium (Caride, Twickler et al. 1984).
Additionally, post-infarction medium contains a large variety of diverse cell types,
which can be targeted to improve outcomes of the accumulated therapeutics
(Dasa, Suzuki et al. 2015) . Liposomal dosage forms are effective as a drug
delivery strategy for phagocyte-targeted therapy, producing lower immunogenic
reaction, higher biocompatibility and specificity, and greater drug stability. After
parenteral administration, liposomes are naturally taken up by mononuclear
phagocytes (Kelly, Jefferies et al. 2011). Liposomes can harness the physiological
function of these cells to mediate a targeted delivery and promote the therapeutic
efficacy of the agent (Kelly, Jefferies et al. 2011). Therefore, we designed this
study to overcome the limitations of our previous work and to improve outcomes
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of AZM cardioprotective therapy. Additionally, we expect the encapsulated dosage
form to reduce potential off-target effects of AZM. In this report we test the
hypothesis that low dose liposomal AZM (Lazm) treatment, started immediately
post-MI, yields an enhanced immunotherapeutic potential and cardiac recovery
with low risk of adverse effects.

3.3 Materials and methods
3.3.1 Study Design
C57BL/6 male mice (Jackson Laboratory, BarHarbor, ME), age 6-8 weeks,
were treated with one of two doses of liposomal or free AZM (10mg/kg/day or
40mg/kg/day) or vehicle (PBS or empty liposomes) using retro-orbital injection,
starting immediately after MI or sham surgery for 7 days (Fig 3.1A). The doses
used represent commonly prescribed comparable human dosages (Evans, Smith
et al. 2005, Evans, Rogers et al. 2011), as well as provide effective distribution and
tissue accumulation in animals (Shepard and Falkner 1990). Treatment continued
for 7 days to span the duration of the post-MI inflammatory period (Heidt, Courties
et al. 2014). All procedures were conducted under the approval of the University
of Kentucky IACUC in accordance with the NIH Guide for the Care and Use of
Laboratory Animals (DHHS publication No. [NIH] 85–23, rev. 1996).
3.3.2 Murine model of myocardial infarction
Anesthesia was induced through a small animal vaporizer system with 1–
3% isoflurane. Pain reflexes were appropriately tested to confirm adequate
anesthesia before and during the surgical procedure. Lateral thoracotomy between
the left fourth and fifth ribs was performed, the pericardial space was accessed,
and the heart protruded from the intercostal space. The left anterior descending
coronary artery (LAD) was identified and permanently ligated with 6–0 silk suture
3 mm distal to its origin, as previously described (Al-Darraji, Haydar et al. 2018).
Sham surgery consisted of the same procedure without LAD ligation. The heart
was immediately returned to the intrathoracic cavity and air manually evacuated to
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prevent pneumothorax. Finally, the muscle and skin were sutured using a 4–0
Prolene running suture.
3.3.3 Preparation of liposomes
Liposomal formulations were prepared according to previously established
protocol (Kierstead, Okochi et al. 2015), using the thin film hydration method with
equal

molar

ratios

of

distearyl

phosphatidylcholine

(DSPC),

distearyl

phosphatidylglycerol (DSPG) and cholesterol (Avanti polar lipids). AZM was
included at 10 and 30 mol% based on phospholipid content. Formulations
containing fluorophores were prepared in the same manner using 0.5 mol% of the
lipophilic dye with 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindodicarbocyanine (DiD).
Lipids and AZM were mixed in chloroform and methanol at the desired ratio and
the organic solvents removed by rotary evaporation to yield a thin film. After placing
under a vacuum overnight, the lipid/drug films were hydrated in phosphate buffered
saline (pH 7.4) and sonicated at 65°C for 30 min. The resulting unilamellar vesicles
were extruded through 200 nm polycarbonate membranes to obtain uniform
particle size. Liposome size, polydispersity and stability over time were determined
by dynamic light scatter testing.
3.3.4 Flow cytometry
3.3.4.1 Blood
Cell phenotype, in addition to gene profile, analyses of monocytes and
neutrophils were investigated in peripheral blood as previously described (AlDarraji, Haydar et al. 2018). Briefly, blood was collected in tubes with a 1:5 ratio of
ethylene

diaminetetraacetic

acid

(EDTA)/citrate-theophylline-

adenosinedipyridamole (CTAD) on days 1, 3 and 7 post-MI. Whole blood was
centrifuged for 5 minutes at 500 x g, and the plasma layer was separated and
reserved at -80°C. To lyse red blood cells, the residual cell pellet was incubated
with 0.5 ml of diluted red blood lysing buffer (BD pharm lyse) for 10 minutes with
mild agitation. To end the lysis process, 0.5 ml of staining buffer (5% goat serum,
0.05% sodium azide in phosphate-buffered saline) was added to the suspension
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of red blood cell lysed blood. Then, the suspension was centrifuged at 400 x g for
5 minutes, and the supernatant was removed. This step was repeated if the red
blood cells were still detectable in the cell pellet. White blood cell pellet was
washed twice in staining buffer to remove any residual lysis buffer. After
supernatant removal, the pellet was resuspended in a pre-determined volume of
staining buffer and counted. Cells of each blood sample were divided into two parts
depending on cell count to have ∼106 live (trypan blue-negative) cells in each part.
One portion was collected for surface marker staining, and the other part incubated
with cell lysis buffer (Life technologies) to lyse cells for 10 minutes with multiple
aggressive agitations, and then kept at -800C for further gene expression analysis.
Cells for staining were incubated immediately with conjugated primary antibodies
against PERCPCY5.5-conjugated Ly6G/C (BD Pharmingen), PECY7-conjugated
F4/80 (Biolegend), brilliant violet 421-conjugated CD11b (Biolegend), APC-CY7conjugated CD45 (Biolegend), and PE-conjugated CD115 (Biolegend) for 30
minutes on ice. Following incubation, cells were washed twice with staining buffer
and analyzed by an LSR II (Becton Dickinson) in the University of Kentucky Flow
Cytometry Core. Using unstained cells and single fluorescent controls, laser
calibration and compensations were performed for all experiments. We identified
monocytes with the CD45hi/CD115hi/Ly6-Chi profile as classical (pro-inflammatory),
and cells with the CD45hi/CD115hi/Ly6-Clo profile were identified as non-classical
(anti-inflammatory). Neutrophils were identified as CD45 hi/CD115 lo /Ly6-C/Glo.
3.3.4.2 Heart
Phenotypic cell analysis of macrophages and neutrophils and gene
expression analysis was conducted in the heart as previously described (AlDarraji, Haydar et al. 2018). Briefly, mice were sacrificed, and hearts were rapidly
isolated and placed in ice cold PBS (VWR International). Using a razor blade, the
heart was manually minced. After mincing, tissue was incubated with a
Collagenase B (Roche, Indianapolis, IN) and Dispase II (Roche, Indianapolis, IN)
mixture at 37°C for 30 minutes, with gentle agitation every 5-10 minutes. Tissue
digestion ceased using cold staining buffer and the suspension was placed on ice
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and filtered using a 70 μm cell strainer, followed by centrifugation at 400 x g for 5
mins at 4°C. Supernatant was discarded and the pellet was resuspended in 0.3 ml
of staining buffer. Individual heart cells were divided into approximately three equal
portions depending on cell count with ∼106 live (trypan blue-negative) cells in each.
Two portions were used for cell staining while the remainder was incubated with
cell lysis buffer (Life technologies) using multiple aggressive agitations, for 10
minutes and reserved at -800C for further gene expression analysis. Cells for flow
cytometry were incubated immediately with conjugated primary antibodies against
FITC-conjugated Ly6G (BD Pharmingen), PE-conjugated CD206 (Biolegend),
PECY7-conjugated F4/80 (Biolegend), brilliant violet 421-conjugated CD11b
(Biolegend), brilliant violet 510-conjugated CD11c (Biolegend), APC-CY7conjugated CD45 (Biolegend), or
Pharmingen),

PECY7-conjugated

PERCPCY5.5-conjugated Ly6G/C (BD
F4/80

(Biolegend),

brilliant

violet

421-

conjugated CD11b (Biolegend), APC-CY7-conjugated CD45 (Biolegend), and PEconjugated CD115 (Biolegend) for 30 minutes on ice. Cells were then washed
twice with staining buffer and analyzed by an LSR II (Becton Dickinson) in the
University of Kentucky Flow Cytometry Core. Using unstained cells and single
fluorescent controls, laser calibration and compensations were performed for all
experiments. CD45hi/Ly6Glo/F4-80hi cells were identified as macrophages and
further classified as pro-inflammatory or reparative based on the expression of
CD206 and CD11c. Neutrophils were defined as CD45

hi/

CD115

lo

/Ly6-C/Glo,

CD206 was used to further identify N1 neutrophils.
3.3.5 Histology
Histological analysis was performed on deparaffinized and rehydrated
sections as previously described (Al-Darraji, Haydar et al. 2018). Briefly, 30 day
post-MI mice (N = 6-10/treatment group) were sacrificed under isoflurane
anesthesia and hearts were isolated. Hearts were perfused first with PBS (VWR
International), then by 10% buffered formalin (VWR International). Perfused hearts
were placed in 10% neutral buffered formalin (VWR) overnight at room
temperature, then sectioned into 3-mm cross-sections starting at the level of
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coronary ligation then embedded in paraffin and sectioned into 4-μm sections.
Sections were stained with Masson’s trichrome to evaluate scar size as previously
described (Al-Darraji, Haydar et al. 2018). Digital images of stained sections were
acquired, and areas of interest were assessed using NIH ImageJ (version 7)
software. The LV area, LV cavity area, and infarct area were measured as
previously described (Al-Darraji, Haydar et al. 2018). Scar size was presented as
a percentage of the total LV volume.
3.3.6 Immunohistochemistry
Heart sections (N = 4/treatment group) were prepared as described in the
previous section. Immunostaining of heart sections was performed on
deparaffinized and rehydrated sections as previously described (Al-Darraji, Haydar
et al. 2018). Briefly, sections were incubated with primary antibodies: rabbit antimouse IBA1 (Wako), goat anti-mouse CD206 (R and D Systems), and/or goat antimouse IL-1β (R & D Systems) overnight at 4°C, then washed and incubated with
secondary antibodies conjugated to Alexa Fluor 488 or 594 (Invitrogen), followed
by incubation with DAPI. In the peri-infarct area, 10-15 adjacent zones per section
(1–2 sections/animal) were imaged at 40x magnification utilizing a Nikon Confocal
A1 Microscope in the University of Kentucky Confocal Microscopy facility.
Nucleated cells that were antibody-positive were quantified using Cell Counter
plugin for Nikon NIS-Elements (version AR 3.2). Findings are presented as total
number of positive cells per high power field in the area of interest.
By using a similar protocol to the above, heart sections (N=5-7/treatment
group) were prepared from mice sacrificed at day 30 post-MI. Sections were
stained with FITC-conjugated isolectin B4 (FL1201, Vector Labs, Burlingame, CA).
In the peri-infarct region, 10-15 adjacent zones per section (1–2 sections/animal)
were imaged at 40x magnification utilizing Nikon Confocal Microscope A1.
Quantification was performed using Cell Counter plugin for Nikon NIS-Elements
(version AR 3.2). Findings are presented as total capillary density per mm2 in the
peri-infarct zone. All measurements were performed in the peri-infarcted areas
only and analyzed by blinded observer.
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Cell apoptosis was examined on deparaffinized and rehydrated sections
from mice (N = 4/treatment group) sacrificed at day 3, as previously described (AlDarraji, Haydar et al. 2018). TUNEL and caspase-3 staining was performed in the
Biospecimen Procurement and Translational Pathology Shared Resource Facility
(BPTP SRF) at the University of Kentucky. Nucleated positively stained cells were
estimated. Quantification was performed using Cell Counter plugin for ImageJ
(version 1.51d). Findings are presented as total positive cells per high power field
in the peri-infract region. All measurements were obtained in the peri-infarcted
areas only and analyzed by blinded observer.
3.3.7 Reverse Transcription Polymerase Chain Reaction (RT-PCR).
PureLink RNA Mini Kit (ThermoFisher Scientific) was used to isolate total
mRNA from heart and blood cells according to manufacturer protocol. Isolated
RNA was quantified using a NanoDrop 8000 spectrophotometer (Thermofisher).
Next, cDNA was generated using the SuperScript VILO cDNA synthesis kit
(Invitrogen). Using a QuantaStudio 7 Flex real-time thermocycler (Applied
Biosystems by life technology), Reverse Transcription-Polymerase Chain
Reaction (RT-PCR) was performed to measure the mRNA expression of markers
identifying: inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha
(TNF-α), monocyte chemotactic protein-1 (MCP-1), transforming growth factor
beta (TGF-β), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), interleukin-4 (IL-4),
chitinase-like3 Chil3 (YM1), interleukin-10 (IL-10), arginase-1 (ARG-1), and
Peroxisome proliferator-activated receptor gamma (PPARg). We used the
comparative Ct method for relative estimation of mRNA expression, which was
normalized to 18s (a housekeeping gene). Certain strategies to avoid bias and
error inducible by contaminated DNA were taken: (a) primers were adjusted to
bridge an intron for specific cDNA augmentation, (b) appropriate negative control
reactions (template free controls) were used, (c) careful examination of the melting
curve of augmented products (dissociation graphs) for consistency was performed,
and (d) the probe Tm was at least 10°C more than the primer Tm , while the melting
temperature (Tm) was 57°C–60°C.
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3.3.8 Echocardiography
Mice were anaesthetized using 1–3% isoflurane during echocardiography
to maintain a heart rate of 450-500 BPM during imaging. A Vevo 3100 system
coupled with a 15-7-MHz linear broadband transducer and a 12-5-MHz phased
array transducer was used to perform echocardiogram analyses. Heart function
was examined at baseline (before cardiac surgery) and then remeasured at one
and 4 weeks post-MI. During acquisition, a heating pad was used to preserve the
body temperature at 37°C and the temperature was continuously assessed by
rectal temperature probe. Using modified parasternal long-axis and short-axis
probe placement, two-dimensional and Doppler echocardiography was used to
assess the LV function and volume in M-mode. Tracings at the mid-papillary level
were used to investigate the systolic and diastolic parameters and Teichholz
formula was applied to quantify LV function. Echocardiographic imaging and
analyses were carried out by a blinded investigator.
3.3.9 Luminex assay
At 1 and 3 days post-MI, plasma was collected using the PB collection
protocol detailed earlier. Inflammatory biomarkers (IL-12, IL-1β, IL-1α ITNF-α,
MIP-1, MIP-1α, MIP1β, MIP2, IP-10, G-CSF, RANTES, and KC) were quantified
using the Milliplex mouse cytokine magnetic kit (MILLIPLEX MAP for Luminex
xMap Technology, Millipore, USA) according to the manufacturer’s protocol.
3.2.10 Maestro in vivo fluorescence imaging
Mice were placed inside the Maestro imaging system under isoflurane anesthesia.
They were positioned so that the chest and abdomen of the animal were in the
field of view. We used an orange filter (excitation 605nm, emission 675nm long
pass) to capture the APC signal that comes from liposomes. Acquisition settings
were in range from 640 to 820nm in 10-nm steps. To enhance the quality of the
images we adjusted various variables like stage height, focus, and exposure
length, within time points. Images were taken with side-by-side Lazm and vehicle101

injected control animals and were analyzed using Maestro software (Cambridge
Research & Instrumentation, INC. (CRI), USA).
3.3.11 Cell culture
We used a murine macrophage cell line, J774 monocyte/macrophage cell
line

(ATCC,

Manassas,

VA),

for

in

vitro

experiments

examining

the

immunomodulatory effects of free and liposomal AZM. Using DMEM media
(supplemented with 10% FBS, 1% penicillin/streptomycin, 1% sodium pyruvate, LGlutamine, and Glucose), cells were plated in 6 well plates at a concentration of
0.3×106 cells/well. After adhesion, cells were treated with 30 μM free or liposomal
AZM (Sigma-Aldrich, St. Louis, MO) and 20 ng/ml IFNγ (eBioscience 14-8311-63)
diluted in DMEM. Following overnight incubation at 37°C with 5% CO2, cells were
stimulated using 100 ng/ml of LPS (Invivogen) diluted in DMEM. Supernatant was
collected 48 hours after stimulation to quantify pro- and anti-inflammatory cytokine
(TNF-α and IL-10) concentration.
3.3.12 ELISA assays
Levels of TNF-α and IL-10 were assessed in the supernatant from in vitro
cell culture experiments using standard ELISA kits (BD Biosciences, San Deigo,
CA) according to the manufacturer protocol. Results are presented for each
cytokine (picogram/ml) with different treatments.
3.3.13 Non-invasive electrocardiogram (ECG) system
Mice were anesthetized with 2% isoflurane, then placed on the ECG
platform. Electrodes were placed through the skin on the torsos followed by ECG
recording for 2-3 minutes. Once the recording was completed, the data were
analyzed using Chart software (PhysioTel).

102

3.3.14 Statistical Analysis
Data are presented as mean ± standard error of the mean (SEM). Unpaired
Student t test or analysis of variance (one-way or multiple comparisons) were used
for group comparisons, as appropriate. Two-sided Dunnett or Dunn tests for post
hoc multiple comparison procedures were used, with control samples as the
control category. P value less than 0.05 was considered statistically significant
during the analyses. Statistical analyses were performed using the Prism 8
software package (GraphPad, La Jolla, CA).
3.4 Results
3.4.1 Lazm formulation accumulates in the injured myocardium, particularly
in immune cells.
Several therapeutic agents have been tested to alleviate cardiac
remodeling post-MI through systemic administration; however, they suffer limited
efficacy due to poor bioavailability in the heart or dose-limiting adverse effects
(Dasa, Suzuki et al. 2015). The increased vascular permeability post-MI facilitates
the accumulation of nanocarriers such as liposomes in the injured myocardium
(Takahama, Minamino et al. 2009). In our studies, we elected to use nonPEGylated liposomes which are readily engulfed by phagocytes at sites of tissue
injury (Oh, Nix et al. 1995). First, we were interested in determining whether Lazm
accumulates in the injured heart after parenteral administration. We utilized a
Maestro EX in vivo imaging system in combination with APC-labeled liposomes for
visualization (Figure 3.1B). We found that Lazm accumulates in the injured heart
as early as the first day after infarct and peaks at day 3 after injury (Figure 3.1B).
The ex vivo imaging shows that these liposomes more likely accumulate in the
infarct and peri-infarct regions of the heart, which is consistent with geographic
accumulation of infiltrating phagocytes (Figure 3.1B). Importantly, no signal was
determined in the heart of sham-operated mice either in vivo or ex vivo.
Post-infarcted myocardium contains diverse cell populations that may be
targeted therapeutically to enhance cardiac recovery (Dasa, Suzuki et al. 2015).
Liposomal formulations have been extensively tested as targeted delivery tools for
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phagocytic cells, with lower immunogenicity, higher bioavailability and specificity,
and greater drug stability (Kelly, Jefferies et al. 2011). We examined liposomal
accumulation in the heart at a cellular level using flow cytometry. FACS analysis
of labeled Lazm shows that liposomes concentrate in phagocytes such as
neutrophils and macrophages beginning on day 1 post-MI. Importantly, less than
1% of non-immune cells in the heart show liposomal uptake, implying preferential
liposomal accumulation in our cells of interest (Figure 3.2). We confirmed these
observations using Celigo analyses, which show an enhanced liposomal
colocalization with phagocytic cells isolated from the heart after MI (Figure 3.3).
These findings strongly indicate that our designed non-PEGylated liposomes
accumulate at the peri-infarct region, particularly in phagocytic cells, early after MI.
Liposomal accumulation exhibits temporal trends consistent with infiltration of
inflammatory cells.
3.4.2 Liposomal formulation reduces the risk of AZM side effects.
Studies show that AZM produces a negative inotropic effect and delays
ventricular repolarization. These hemodynamic effects of AZM are likely mediated
by a Ca+2 channel-independent pathway and delayed rectifier K+ current (Ohara,
Nakamura et al. 2015). Additionally, the cardiac action potential is much shorter in
mice compared to humans (Perlman 2016). Therefore, we were interested in
examining the potential arrhythmogenic and hemodynamic effects of AZM in the
heart when administered post-MI. Baseline parameters do not differ among the
monitored groups. The retro-orbital administration of free AZM at 40mg/kg
remarkably reduces heart rate, RR, ejection fraction, and cardiac output interval
compared with baseline (Figure 3.4A and B). Moreover, we note that the QT
interval is also prolonged after free AZM administration (Figure 3.4C). In contrast,
administration of Lazm at the same dose does not induce any noticeable
conduction or electrical changes in vivo (Figure 3.4A, B, and C). These findings
imply that the liposomal dosage form of AZM is indeed protective against
hemodynamic drug modifications, which is most likely attributed to the specific
delivery of AZM to immune cells, avoiding cardiomyocytes. It is likely that
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encapsulation of AZM rescues other adverse drug effects as well, making it an
attractive method of delivery for clinical practice, especially in high risk patients.
3.4.3 Lazm therapy recruits reparative macrophages to the infarcted
myocardium.
Macrophages are the primary cardiac immune cells during steady state and
after ischemic injury, where they organize the ensuing inflammatory and healing
events (Hulsmans, Sam et al. 2016) ((Ben-Mordechai, Palevski et al. 2015). We
previously identified a cardioprotective role of oral free AZM in the setting of MI via
its immunomodulatory effects on macrophages in post-MI inflammation. However,
the pre-MI administration and high dose of AZM limit the clinical translation of this
study. Therefore, here we used an encapsulated dosage form in an attempt to
promote early cardiac bioavailability of AZM therapy. This is the first study to
examine the anti-inflammatory and immunomodulatory properties of liposomal
AZM, which may potentially expand to other inflammatory pathologies. First, we
find significantly lower heart weight in Lazm treated groups, suggestive of less
tissue edema and potentially less inflammatory change (Figure 3.5). In our
investigation of macrophage phenotype in the injured heart at multiple timepoints
after injury using flow cytometry (Figure 3.6), we observe a decrease in proinflammatory macrophages (CD45+/Ly6G-/F4-80+/CD11c+) at day 1 with a more
profound effect on day 3 post-MI in Lazm treated groups compared to free AZM
and control groups (Figure 3.6A). Conversely, reparative macrophages
(CD45+/Ly6G-/F4-80+/CD11c-/CD206+) significantly increase at day 3 in Lazm
treated groups compared to free AZM and control groups (Figure 3.6B).
Collectively, these changes translate into a significant reduction in the ratio of pro/anti-inflammatory macrophages in Lazm groups, indicating a shift in macrophage
phenotype towards the reparative state (Figure 3.6C).
Repolarizing macrophages towards the anti-inflammatory activation state in
peri-infarct zones can protect more cardiomyocytes from death, reducing infarct
expansion and the subsequent adverse cardiac remodeling (de Couto, Liu et al.
2015) (Ben-Mordechai, Palevski et al. 2015). To confirm the immunomodulatory
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effects of AZM on macrophages in the peri-infarct zone, we quantified cells
expressing a general macrophage marker (Iba1), a reparative macrophage marker
(CD206+), and IL-1β as a marker of pro-inflammatory macrophages on day 3 postMI using immunohistochemistry. We found a significant increase in reparative
(CD206+) macrophages in free and liposomal AZM treated mice compared to
control groups (Figure 3.7A). At the same time, we observe significantly higher
numbers of pro-inflammatory (Iba1+IL-1β+) macrophages in the control groups
(Figure 3.8A). Generally, the total number of macrophages (Iba1+ cells) were not
different between groups, implying that Lazm therapy does not affect total
macrophage count, but rather influences polarization in favor of the reparative
phenotype, and this effect is increased with liposomal AZM (Figure 3.7B). This
shift in alternatively activated macrophages in AZM treated groups is observed in
both our immunohistochemical and flow cytometric data. These effects may be
therapeutically harnessed to resolve the detrimental inflammation post-MI.
Monocytes dominate the infarcted heart following MI, providing a rich
source of macrophages (Zlatanova, Pinto et al. 2016). Recruitment of the two
subsets of monocytes (Ly6Chi and Ly6Clo) to the heart occurs in two waves: a first
wave of Ly6Chi and a subsequent wave of Ly6Clo. These subpopulations mediate
essential activities in early inflammation and the later reparative process (Swirski,
Nahrendorf et al. 2009) (Nahrendorf, Swirski et al. 2007). In the heart (Figure
3.9A), we find that the Ly6Chi (CD45+/Ly6C/Ghi/CD115hi) monocytes (proinflammatory) significantly decrease in the first day after injury in liposomal and
free AZM treated groups, an effect that disappears at later timepoints. In the blood
(Figure 3.9B), the Ly6Chi monocytes were considerably low on day 3 with
comparable numbers on other days in the Lazm groups. These observations
suggest that the liposomal and free AZM treatments can modulate other members
of the immune response to MI both locally in the heart and systemically.
3.4.4 Lazm treatment reduces neutrophils, particularly N1.
Neutrophils orchestrate the clearance of dead cells and debris (OrtegaGomez, Perretti et al. 2013). Additionally, apoptotic neutrophils initiate anti106

inflammatory changes in macrophages and hence contribute to the resolution of
inflammation

(Horckmans,

Ring

et

al.

2017).

Neutrophil

(CD45+/CD115lo/Ly6G/Clo) analysis in the heart and blood using flow cytometry
reveals that Lazm treatment significantly reduces neutrophil counts during their
peak at day 1 (Figure 3.10A). However, we did not see significant changes in mice
treated with free AZM.
To further investigate the immunomodulatory actions of AZM, we examined
the distribution of N1 neutrophils (CD11b+/Ly6G+/CD206-) in the heart over time.
We found a substantial decrease in N1 neutrophils at day 1 in Lazm treated groups
(Figure 3.10C), which may explain the reduction in total neutrophil number. These
findings may represent a novel therapeutic avenue in the treatment of MI patients
who experience prolonged neutrophilia after infarct.
3.4.5 Lazm treatment shifts inflammatory gene expression towards the antiinflammatory state.
The gene expression profile of macrophages relates to the activation status
of these cells. Pro-inflammatory macrophages produce large amounts of proinflammatory cytokines (IL-1β, TNF-α, IL-6) and toxic effector molecules (reactive
oxygen species, nitric oxide) (Martinez, Sica et al. 2008). On the other hand,
reparative macrophages are potent generators of anti-inflammatory cytokines
(TGF-β and IL-10) in addition to the expression of scavenger, mannose, and
galactose-type receptors (Song, Ouyang et al. 2000). To identify whether
liposomal formulation enhances the anti-inflammatory effects of AZM, we
conducted in vitro experiments to identify the production of pro-inflammatory/antiinflammatory cytokines in the J774 macrophage cell line. After 48 hours of
stimulation, we observed accentuated immunomodulatory effects with liposomal
AZM, confirmed through significant shift in the production of TNF-α and IL-10
towards the anti-inflammatory pattern (Figure 3.11).
We also assessed the mRNA expression of inflammatory and reparative
genes in the heart and blood cells using RT-PCR. We observed a significant shift
in the gene expression profile towards the anti-inflammatory state associated with
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liposomal/free AZM treatment. In cardiac tissue, mRNA levels of a proinflammatory macrophages (iNOS) and pro-inflammatory cytokines (MCP-1, TNFα, IL-6, and IL-1β) are substantially downregulated in mice treated with free and
liposomal AZM, particularly on days 1 and 3 post-infarct (Figure 3.12A).
Conversely, the expression of anti-inflammatory cytokines and reparative
macrophages (TGF-β and IL-10; IL-4, ARG, Fizz1, PPARγ and YM1) are
significantly upregulated in the same groups of mice with consistent effects up
through day 7 (Figure 3.12B). Interestingly, we observe a similar trend in the gene
expression of cytokine and macrophage markers in PB cells in the same groups
(Figure

3.12C

and

D),

suggesting

systemic

anti-inflammatory

and

immunomodulatory effects of Lazm therapy in addition to local effects at the site
of injury. Additionally, we observe that inflammatory cytokine and chemokine (IL12, IL-1β, IL-1α ITNF-α, MIP-1, MIP-1α, MIP1β, MIP2, IP-10, G-CSF, RANTES,
and KC) concentrations are reduced in plasma of AZM treated groups (Figure
3.13). Based on our prior published studies, we see no changes at day 7 so we
did not run that analysis. Collectively, these consistent results from multiple in vitro
and in vivo studies suggest that AZM may have therapeutic clinical potential in MI
patients.
3.4.6 Lazm therapy reduces cell death and scar size, and increases
angiogenesis in the infarcted heart.
To identify the pro-survival effect of AZM therapies on cardiac cells post-MI,
we assessed apoptosis in peri-infarct borders 3 days post-MI using caspase-3
(early apoptosis) and TUNEL (late apoptosis) assays. We observed that free and
liposomal AZM therapy markedly reduce apoptosis in comparison to controls
(Figure 3.14A and 3.15A respectively), likely related to pro-survival factors
produced by reparative macrophages (Aurora, Porrello et al. 2014). We next
assessed the infarct size 30 days post-MI using Masson’s trichrome-stained
sections from the heart. We found that Lazm treatment significantly reduced scar
size in comparison to controls (Figure 3.16). These data indicate that AZM
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preserves the heart from acute injury after ischemia as well as reduces
susceptibility to chronic scar enlargement.
Reparative macrophages, through secretion of protective cytokines and
pro-angiogenic factors such as VEGF, may promote reparative power (Aurora,
Porrello et al. 2014). To determine blood vessel density at the infarct borders, we
quantified isolectin-positive cells (a marker for endothelial cells) in the peri-infarct
region 30 days post-MI. We observed a significant increase in density of newly
formed blood vessels in the Lazm groups compared to controls (Figure 3.17). This
is another important factor in AZM/Lazm therapy that may contribute to reduced
scar size. The- shift in macrophage phenotype may explain the reduction in
apoptotic cells and enhanced angiogenesis and provide the mechanism for
reduced scar size observed in these groups.
3.4.7 Lazm therapy enhances cardiac functional recovery after MI.
Adverse cardiac remodeling and the ensuing heart failure post-MI are likely
related to an imbalance between pro-inflammatory and pro-reparative phases after
injury (de Couto, Liu et al. 2015). By modulating the inflammatory response, we
investigated the role of AZM in cardiac recovery after MI. We performed
echocardiography at 1- and 4-weeks post-MI and analyzed cardiac function and
remodeling. We observed a significant attenuation of LV functional decline in Lazm
treated groups compared to controls (Figure 3.18A). We noted a similar trend in
other cardiac remodeling parameters such as LV end-systolic and LV end-diastolic
diameters in the same groups (Figure 3.18B and C). Finally, survival rates indicate
that the cardioprotective effects of free/liposomal AZM translated into a remarkable
reduction in mortality (Figure 3.19).
Collectively, the immunomodulatory effects of Lazm therapy were potent at
inducing favorable resolution of the overactive and/or extended pro-inflammatory
cascades and their associated cardiac damage and impaired recovery. As a result,
we found significant improvement in the structural/functional complications postMI.
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3.5 Discussion
Macrophages are the primary immune cells in the heart post-MI, organizing
the early inflammatory stage and the later reparative events. The two activation
states of macrophages (pro-inflammatory vs. reparatory) make them an attractive
therapeutic target to induce earlier resolution of post-MI inflammation. We recently
found that azithromycin (AZM) improves cardiac remodeling and recovery post-MI
through a shift in macrophages to the reparatory state using a proof-of-concept
experimental model. In this study, we utilized a clinically relevant experimental
design using targeted liposomal AZM delivery to potentiate its bioavailability and
immunomodulatory effects post-MI. Lazm enhanced resolution of post-MI
inflammation as evidenced by a shift of pro-inflammatory to reparatory
monocytes/macrophages. Neutrophils were substantially decreased as well,
particularly the pro-inflammatory N1 neutrophils. These observed cellular changes
occurred primarily at the site of cardiac injury and were paralleled by a shift towards
anti-inflammatory cytokine production and cellular preservation, leading to reduced
scar size, enhanced angiogenesis, and improved cardiac functional recovery. In
addition to these findings, we observed that the liposomal formulation is protective
from adverse drug effects such as conduction abnormality. These findings imply
that post-MI treatment with low dose Lazm is a promising therapeutic target in
patients with MI.
Several therapeutic agents have been tested to alleviate cardiac
remodeling post-MI through systemic administration, however; they had limited
efficacy due to poor accumulation in the target site/cells, incompatible
pharmacokinetic properties with MI, or dose-limiting adverse effects (Dasa, Suzuki
et al. 2015). As a result, an optimal drug delivery system capable of favorably
accumulating therapeutic agents in the injured myocardium while upholding a
reservoir that is not intensely processed by other non-targets (Dasa, Suzuki et al.
2015) is urgently needed. In the present work, in vivo imaging and flow cytometric
analyses confirm that liposomes accumulate preferentially in the peri-infarct and
infarct regions post-MI beginning in the first 24 hours after infarct, indicating
specific localization to the damaged myocardium. Flow cytometric analysis
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investigating the accumulation of liposomes in cardiac cells indicates that
liposomes concentrate in immune cells, with less than 1% of non-immune cells
testing positive for liposomes. This distribution strongly suggests that liposomes
increase the on-target effects (enhanced efficacy), as well as reduce the off-target
effects (less potential of adverse effects). Indeed, our in vivo electrophysiological
monitoring of the heart confirmed the observed reduction of conduction
abnormalities with Lazm formulation compared to free AZM. By using nonPEGylated liposomes, inflammatory cells phagocytize Lazm in the leaky
vasculature of the infarcted myocardium. However, more studies are needed to
further refine drug delivery and release in the setting of MI.
We previously demonstrated the immunomodulatory effectiveness of AZM
as a potential therapy for cardioprotection after ischemic injury (Al-Darraji, Haydar
et al. 2018). In this earlier proof-of-concept study, pre-MI treatment provided time
for the drug to reach steady levels before MI induction (Feola, Garvy et al. 2010).
We also used a relatively high dose of AZM (160 mg/kg/day), consistent with
previous animal studies (Feola, Garvy et al. 2010, Zhang, Bailey et al. 2015). We
are currently working with our collaborators to prepare a biotinylated form of AZM
for both in vivo and in vitro experiments to enable its quantitative tracking in cells
and tissue using different encapsulation strategies. However, AZM administration
may be related to cardiac conduction and hemodynamic changes. Therefore, we
stopped pursuit of a long-term follow up study with free AZM due to profound
adverse effects (Fig 3.4).
To avoid these translational barriers and warrant post-MI low dose AZM, we
considered an encapsulated dosage form of AZM, which may enhance the
immunomodulatory efficacy and facilitate faster mode of action of drugs as
previously shown with other compounds (Cynamon, Klemens et al. 1992, Oh, Nix
et al. 1995). Our data confirm enhanced pharmacological effects with low dose of
Lazm compared to free AZM. Furthermore, our studies reveal that liposomal
formulation is protective against adverse effects of free AZM such as the observed
reduction in heart performance, presumably by reducing the uptake of AZM in nonimmune cells in the heart.
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It is widely accepted that neutrophils are the first immune cells to infiltrate
the infarcted heart and their extended existence is associated with exacerbation of
cardiac injury after ischemia. We showed in our first study that neutrophil counts
substantially decrease in mice receiving AZM, due to enhanced apoptosis (AlDarraji, Haydar et al. 2018). Recently, research shows that there are two activation
states of neutrophils in the ischemic heart: early pro-inflammatory (N1) and late
anti-inflammatory (N2) (Ma, Yabluchanskiy et al. 2016). Interestingly, PB
neutrophils are CD206-, becoming CD206+ in the heart, which indicates the
plasticity of neutrophils and their ability to change in response to the surrounding
microenvironment. Here, we observed that N1 neutrophils significantly decrease
with Lazm therapy, perhaps attributable to the apoptotic effects of AZM or reduced
neutrophil recruitment due to suppressed production of chemokines such as
Macrophage Inflammatory Protein (MIP) and Keratinocyte Chemoattractant (KC).
It is possible that removal of apoptotic cells from the injured myocardium is an
essential cellular mechanism to resolve inflammation by shifting macrophage
phenotype (Huynh, Fadok et al. 2002, Nathan and Ding 2010). Additionally, we
observed a significant reduction in cardiac Ly6Chi monocytes with liposomal and
free AZM, suggesting a possible mechanism for the reduced number of proinflammatory macrophages. This phenomenon is most likely related to the
diminished expression of MCP-1 in the heart and blood.
The post-MI healing phase is primarily organized by reparative
macrophages (Ma, Mouton et al. 2018). This could explain the attenuated cardiac
recovery with macrophage depletion and the improved outcomes with adoptive
transfer of alternatively activated macrophages (Leor, Rozen et al. 2006, van
Amerongen, Harmsen et al. 2007). Furthermore, multiple studies demonstrated
the therapeutic utility of shifting macrophages to the reparative phenotype post-MI
(Weirather, Hofmann et al. 2014, ter Horst, Hakimzadeh et al. 2015). We found
that liposomal and free AZM treatment were associated with higher antiinflammatory (Iba1+CD206+ cells) and lower pro-inflammatory (Iba1+IL-1β+)
macrophages after MI in peri-infarct regions. Additionally, we observed a
significant reduction in apoptosis at day 3 post-MI in the same regions, possibly
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attributable to pro-survival factors released from reparative macrophages (Lenardo
and Baltimore 1989, Lakshminarayanan, Beno et al. 1997). These data confirm
our observations and analysis in flow cytometry and inflammatory mediators.
Changes in post-MI inflammation translate into smaller scar, better cardiac
function, and more newly formed blood vessels after MI. Collectively, we observed
a global trend with both AZM and Lazm in shifting immune cells to the antiinflammatory state.
Immune cell modulation was associated with significant downregulation in
the inflammatory genes, and upregulation in the anti-inflammatory genes.
Inflammatory cytokines IL-1β, TNF-α, IL-6, and MCP-1, as well as M1
macrophages marker, iNOS, were markedly reduced in the early time points postMI. These changes could explain the reduced infiltration of inflammatory cells into
the heart. As an example, MCP-1 drives mobilization of Ly6Chi monocytes to the
heart after infarction where they differentiate into M1 macrophages. Furthermore,
reduction of MCP-1 promotes alternative activation of macrophages (Carbone,
Nencioni et al. 2013). Moreover, IL-1β promotes generation of chemotactic
mediators inducing myocardial injury via increased recruitment of immune cells to
the heart (Bujak and Frangogiannis 2009). Recent, data shows that targeting IL1β with the monoclonal antibody, canakinumab, significantly decreases
cardiovascular event reoccurrence (Ridker, Everett et al. 2017). In agreement, we
observed a robust decrease in the expression of IL-1β, which contributes to the
improvement of outcomes in this study, at least partially.
Simultaneously, anti-inflammatory genes such as TGF-β, IL-4, and IL-10,
as well as M2 macrophage markers FIZZ1, YM1, PPAR-ɣ, and ARG are
upregulated by free and liposomal AZM treatments. These mediators have been
shown to exert multiple beneficial functions in the myocardium following MI. IL-10
modifies monocyte-macrophage function, morphology, and phenotype. Secretion
of IL-1α, IL-1β, TNF-α, IL-6, and IL-8 is inhibited by IL-10 in activated monocytes
(Frangogiannis 2012). Furthermore, IL-10 could participate in matrix remodeling
via enhancement of tissue inhibitor of metallopeptidase 1 (TIMP-1) synthesis, thus
stabilizing the ECM (Lacraz, Nicod et al. 1995, Frangogiannis 2012). TGF-β is an
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essential regulator of both the transition from inflammation to healing and
organized scar formation (Bujak and Frangogiannis 2007). Through activation of
endothelial mononuclear cells, TGF-β inhibits production of various proinflammatory cytokines and chemokines (Frangogiannis 2012). Additionally, TGFβ stimulates fibroblasts to produce ECM proteins (collagen, fibronectin, tenascin,
and proteoglycans) (Bassols and Massague 1988). Moreover, TGF-β reduces the
expression of proteinases (plasminogen activator and collagenase) and enhances
the production of proteinase inhibitors (plasminogen activator inhibitor and TIMP1), suppressing matrix breakdown and helping scar maturation (Laiho, Saksela et
al. 1986, Frangogiannis 2012). We noticed increased expression of IL-10 and
TGF-β with free and liposomal AZM therapy, which may explain the reduction in
heart failure and mortality observed in our study. Interestingly, changes in proinflammatory and anti-inflammatory genes are consistent between heart and
peripheral blood, suggesting a systemic effect moderating the severity of post-MI
inflammation. This feature is also important from a clinical prospective since it
provides a more feasible way to monitor the pharmacological effects of AZM.
Conclusion
The present study is the first to demonstrate the immunomodulatory
properties of liposomal AZM, which has wide therapeutic applications beyond the
cardiovascular field. It is expected that liposomal AZM will be beneficial as a carrier
and anti-inflammatory drug in other sterile inflammatory diseases that share a
similar inflammatory profile with MI, such as ischemic stroke and spinal cord injury
(Zhang, Bailey et al. 2015, Amantea, Certo et al. 2016). Immunomodulatory effects
of AZM are time-and dose-dependent and are enhanced by improving the
pharmacokinetics and pharmacodynamics of the drug through liposomal
formulation. We note that low dose Lazm, started after MI, effectively resolves
post-MI inflammation and improves adverse cardiac remodeling with lower risk of
adverse effects. Interestingly, we observe also that the liposomal encapsulation is
truly protective from the potential unwanted effects of AZM, which is of utmost
importance to clinical application. The facts that AZM is a widely prescribed
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antibiotic and liposomes are effective drug delivery systems for multiple
therapeutic agents promotes rapid clinical translation of our findings. Finally,
researchers can harness the method of preparing liposomes used in this studyto
deliver other therapeutic agents to the injured myocardium. Our findings strongly
support clinical trials using AZM as a novel and clinically relevant therapy to
improve cardiac recovery and reduce heart failure post-MI in humans.
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Figure 3.1. Experimental design and targeting myocardium with labeled Lazm after
infarction.
(A) Experimental design for the in vivo study. (B) Imaging system images of mice (in vivo)
injected with labeled Lazm 1, 2, 3, and 6 days after infarction. Hearts were collected 24
hours after injection and imaged (ex vivo). Images show that Lazm liposomes are
accumulated in the heart starting the first day after infarction, an effect persisting during
the time of follow-up (6 days). No signal was determined from the heart of the mouse with
sham surgery either in vivo or ex vivo. The ex vivo imaging show s that liposomes are
preferably accumulated in the infarct and peri-infarct regions of the heart (red arrow). (C)
Represents quantitative assessments of signal intensity emitted from the infarcted heart
day 1, 2, 3, and 6 after infarction in comparison to the control (CON) (a mouse injected
with vehicle), which shows a marked increase in the intensity of the signal during all time
points. Lip, labeled liposomal azithromycin.
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Figure 3.2. Targeting immune cells with labeled Lazm after infarction.
FACS analysis with labeled Lazm at days 1 and 3 post-MI shows liposomes are
accumulated in cardiac immune cells after IP or IV administration, with more significant
effect after IV administration. Data suggests that Lazm liposomes begin to concentrate in
the immune cells on day 1 post-MI using IV but not IP route. No significant accumulation
was noted in non-immune cells (N = 3 animals/group/timepoint, *P<0.05, **P<0.01, and
***P<0.001, and ****P<0.0001 compared to sham). Data presented as mean ± SEM. IV,
intravenous; IP, intraperitoneal; Lazm, liposomal azithromycin; Macs, macrophages;
Control, mice did not receive liposomes.
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Figure 3.3. Liposomes co-localize with cardiac macrophages.
Representative images from Celigo of heart cells of Lazm- treated mice show spatial
localization of macrophages (orange) and liposomes (purple). Images show a remarkable
localization of macrophages with liposomes. Lazm, liposomal azithromycin.
In this experiment, a similar protocol to flow cytometry was used to prepare cell
suspension; however, Celigo was used instead of flow cytometry to identify co-localization
of different cell populations with liposomes (N=3 mice).
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Figure 3.4. Hemodynamic Effects of free and liposomal AZM.
Changes in heat rate (Panel A), RR interval (Panel B), QT interval (Panel C), ejection
fraction (Panel D), and cardiac output (Panel E) after retro-orbital administration of
various doses of Lazm or free AZM. Data shows that the liposomal formulation of AZM
is protective against hemodynamic changes induced by free AZM. (N=3, **P<0.01 and
*** P<0.001 compared to baseline of the corresponding group). Data presented as
mean ± SEM. AZM, azithromycin; Lazm, liposomal azithromycin.
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Figure 3.5. Lazm therapy rescues heart and spleen from inflammatory induced
hypertrophy.
Quantitative assessment of spleen (Panel A) and heart (Panel B) as a percent of
body weight suggests that Lazm therapy is protective against heart and spleen
enlargement after infarction, indicative of less potent inflammation. (n = 4
animals/group/timepoint, *P<0.05 and **P<0.01 compared to the vehicle control).
Data presented as mean ± SEM. AZM, azithromycin; Lazm, liposomal azithromycin;
HT, heart.
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Figure 3.6. Lazm treatment shifts macrophages to the reparatory phenotype in the
injured myocardium.
Immunomodulation of macrophages by Lazm in heart tissue post-MI. FACS analyses
of the relative expression of macrophage markers to assess their activation state in
vehicle, free AZM, and Lazm treated groups. Quantitative data suggests that
inflammatory (F4/80+/CD11c+) macrophages markedly decrease in Lazm treated
groups relative to controls starting at day1, with a more profound effect on day 3 postMI (Panel A). In contrast, the reparatory macrophages (CD206+) increase significantly
at day 3 post-MI in the same groups of mice (Panel B). The immunomodulatory effects
translate into a substantial reduction in the pro-/anti-inflammatory (CD11c+/ CD206+)
ratio at all tested timepoints post-MI (Panel C). Less powerful immunomodulatory
changes were noted with free AZM treatments. (N = 4 animals/group/timepoint,
**P<0.01, ***P<0.001, and ****P<0.0001 compared to the vehicle control). Data
presented as mean ± SEM. AZM, azithromycin; Lazm, liposomal azithromycin; Ht,
heart.
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Figure 3.7. Lazm shifts macrophages towards the anti-inflammatory phenotype
Immunohistochemical assessment of general and reparative macrophages (IBA1+ and
CD206+, respectively) 3 days post-MI. Panel A shows representative images from
controls, free AZM, and Lazm treated mice illustrating IBA1 (green) and CD206 (red)
positive macrophages in peri-infarct zones. Images show increased expression of CD206
by macrophages in free and liposomal AZM treated groups compared to controls. Panel
B represents quantitative assessment of IBA1and CD206 3-days post-MI (n = 4
animals/group, ***P<0.001 and ****P<0.0001 compared to vehicle control). Scale bars
represent 50 μm. Data presented as mean ± SEM.
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Figure 3.8. Lazm reduces pro-inflammatory macrophages in the ischemic heart.
Immunohistochemical assessment of a general macrophage marker (IBA1) co-localized
with a pro-inflammatory cytokine (IL-1β) 3 days post-MI. Panel A shows representative
images from controls, free AZM, and Lazm treated mice illustrating IBA-1 (green) and IL1β (red) positive macrophages in peri-infarct zones. Images indicate a marked reduction
in the expression of IL-1β in macrophages with free and liposomal AZM treatments
compared to controls. Panel B represents quantitative assessment of IBA-1 and IL-1β 3days post-MI (n = 4 animals/group, *P<0.05 **P<0.01, and ****P<0.0001 compared to
vehicle control). Scale bars represent 50 μm. Data presented as mean ± SEM.
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Figure 3.9. Lazm reduces inflammatory monocytes after infarct.
Immunomodulation of monocytes by free and liposomal AZM in Ht and blood post-MI.
FACS analyses for the relative expression of Ly6C to assess monocyte activation state
in controls, free AZM, and Lazm treated groups of mice. Quantitative data indicate that
inflammatory monocytes (Ly6CHi) markedly decrease in liposomal and free AZM treated
mice, with a more powerful effect in Lazm groups (PanelA). Very little change was noted
in the blood (Panel B). (N = 4 animals/group/time point, **P<0.01, ***P<0.001, and
****P<0.0001 compared to vehicle control). Data presented as mean ± SEM. AZM,
azithromycin; Lazm, liposomal azithromycin; Ht, heart.
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Figure 3.10. Lazm treatment reduces neutrophil counts, in particular N1 neutrophils.
FACS analyses suggest that neutrophil counts are significantly decreased in the Ht
(Panel A), specifically N1 (CD11b+Ly6G+CD206-) neutrophils in Lazm treated mice
on day 1 post-MI (Panel C). No changes in neutrophils were noted with free AZM
treatment. Neutrophils were reduced on day 7 in Lazm groups in blood (Panel C) (N =
4 animals/group/time point, **P<0.01 and ***P<0.001 compared to vehicle control).
Data presented as mean ± SEM. AZM, azithromycin; Lazm, liposomal azithromycin;
Ht, heart; PB, peripheral blood.
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Figure 3.11. Liposomal azithromycin produces a more significant shift in macrophage
response towards the anti-inflammatory state.
This figure shows quantitative analyses of pro-inflammatory cytokine, TNF-α, and antiinflammatory cytokine, IL-10, production from J774 macrophages subjected to LPS
stimulation for 48 hours. The analyses demonstrate a more significant reduction of
TNF- α with Lazm compared to free AZM at 48 hours post-MI. Moreover, IL-10
production is additionally enhanced with Lazm. Treatment (two independent
experiments and 4 replicates/time point, ***P<0.001 and **** P<0.0001 compared to
free AZM). Data presented as mean ± SEM. AZM, azithromycin; Lazm, liposomal
azithromycin; IL-10, interleukin 10; TNF-α, tumor necrosis factor-alpha.
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Figure 3.12A. Lazm modulates pro- and anti-inflammatory cytokine expression.
Heart homogenate (Ht) cells were used to quantify pro-inflammatory cytokine secretion
via RT-PCR. Pro-inflammatory cytokine expression, including iNOS, TNF-α, MCP-1,
IL-1β and IL-6c(A). Data shows significant reduction in inflammatory cytokines at days
1 and 3 with Lazm treatment in Ht (n = 4 animals/group/time point, *P<0.05, **P<0.01,
***P<0.001, and ****P<0.0001 compared to the vehicle control). Fold change relative
to sham control. Data presented as mean ± SEM. AZM, azithromycin; Lazm, liposomal
azithromycin; Ht, heart; IL-1β, interleukin 1 beta; IL-6, interleukin 6; iNOS, inducible
nitric oxide synthase; MCP-1, monocyte chemoattractant protein-1; TNF-α, tumor
necrosis factor-alpha.
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Figure 3.12B. Lazm modulates pro- and anti-inflammatory cytokine expression.
Heart homogenate (HT) cells were used to quantify anti-inflammatory cytokine
secretion via RT-PCR. Anti-inflammatory IL-10, TGF-β, Fizz1, and YM1, ARG, PPARg,
IL-4 expression (B). Data shows significant increase in anti-inflammatory cytokines on
days 1, 3 and, 7 with Lazm treatment in HT (n = 4 animals/group/time point, *P<0.05,
**P<0.01 , ***P<0.001, and ****P<0.0001 compared to the vehicle control). Fold change
relative to sham control. Data presented as mean ± SEM. AZM, azithromycin; Lazm,
liposomal azithromycin; HT, heart; IL-4, interleukin 4; ARG, arginase; Fizz1, found in
inflammatory zone 1; PPARγ, peroxisome proliferator-activated receptor gamma; TGF1β, tissue growth factor 1 beta; YM1 (Chil3), chitinase-like 3; IL-10, interleukin-10.
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Figure 3.12C. Lazm modulates pro- and anti-inflammatory cytokine expression.
Peripheral blood cells were used to quantify pro-inflammatory cytokine secretion via
RT-PCR. Pro-inflammatory cytokine expression, including TNF-α, MCP-1, IL-1β and
IL-6(C). Data show significant reduction in inflammatory cytokines at days 1 and 3, and
7 with Lazm treatment in blood (n = 4 animals/group/time point, *P<0.05, **P<0.01,
***P<0.001, and ****P<0.0001 compared to the vehicle control). Fold change relative
to sham control. Data presented as mean ± SEM. AZM, azithromycin; Lazm, liposomal
azithromycin; HT, heart; IL-1β, interleukin 1 beta; IL-6, interleukin 6; MCP-1, monocyte
chemoattractant protein-1; PB, peripheral blood; TNF-α, tumor necrosis factor-alpha.
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Figure 3.12D. Lazm modulates pro- and anti-inflammatory cytokines expression.
Peripheral blood cells were used to quantify anti-inflammatory cytokine secretion via
RT-PCR. Anti-inflammatory TGF-β, Fizz1, and YM1 expression (D). Data show
significant increase in anti-inflammatory cytokines in days 1, 3 and, 7 with Lazm
treatment in blood (n = 4 animals/group/time point, *P<0.05, **P<0.01, ***P<0.001, and
****P<0.0001 compared to the vehicle control). Fold change relative to sham control.
Data presented as mean ± SEM. AZM, azithromycin; Lazm, liposomal azithromycin;
HT, heart; IL-4, interleukin 4; Fizz1, found in inflammatory zone 1; PB; TGF-1β, tissue
growth factor 1 beta; YM1 (Chil3), chitinase-like 3.
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Figure 3.13. Lazm modulates pro-inflammatory cytokine and chemokine production.
Plasma quantification of pro-inflammatory cytokine and chemokine secretion via Luminex
assay. Data shows significant reduction in inflammatory cytokines and chemokines at
days 1 and 3 with Lazm therapy (n = 4 animals/group/time point, *P<0.05, **P<0.01,
***P<0.001, and ****P<0.0001 compared to the vehicle control). Data presented as mean
± SEM. AZM, azithromycin; Lazm, liposomal azithromycin; IL-1, interleukin 1; TNF-α,
tumor necrosis factor-alpha; RANTES, regulated on activation, normal T cell expressed
and secreted; Il-12, interleukin 12; MIP, macrophage inflammatory protein; KC,
Keratinocyte chemoattractant; IP, Inducible protein; LIX, Lipopolysaccharide-induced
CXC chemokine ; G-MCSF, Granulocyte-Macrophage Colony-Stimulating Factor.
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Figure 3.14. AZM reduces apoptosis in the heart post-infarction.
Panel A shows representative light microscope images of TUNEL staining of periinfarct regions in controls, free AZM, and Lazm treated mice 3 days post-MI. Panel B
represents quantitative analysis of apoptosis which reveals a remarkable reduction of
TUNEL positive cells in free and liposomal AZM treated groups compared to the vehicle
control group (n = 4 animals/group, **P<0.01 and ***P<0.001 compared to vehicle
control). Scale bars represent 100 μm. Data presented as mean ± SEM. AZM,
azithromycin; Lazm, liposomal azithromycin
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Figure 3.15. AZM reduces apoptosis in the heart post-infarct.
Panel A shows representative light microscope images of caspase-3 staining for periinfarct regions in controls, free AZM, and Lazm treated mice 3 days post-MI. Panel B
represents quantitative analyses of apoptosis which reveal a remarkable reduction of
caspase-3 positive cells in free and liposomal AZM treated groups compared to the
vehicle control group (n = 4 animals/group, **P<0.01 and ****P<0.0001 compared to
vehicle control). Scale bars represent 100 μm. Data presented as mean ± SEM. AZM,
azithromycin; Lazm, liposomal azithromycin.
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Figure 3.16. Lazm therapy reduces scar size after infarct.
Panel A shows representative Masson's trichrome staining at 30 days post-MI in
control, free AZM, and Lazm treated groups, indicating a marked reduction in scar size
with liposomal and free AZM. Panel B represents quantitative analysis of scar as a
percentage of LV area, which shows significant reduction in liposomal and free AZM
treated groups relative to the vehicle control group (n = 6-10 animals/group, **P<0.01,
***P<0.001 and ****P<0.0001 compared to the vehicle control). Scale bars represent
1000 μm. Data presented as mean ± SEM. AZM, azithromycin; Lazm, liposomal
azithromycin.
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Figure 3.17. Lazm therapy promotes angiogenesis after infarct.
Panel A shows representative isolectin staining (Green) at 30 days post-MI for capillary
density in the peri-infarct region in control, free AZM, and Lazm treated animals. This
data demonstrates higher capillary density in Lazm groups compared to vehicle control.
Panel B is quantitative analysis of capillary density, which confirms a higher rate of
angiogenesis and capillary density in Lazm treated groups (n = 5-10 animals/group,
****P<0.0001 compared to the vehicle control). Scale bars represent 50 μm. Data
presented as mean ± SEM. AZM, azithromycin; Lazm, liposomal azithromycin.
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Figure 3.18. Lazm therapy improves adverse cardiac remodeling.
30 days following MI, echocardiography was performed on control, free AZM, and Lazm
treated animals to evaluate left ventricular function and remodeling parameters.
Quantitative analyses demonstrate significant recovery in LV function as assessed by
ejection fraction (LVEF) (Panel A), which significantly improved in Lazm groups. Data
also show significant improvements in LV adverse remodeling parameters such as endsystolic diameter (LVESD) (Panel B) and end-diastolic diameter (LVEDD) (Panel C). (n
= 6-10 animals/group, *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001 compared to
the vehicle control). Data presented as mean ± SEM. AZM, azithromycin; Lazm,
liposomal azithromycin.
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Figure 3.19. AZM therapies enhance survival.
Survival curves of free/liposomal AZM and vehicle-treated mice 35 days post-MI
demonstrate a marked improvement in survival with Lazm and low-dose free AZM
treatment. Mortality in 40 mg/kg IV AZM group occurs during the drug administration due
to severe changes in cardiac conduction and hemodynamic parameters. While mice in
other groups died of cardiac rupture, a common complication after MI surgery. (vehicle
group, n =34, 40 mg/kg IV AZM group, n=33, 40 mg/kg Lazm group, n=35, 10 mg/kg Lazm
group, n=31, 10 mg/kg IV AZM, n=35). AZM, azithromycin; Lazm, liposomal azithromycin.
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CHAPTER IV. General discussion
4.1 Summary
The purpose of the work in this dissertation is to determine the role of
azithromycin (AZM) as an immunomodulatory therapeutic agent in reducing the
inflammatory response and related adverse cardiac remodeling after infarction.
The ultimate goal of our research is to provide a clinically translatable approach
with rapid onset of action and low off-target effects by using a liposomal
formulation. To achieve our goals, we adopted a comprehensive approach utilizing
various in vivo and in vitro models to examine the effects of free and liposomal
encapsulation formulations of AZM in an established murine MI model.
First,

we

sought

to

investigate

the

efficiency

of

AZM

as

an

immunomodulatory and anti-inflammatory drug in switching macrophage
phenotypes towards the reparative state, and thus, alleviating the exaggerated
post-MI inflammation. These studies are based on a growing body of evidence
showing that altering the inflammatory response by repolarizing macrophages to
the reparative phenotype is protective against acute ischemic injury and improves
cardiac recovery. Research has shown that AZM, a macrolide antibiotic, alters
inflammation and polarizes macrophages to the alternatively activated state in
inflammatory conditions. Therefore, we hypothesized that AZM therapy reduces
cardiac inflammation and mitigates adverse cardiac remodeling after MI. We
treated mice with either AZM (160 mg/kg/day, oral) or vehicle, starting 3 days prior
to MI. We selected the timing of AZM therapy to ensure appropriate steady state
levels at the time of injury. We found that AZM treatment significantly decreased
inflammatory macrophages while increasing reparative ones. Neutrophils also
decreased with AZM treatment via enhanced apoptosis. Furthermore, AZM
treatment significantly reduced infiltration of inflammatory monocytes to the heart,
while anti-inflammatory monocytes were increased. Immune cell modulation was
associated with significant downregulation of pro-inflammatory genes, and
upregulation of anti-inflammatory genes. Taken together, AZM treatment resulted
in a systemic and local shift in the post-MI inflammatory response. The
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immunomodulatory effects of AZM translated into reduced cardiac cell death and
scar size, and enhanced angiogenesis. Finally, these protective effects led to
improved cardiac functional recovery and reduced adverse remodeling (Figure
4.1).
Due to limited clinical translational perspective (pre-MI treatment and
relatively high dose of AZM) of our initial proof-of-concept study, we executed a
follow-up study using a liposomal formulation of AZM (Lazm) to achieve rapid
onset of action via targeted accumulation in the damaged myocardium. Liposomes
are a valuable tool in producing a faster mode of action since they extensively
localize in the injured myocardium and are specifically taken up by phagocytes.
Furthermore, liposomal formulation is an efficient tool to enhance on-target and
reduce off-target effects. Based on our preliminary studies with Lazm, we
hypothesized that low dose of liposomal AZM (Lazm) treatment, started after MI,
yields enhanced immunomodulatory potential and cardiac recovery with low risk
of adverse effects. Therefore, we treated mice with low doses of encapsulated
AZM immediately after infarction. We observed that Lazm induces early resolution
of the post-MI inflammatory response as evidenced by switching of the activation
state of monocytes/macrophages towards the reparatory phenotype. Neutrophils
were substantially decreased, particularly pro-inflammatory neutrophils. Cytokine
profiles also shifted to the anti-inflammatory status with Lazm therapy.
Inflammation-resolving effects of Lazm were associated with reduced apoptosis in
the injured heart, as well as improved scar size, angiogenesis, and LV function in
our long-term studies. These findings imply that low dose, post-MI treatment with
Lazm improves outcomes post-MI through early resolution of inflammation and
initiation of the repair phase (Figure 4.1). Besides the immunomodulatory effects
of Lazm, we observed that encapsulation of AZM substantially reduces the risk of
off-target effects as well.
This work is early evidence demonstrating the efficacy of free and liposomal
AZM as an immunomodulatory pharmacological agent after MI. Our results
indicate that the anti-inflammatory effects of AZM relate to its direct effects on
immune cells, which lead to alleviation of post-MI inflammation. Assessments of
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cardiac and systemic changes demonstrate that the beneficial effects of AZM
result in significant improvements in scar size, adverse cardiac remodeling, cardiac
function, and survival post cardiac ischemia. Additionally, this is the first study
demonstrating the immune modulation properties of liposomal AZM, which have
potential wide therapeutic applications beyond the cardiovascular field. In addition,
this work is the first to demonstrate that liposomal encapsulation is significantly
protective from adverse drug effects such as hemodynamic changes, which are
previously unexamined. These data introduce a novel and clinically relevant
immunomodulatory therapy for ischemic heart and other sterile inflammatory
diseases. AZM has a wide therapeutic window, allows oral administration, has a
low side effect profile, and has clinical approval in humans. These criteria make it
an ideal candidate for drug repurposing to improve survival and reduce heart
failure following MI in humans.
4.2 Inflammation after infarction
Coronary artery occlusion of prolonged duration results in a time-dependent
increase in cardiomyocyte death, particularly in the peri-infarct zones of the injured
myocardium, and thus, restoration of blood flow plays a crucial role in
cardiomyocyte protection and prevention of further deterioration in heart function
(Lucchesi, Werns et al. 1989). With progression of cardiomyocyte death and tissue
degradation, there is increased activity of the complement system, production of
chemotactic factors, and a pro-inflammatory cytokine storm. All these events
mediate propagation of post-MI inflammation, which is an essential element to
replace the nonfunctional injured myocardium with scar of fibrotic nature to
maintain the integrity of the heart (Romson, Hook et al. 1983). Following the initial
heightened inflammatory response, a phase characterized by inflammation
resolution starts. This phase includes removal of damaged tissue and dead cells,
inhibition of inflammatory mediators, activation of healing mechanisms, and
induction matrix turnover (Frangogiannis 2012). However, the detrimental effects
of the initial inflammatory phase may persist (days) even when inflammation has
been resolved (Lucchesi, Werns et al. 1989).
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Data from clinical studies suggests that elevated levels of inflammatory cells
and chemokines in MI patients increase the likelihood of developing impaired
cardiac recovery and poor clinical outcome on long-term follow up. The profound
recruitment of inflammatory cells to the ischemic heart forms the background to
conclude that post-MI inflammation contributes to further infarct expansion after
the initial insult (Frangogiannis 2014). Moreover, prolonged presence of proinflammatory macrophages (M1) in the damaged myocardium may result in infarct
expansion (ter Horst, Hakimzadeh et al. 2015). Indeed, high numbers of
inflammatory cells in the heart negatively relate to the degree of myocardial
salvage (Maekawa, Anzai et al. 2002, Tsujioka, Imanishi et al. 2009). Therefore,
timely resolution of inflammation is critical in infarct expansion prevention and
reduction of adverse cardiac remodeling. We note that AZM mediates an earlier
resolution of post-MI inflammation and enhanced healing, as demonstrated by
phenotypic cell analyses of immune cells and gene expression of inflammatory
mediators, inducing better protection against post-MI complications.
4.2.1 Anti-inflammatory therapies in MI
The major contributing mechanism to the pathophysiology of MI is the
inflammatory response (Frangogiannis 2014). The inflammatory pathways
primarily regulate heart healing and remodeling after infarction. Literature suggests
that the involvement of the inflammatory response in the pathogenesis of cardiac
remodeling may include the following mechanisms: a) damaged matrix proteins
via cytokine-induced MMP activation diminish tensile strength of the injured
myocardium, accompanied with slippage of myocytes and loss of stimuli that
supports cardiomyocyte function; b) a prolonged uncontrolled inflammatory
reaction could activate apoptosis in surviving cardiomyocytes, forming new
jeopardized regions (Frangogiannis 2014). Therefore, therapeutic interventions
targeting

inflammation

represent

attractive

strategies

after

infarction

(Frangogiannis 2014). However, multiple clinical trials fail to demonstrate the
effectiveness of traditional anti-inflammatory drugs such as corticosteroids,
cyclosporine, and non-steroidal anti-inflammatory drugs in treating patients with
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MI. (Bulkley and Roberts 1974, Akgur, Brown et al. 2000, Schjerning Olsen, Fosbol
et al. 2011).
Furthermore, inhibition of other inflammatory mediators (integrin, PI3K, and
C5) was not successful in clinical trials, despite success in animal experiments
(Frangogiannis 2014, Seropian, Toldo et al. 2014). More selective targeting of
inflammatory mediators such as IL-1β showed some promise in improving clinical
outcomes in high-risk patients with ischemic heart disease, albeit with high cost
and modest benefits (Seropian, Toldo et al. 2014). Blocking of pro-inflammatory
signals such as IL-1 and MCP-1 could add benefits in patients who have prolonged
post-MI inflammation (Christia and Frangogiannis 2013). However, these venues
have not been tested in large clinical trials of post-MI patients (Hartman, Groot et
al. 2018). Heart failure has a complex pathophysiology; hence it is unlikely to be
reversed by the manipulation of one receptor, cytokine or pathway (Hartman, Groot
et al. 2018). It is important to mention that some studies targeting cytokines and/or
their receptors yielded contradictory results due to limitations in these kinds of
studies (Hartman, Groot et al. 2018). Limitations in translating pre-clinical studies
are discussed in more detail later.
Taken together, targeting inflammation after MI has proven an elusive goal
in clinical trials and there is unmet need for clinically relevant therapies. The
exacerbated inflammatory response after myocardial injury creates difficult
challenges to develop therapies that govern this response without altering its
beneficial effects, mainly clearing dead cells and tissues and preparing the
myocardium for the healing phase. Modulation of the inflammatory response at the
cellular level, instead of its complete suppression, may represent a promising
therapeutic avenue in treating MI as demonstrated by multiple studies (de Couto,
Liu et al. 2015, Kain, Liu et al. 2017) (will be discussed in more detail in modulation
of the inflammatory response). However, limited data exists on similar approaches
with proven safety in humans. Here, we observed that AZM is successful in
reducing the intensity and duration of the inflammatory phase and inducing an
earlier transition to the reparatory phase through reprogramming of, rather than by
a profound suppression of, post-MI inflammation. Our findings show that AZM
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reduces the expression of pro-inflammatory cytokines and M1 markers and
simultaneously raises anti-inflammatory genes and M2 markers. Changes in proinflammatory and anti-inflammatory genes are consistent between heart and
blood, suggesting systemic immunomodulatory actions. Interestingly, AZM
substantially reduces the expression of IL-1 and MCP-1, which is an attractive
therapeutic aim in clinical practice. In addition, repurposing AZM is more clinically
relevant and can be a safe and cost-effective immunotherapy for post-MI patients.
In another direction, it could be an interesting avenue to examine the effect
of AZM on immune response post-MI in MCP-1 and/or IL-1 knock out mice in order
to explore mechanisms of these modified immune cells’ recruitment to the injured
myocardium. These experiments can be potentially extended to include more
chemokines and cytokines such as IL-6 knock out mice, since IL-6 is involved in
trafficking of inflammatory cells in the first day after infarction (de Couto, Liu et al.
2015).
Studies confirm a second inflammation phase peaking 8 days after the initial
inflammatory response but limited data has been published about the specifics of
this phase (Moro, Jouan et al. 2007). The etiology of the second wave of
inflammatory cells and cytokines has not been studied but could be related, at least
in part, to wall stress caused by adverse remodeling of the left ventricle. Therefore,
the therapeutic utility of AZM in the second inflammatory wave after MI warrants
further examination.
4.2.2 Modulation of the post-MI inflammatory response
Early

activation

of

inflammatory

cells

and

production

of

cytokines/chemokines are important for removing tissue debris and dead cells, as
well as for successful initiation of the subsequent reparative response
(Frangogiannis 2014). Uncontrolled and/or extended pro-inflammatory cascades
are associated with more severe damage, worsened cardiac remodeling, and
impaired cardiac recovery (Frangogiannis 2014). Even though the role of
inflammation in the progression of cardiomyocyte death is controversial,
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involvement of the inflammatory and fibrotic cascades in adverse cardiac
remodeling and the ensuing heart failure is well-established (Frangogiannis 2014).
Macrophages are essential players in inflammation and fibrotic processes
post-MI (Chen and Frangogiannis 2017). Macrophages mediate cardioprotection
through their phagocytic properties, suppression of pro-inflammatory cascades,
promotion of cytoprotective signaling, activation of reparative fibroblasts and
angiogenic cells, and stimulation of regenerative pathways (Chen and
Frangogiannis 2016). Furthermore, macrophages may enhance cardiomyocyte
survival through production of myeloid-derived growth factor (MYDGF) (KorfKlingebiel, Reboll et al. 2015). Considering the activation state of macrophages,
the reparative phenotype (M2) is the most abundant phenotype in the heart during
post-MI healing. Animal experiments show that early intervention aimed at altering
the macrophage activation state or shifting the balance towards the antiinflammatory phenotype can substantially reduce the risk of heart failure
development (de Couto, Liu et al. 2015, Kain, Liu et al. 2017). Kain et al. (need
year) initiated a phenotypic switch in macrophages after myocardial injury by using
either free or encapsulated 15-epi-Lipoxin A4. They demonstrated upregulation of
reparative macrophages, as well as anti-inflammatory/macrophage modulatory
genes (Mrc-1, Ym-1, Arg-1). Furthermore, cardiac function improved in 15-epiLipoxin A4 treated mice compared to controls (Kain, Liu et al. 2017). Multiple
studies confirmed these findings using different therapeutic approaches, such as
cardiosphere-derived cells (de Couto, Liu et al. 2015) and endogenous AnnexinA1 (Qin, Finlayson et al. 2017). However, previous studies on alternative
macrophage activation in MI utilized experimental therapeutics that had limited
safety data in humans. Conversely, our strategy of using AZM is more clinically
relevant and translatable to clinical trials since AZM is already approved and widely
used in humans.
In this work, we used AZM for the first time in the setting of MI to enhance
inflammation resolution via repolarization of macrophages towards the reparative
phenotype. We demonstrated that inflammatory macrophages significantly
decrease with AZM treatments, while reparatory cells increase. Inflammatory
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neutrophils also decrease with AZM treatments. Furthermore, infiltration of
inflammatory monocytes to the heart are significantly reduced with AZM treatment,
while anti-inflammatory monocytes are increased. Immune cell modulation is
associated with significant downregulation in pro-inflammatory genes (TNF-α, IL1β, MCP-1, and IL-6), and upregulation of anti-inflammatory genes (TGFβ and IL10). Therefore, AZM treatment is associated with a global trend of shifting immune
cells to the reparatory state. These results are in agreement with the observed
immunomodulatory effects of AZM in spinal cord injury and lung infection (Feola,
Garvy et al. 2010, Zhang, Bailey et al. 2015). The immunomodulatory effects of
AZM translate into reduced cardiac cell death and scar size, and enhanced
angiogenesis. Finally, these outcomes reduce adverse cardiac remodeling and,
thus, improve cardiac function. This is early evidence of a promising and clinicallyrelevant approach to modulate post-MI inflammation via the repolarization of
macrophage phenotypes. In addition, AZM has an excellent safety profile and is
approved for use in humans. All these specifics make it an ideal agent for novel
and effective therapeutic interventions to improve survival and reduce heart failure
following MI in humans.
4.2.3 Resolution of inflammation through phagocytosis of apoptotic cells
Timely resolution of inflammatory signals is a prerequisite for successful
initiation of healing and cardiac recovery. Phagocytosis of apoptotic cells is an
essential component in suppressing these signals (Frangogiannis 2015). It has
been shown that cardiomyocyte efferocytosis markedly reduces post-MI
inflammation (Wan, Yeap et al. 2013), and inhibition of this process produces an
extended inflammatory response and more severe adverse cardiac remodeling
(Frangogiannis 2015). It is also reported that macrophage myeloid-epithelialreproductive tyrosine kinase (MERTK) in cardiac macrophages is an important
mediator for the efficient removal of apoptotic cardiomyocytes (Maekawa, Anzai et
al. 2002).
Neutrophils are extensively recruited to the injured myocardium, and are
then cleared by apoptosis. There is a well-established relationship between
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reduced myocardial neutrophil infiltration and rescue of the heart from ischemic
injury (Hansen 1995). However, the use of neutrophils as a therapeutic target to
reduce adverse cardiac remodeling after MI is controversial. On one hand,
inefficient clearance of neutrophils post-MI leads to matrix breakdown, collagen
malposition, and increased risk of cardiac rupture (Lorchner, Poling et al. 2015).
On the other hand, complete or near complete neutrophil depletion after MI is
detrimental and is associated with poor healing and cardiac rupture (Horckmans,
Ring et al. 2017) . Apoptosis is much less significant than necrosis post-MI as
shown in clinical studies, which is the proposed mechanism of uncontrolled postMI inflammation, causing further tissue destruction (Garlichs, Eskafi et al. 2004).
Although the effect of apoptotic neutrophil clearance on initiating the antiinflammatory phase was not investigated, timely removal of infiltrated immune cells
is necessary for post-MI inflammation resolution (Frangogiannis 2012).
Here, we show that AZM treatment results in a statistically significant
decrease in neutrophil counts. We postulate that this reduction is related to a
reduced neutrophil lifespan since macrolides can stimulate programmed cell death
in activated neutrophils (Inamura, Ohta et al. 2000). Interestingly, we find that AZM
enhances apoptosis in neutrophils after infarction. These findings suggest a
potential mechanism to modulate macrophages and to alter the inflammatory
response after MI. Engulfment of apoptotic neutrophils by macrophages stimulates
the anti-inflammatory machinery by blockade of

pro-inflammatory cytokine

production and generation of IL-10, TGF-β, and pro-resolving lipid mediators
(Horckmans, Ring et al. 2017).
We are planning future in vitro studies to explore the interaction between
neutrophils and macrophage polarization. These studies include:
a) Treating stimulated macrophages, pre-exposed to AZM or vehicle, with
conditional media from stimulated neutrophils, also pre-exposed to AZM or vehicle,
then examining M1 and M2 macrophage markers. These experiments explore
whether neutrophils produce certain mediators that influence the activation state
of macrophages.
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b) Co-culturing macrophages with neutrophils pre-exposed to AZM to examine
neutrophil apoptosis and macrophage phenotype. This approach could determine
whether AZM directly affects promotion of neutrophil apoptosis, and whether the
expected apoptotic effect drives macrophage polarization to the alternative
activation state.
Additionally, we can test the relationship between neutrophils and
macrophages in vivo. These experiments could include:
a) Depleting neutrophils in groups of mice, except a group treated with AZM,
then resupplying them with neutrophils treated with AZM after MI induction to
examine macrophage polarization. This offers a tool to test whether resorption of
neutrophils, either apoptotic or not (control), regulates macrophage polarization
and cardiac recovery. There are limitations to this study since neutrophil depletion
is associated with undesirable effects on cardiac recovery, as mentioned earlier,
which could complicate any analysis.
b) We can test the role of AZM-induced neutrophil apoptosis by examining the
effect of AZM in MPO knock out mice since these mice have a depleted ability for
induction of programmed cell death in infiltrated neutrophils (Milla, Yang et al.
2004). It would be of interest if these studies were repeated in an I/R model since
the role of neutrophils in MI pathogenesis in this model is more profound (Baxter
2002).
Research in an ischemic stroke model shows that preferentially increased
numbers of N2 neutrophils induced by using the PPARg agonist, rosiglitazone,
decrease the volume of brain infarction (Cuartero, Ballesteros et al. 2013).
Increment of N2 and/or decrement of N1 neutrophil count may be a promising
therapeutic strategy in MI patients (Ma, Yabluchanskiy et al. 2016). We find that
AZM profoundly reduces N1 (pro-inflammatory) neutrophils, which could represent
a novel therapeutic avenue in treatment of MI patients who experience prolonged
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neutrophilia after infarction. This feature is likely to have wider therapeutic
applications in other inflammatory diseases in which neutrophils are key players.
Moreover, N1 neutrophil and M1 macrophage states could be activated by linked
mechanisms. It is also likely that reduction in N1 neutrophils relates to increased
protection against cardiomyocyte death. It is also highly possible that the enhanced
apoptosis by AZM is specific for N1 neutrophils, suggesting potential differences
in the metabolism/fate between the N1 and N2 neutrophils, which needs more
investigation.
4.3 Studies to explore the immunotherapeutic mechanisms of AZM in MI
It

is

important

to

study

the

underlying

mechanisms

of

the

immunotherapeutic effects of AZM. They likely represent cornerstones for a more
complete understanding of MI immunopathology and roles of immune cells in this
process, as well as for ultimate development of successful immunomodulatory
therapies for ischemic heart disease. These potential studies include:
a) Tribbles homolog 1 (Trib1) knock out mice: Trib1 protein modulates the
MAPK pathway through binding to MAPKK. These mice are unable to generate
M2 macrophages after infarction, with a preserved ability to produce M1
macrophages (Mahbub, Deburghgraeve et al. 2012). We can use this model to
explore whether M2 macrophages are principle mediators of the cardioprotective
effects of AZM in MI. We hypothesize that AZM cardioprotection will attenuate or
disappear in these mice. We can extend these experiments to examine M2
macrophage source (bone marrow derived and/or derived from cardiac resident
macrophages) by generating Trib1 cardiac or bone marrow derived specific knock
out mice. These experiments will help to elucidate the local, systemic, or
combinatorial nature of AZM’s effects.
b) Inhibition of colony stimulating factor 1 (CSF-1): CSF-1 stimulates
monocyte and macrophage survival and enhances macrophage activation towards
the M2 phenotype, which can be blocked by using an inhibitor (GW2580) (Leblond,
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Klinkert et al. 2015). Similar to the above experiments, if the immunotherapeutic
effects of AZM are modified by this antagonist, it reinforces the importance of M2
macrophages in mediating cardioprotective effects of AZM in MI. This experiment
would provide additional insights into the protective mechanisms of AZM,
specifically its effects on alternative macrophage polarization.
c) Ex vivo polarization of macrophages: Using adoptive transfer of
macrophages for phenotype reconstitution can define the role of shifted
macrophages by AZM and exclude the contribution of various endogenous factors
like other immune cells to certain levels. This experiment can be achieved by
treating bone marrow derived macrophages with AZM then transfusing them
intravenously into mice, which were previously treated with clodronate-containing
liposomes to deplete endogenous phagocytes and macrophages (Weisser, van
Rooijen et al. 2012). Depletion of systemic macrophages could also be achieved
by crossing back mice onto a CD11b- inducible diphtheria toxin (DTR) background.
Although this approach is useful, it is expensive and time consuming (Weisser, van
Rooijen et al. 2012).
4.4 Potential signaling pathways related to AZM effects in MI
The

current

understanding

of

molecular

mechanisms

mediating

macrophage polarization to a specific activation state remains inadequate and
requires further study. Such studies would enable us to reprogram macrophages
efficiently to the reparative phenotype, prevent harmful interventions, and improve
outcome after infarction. Production of cytokines, chemokines, and adhesion
molecules is primarily regulated by NF-kB and IkBα complex (Lenardo and
Baltimore 1989). Stimuli like cytokines (TNF-α, IL-1β), ROSs, and TLR-stimulated
ligands can activate the expression of NF-kB (Frangogiannis 2006). In the steady
state, NF-kB dimers bind to an inhibitory molecule, IkBα, and reside in the
cytoplasm. In the disease state, IkBα is phosphorylated, ubiquitinylated, and then
degraded by proteolytic cleavage in the proteasome. Cleavage of NF-kB from IkBα
leads to NF-kB activation and translocation to the nucleus, inducing transcription
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of effector genes (Figure 1.2). It is suggested that NF-kB has a primary role in
initiating and maintaining the inflammatory response in an experimental model of
MI (Kupatt, Habazettl et al. 1999, Frangogiannis 2006). Reduction of infarction
results from in vivo transfer of NF-kB decoy oligodeoxynucleotides to inhibit its
activity, which suggests an important role for NF-kB in regulating post-MI
inflammation (Morishita, Sugimoto et al. 1997). It is also shown that NF-kB
depletion reduces adverse cardiac remodeling post-MI by decreasing the severity
of post-MI inflammation and collagen deposition (Frantz, Hu et al. 2006).
Interestingly, NF-kB has a dual role in MI since mice with mutated IkBα, that inhibits
NF-kB translocation to the nucleus in cardiomyocytes, had larger infarction with
increased cardiomyocyte apoptosis (Misra, Haudek et al. 2003).
Unpublished data from Dr. Feola’s lab clearly demonstrates that AZM
inhibits the translocation of p65 to the nucleus and elevates IKKβ kinase levels.
Inhibited translocation is associated with suppression of negative feedback
mechanisms which block IKKβ kinase expression. They also show that using IKKβ
kinase inhibitor blocks Arg-1 expression, which infers that IKKβ kinase is an
important effector molecule in the signaling pathway modulated by AZM.
Moreover, this study suggests that AZM inhibits STAT-1 phosphorylation, which is
also dependent on IKKβ kinase. Collectively, AZM modulates NF-kB and STAT-1
pathways, connected by cross talk including IKKβ kinase, which could explain the
immunomodulatory and anti-inflammatory effects of AZM.
We conducted in vitro studies to examine the effect of hypoxia/reperfusion
injury on the phenotype of J774 macrophages in the presence or absence of AZM.
Following 24 hours of hypoxia and reperfusion, we noted high levels of TNF-α
compared to IL-10 levels. AZM treatment shifted the cytokine production back
towards the anti-inflammatory pattern with a significant increase in IL-10/TNF-α
ratio. These findings demonstrate results from Dr. Feola’s lab.
Based on the findings mentioned above, we can test key decision nodes
that may be involved in inflammation resolution and macrophage polarization in
vivo. The potential molecular targets in the immunomodulatory effects of AZM
include:
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a) NF-kB: We can examine the effects of NF-kB by using mice with targeted
disruption of NF-kB signaling. If the immunomodulatory properties of AZM reduce
or are completely lost in these mice, it would suggest that NF-kB is an important
regulator in the molecular events induced by AZM. Moreover, a study like this also
addresses whether NF-kB mediates macrophage phenotype transition. We can
extend these experiments to include adaptive transfer of immune cells from NF-kB
knock out mice to WT or vice versa to restore the immunomodulatory effects and
exclude the diverse effects of NF-kB in different cells, as discussed earlier.
b) IKKβ and IkBα: After testing the effect of NF-kB, we can test upstream
molecules in the signaling cascade of NF-kB like IKKβ and IkBα by using mice with
targeted disruption of these molecules.
d) STAT1: Based on our observation that AZM upregulates IKKβ which
inhibits phosphorylation of STAT1, we can determine the effect of STAT1 in the
immunomodulatory properties of AZM using STAT1 knock out mice.
By the end of these studies, we can clarify roles of these molecules in
repolarizing macrophages to the anti-inflammatory state and determine if they are
potential mediators of AZM effects.
4.5 Liposomal AZM
Liposomal research bridges urgent intellectual gaps between clinical
targeting of post-MI inflammation and the optimal drug delivery system in MI. We
are the first to demonstrate the immunomodulatory and anti-inflammatory
properties of liposomal AZM, which has wide therapeutic potential beyond the
cardiovascular field. Our work opens doors for more advanced studies to improve
outcomes with AZM or other therapeutic agents post-MI using encapsulated
formulation.
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In addition to the cardioprotective effects of Lazm, we observe that
liposomal packaging of AZM is indeed protective against the drug’s conduction
changes. These findings clearly imply that the liposomal dosage form of AZM is
indeed protective against the drug’s hemodynamic modifications, which is more
likely attributed to the specific delivery of AZM to the immune cells, avoiding
cardiomyocytes. It is very likely that encapsulation of AZM reduces the risk of other
adverse effects related to this drug, which is something that needs to be earnestly
considered in clinical practices of high risk patients.
Liposomes are modifiable in terms of the surface attached groups.
PEGylation of liposomes stabilizes them and prevents their opsonization by serum
proteins and phagocytosis by Kupffer cells and hepatocytes. This results in
liposomes with longer half-life, and thus, more accumulation in the injured
myocardium caused by blood vessel leakage in the infarct areas (Takahama,
Minamino et al. 2009). Due to the dynamic and progressive nature of the injured
myocardium, this strategy may exhibit protective benefits with fewer doses or even
a single dose following MI, improving patient tolerance. We observe potent
immunomodulatory effects with a low dose of AZM encapsulated in liposomes, so
examination of the relationship between immunomodulatory properties and the
dosing interval of AZM using this approach could be an interesting avenue for
future studies.
Additional modulation can be achieved by attaching specific antibodies onto
the surface of the liposomes (immunoliposomes), which is a potential therapeutic
strategy for efficiently targeting certain kinds of cells. For instance, research shows
that incorporating TLR ligands into liposomes promotes the efficacy of vaccines
and the targeting of drugs (Ramirez, Iyer et al. 2014). With liposomal AZM, we can
incorporate a macrophage marker (F4/80), or neutrophil marker (Ly6G) to enhance
the targeted delivery of AZM, and therefore its efficacy. As a broader target, we
can also use fluorescent immunoliposomes to enable monocyte/macrophage
tracking to identify their distribution, function and kinetics in tissue injury.
Expansion of liposomal work can include other therapeutic agents such as gene
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therapy or small interfering RNA (siRNA) for targeting innovative biological
pathways in resolving post-MI inflammation.
AZM was prepared previously in liposomal formulations for antibiotic
purposes. It has been shown that liposomal encapsulation promotes the
antibacterial activities of AZM (Oh, Nix et al. 1995). When comparing the
antibacterial effects of free AZM and liposomal AZM against intracellular M. avium
growth in macrophages, it was found that the encapsulated formulation is 41-fold
more potent than free AZM. Although there is a lack of efficient assays to precisely
determine intracellular concentrations of AZM with liposomal formulation, these
liposomes enhance the intracellular deposition of other antibiotics such as
ciprofloxacin (Oh, Nix et al. 1995). Encapsulated formulations of antibiotics
promote the antibacterial effectiveness both in vivo and in vitro (Cynamon,
Klemens et al. 1992, Oh, Nix et al. 1995). Our data from in vitro experiments
implies a similar trend regarding the immunomodulatory and anti-inflammatory
effects of encapsulated dosage form. We find that liposomal AZM induces a more
significant shift in macrophage response towards the anti-inflammatory state than
free AZM. These findings are significant because they strongly suggest that
liposomal AZM not only favorably modifies pharmacokinetic characteristics, but
also augments pharmacodynamic effects, which are of great importance and
require further exploration. We are currently working with our collaborators to
prepare biotinylated AZM that can be traced both in in vivo and in vitro.
4.6 Clinical applications
Experimental animal models do not recapitulate the heterogeneity of
pathology of complicated diseases like MI and heart failure. Much less is known
about the macrophage phenotypes and functions in humans under normal
physiological conditions and disease states. More studies are needed to
understand human macrophage function, gene expression, and other properties
to improve translation from bench to the bedside (Chen and Frangogiannis 2016).
Therefore, targeting monocytes as precursors of macrophages (ter Horst,
Hakimzadeh et al. 2015) may be more feasible to modulate macrophage
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phenotypes. Harnessing isolated monocytes from MI patients can investigate the
effectiveness of immunotherapies such as AZM and determine the destiny of
monocytes after infiltration to the injured myocardium.
We demonstrate that AZM is a potent immunomodulatory agent of the
exaggerated post-MI inflammatory response. We find that AZM alters monocyte
response in the injured heart via shifting the balance towards anti-inflammatory
monocytes. Similar findings are simultaneously observed in peripheral blood. We
also find that AZM treatment reduces neutrophil counts. Moreover, AZM
significantly suppresses pro-inflammatory cytokine and chemokine levels in
plasma. These effects are important from a clinical prospective as they provide an
effective tool to track the immuno-dynamic characteristics of AZM and its related
cardioprotective properties in humans. Besides these effects, we observe a robust
decrease in M1 macrophages with AZM therapy, suggesting additional advantage
for considering AZM as immunotherapy in MI patients, who are mostly elderly.
Research shows that M1 macrophages increase with age, while M2 macrophages
show a decrease. Reducing M1 activation state may be a promising therapeutic
target for MI patients.
4.7 AZM and oxidative stress in MI
ROS generation is increased in cardiovascular diseases such as MI, in
particular after reperfusion, through enhanced expression of cytokines and growth
factors. ROSs promote production and activity of proteases that control ECM
breakdown and turnover and induce cardiomyocyte and blood vessel cell death
(Frangogiannis 2018). Free radical scavengers which reduce ROSs, such as
enzymes superoxide dismutase and catalase, show beneficial effects in reducing
scar size (Jolly, Kane et al. 1984). Cytokine-related MAPK activation and stressresponsive protein kinases, at least partially induced by redox, participate in
activation master transcription factors like NF-kB and AP-1, which induce MMP
transcription (Siwik and Colucci 2004).
Macrolides, in general, reduce production of free radicals, in addition to their
anti-inflammatory effects. AZM downregulates the expression and activity of GST
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by up to 40% in cystic fibrosis cell lines (IB3-1 and 2CFSMEo cells). The antiinflammatory mediator, IL-10, also decreases GST activity to a similar extent,
indicating a possible link between antioxidant and anti-inflammatory pathways
(Zarogoulidis, Papanas et al. 2012). Studies show that AZM modifies MAPK and
AP-1 cascades (Kanoh and Rubin 2010). Moreover, unpublished data from Dr.
Feola’s lab shows that AZM reduces NF-kB activation through decrease of the
transcription factor translocation to the nucleus, which could indicate that AZM
inhibits NF-kB activity via ROS suppression. We found that AZM significantly
upregulates IL-10 expression after infarction. This evidence implies that in addition
to its immunomodulatory effects, AZM could exhibit novel antioxidant properties
contributing to its cardioprotective effects. As such, these effects can be assessed
in an I/R injury model where ROSs play a central role in the pathophysiology of MI.
Using AZM alone or in combination with ROS scavengers is an important approach
for future myocardial preservation studies.
4.8 AZM and age impact on ischemic heart disease
A linear elevation in M1 macrophages and reduction in M2 macrophages in
the heart is reported with age (Ma, Chiao et al. 2015). It seems that there are
multiple factors mediating this transition, since stimulating bone marrow derived
macrophages with different stimuli in vitro produces both phenotypes, suggesting
no defect in macrophage polarization with age (Mahbub, Deburghgraeve et al.
2012). Proposed theories as to why the M1 macrophage phenotype dominates
with age include over-recruitment of monocytes to the heart and alterations in
cardiac resident macrophage behavior (Ma, Mouton et al. 2018). We observe that
M2 macrophages dominate the heart after infarction with AZM treatment, as
justified by the significant reduction of M1/M2 macrophage ratio. Therefore, AZM
may be more effective in aged mice due to the decrement of M2 and the
abundance of M1 macrophages. This expected benefit is especially important
clinically since most MI patients are elderly and they experience exaggerated
cardiac

damage

with

MI.

Thus,

future
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experiments

should

test

the

immunomodulatory efficacy of AZM in aged animals with MI injury to increase the
clinical relevance of this work.
4.9 AZM and regeneration post-MI
There is a well-recognized regenerative capability in the heart during the
neonatal life stage, which ends 7 days after birth (Inamura, Ohta et al. 2000, Wan,
Yeap et al. 2013). This regenerative capacity is completely disturbed in the
absence of macrophages (Aurora, Porrello et al. 2014). Important questions that
must be addressed are as follows: (a) Are macrophages solely responsible cell
effectors or are other immune cells involved? (b) What is the optimal activation
state of macrophages to induce regeneration? (c) What is the best way to modulate
macrophage activation to enhance regeneration considering the plasticity of
macrophages? AZM administration could address these questions through design
of in vivo and in vitro experiments. Examining changes in the progenitor cells with
AZM administration in multiple organs such as BM, blood, and heart may be the
first step in determining whether AZM influences the cardiac regenerative capacity
post-MI. Markers such as c-kit and Ki-67 can be used to identify stem cells or
regeneration, respectively. In vivo experiments with AZM in neonatal mice may be
useful in examining the mechanisms involved in heart renewal. Additionally, in vitro
experiments such as treating cardiomyocytes with AZM, then challenging them
may highlight whether AZM has a direct effect in enhancing cardiomyocyte
survival. In this regard, treating cardiomyocytes with conditional media from
macrophages incubated with AZM, or co-culturing them with these macrophages
may also be elucidating experiments.
4.10 Advanced research techniques
State-of-the-art technology can provide answers to important questions
related to the immunopathology post-MI and to the role of AZM in MI. These are
some of these technologies:
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a) Histo-cytometry: This technique unites immunohistochemistry with
cytometry software to determine spatially different cell populations in tissues
(Deniset and Kubes 2016). Although we used Celigo in our experiments to
determine the co-localization of immune cells with liposomes, it is likely that this
technique could provide more insights about this interaction such as whether these
liposomes are located inside or outside the cells, or whether they remain separate.
b) Next-generation sequencing: This technique depends on highthroughput sequencing platforms able to generate information about cell-specific
transcriptome and gene regulation profiles (Deniset and Kubes 2016). Relative
contribution of various immune cells in heart-injury-triggered inflammation requires
further exploration. We can isolate inflammatory cells (macrophages, monocytes,
and neutrophils) from the heart post-MI and determine the gene profile for each
cell type and the effect of AZM on the cell activation state. These approaches will
address novel roles for these cells in the pathogenesis of adverse cardiac
remodeling and heart failure, possible cardioprotective mechanisms, and potential
therapeutic targets for myocardial preservation after MI.
c) Mass cytometry: In this technique, cells are labeled with heavy metal
conjugated antibodies and then run through a mass spectrometer. There is no
need for compensation and it can deal with larger panel sizes of antibodies
compared to conventional flow cytometry techniques (Deniset and Kubes 2016).
This technique could be beneficial in determining the multiple activation states of
immune cells (macrophages, monocytes, and neutrophils) with and without AZM
therapy by adding more markers. It is also possible to track whether AZM
influences the activity of progenitor cells, which could explain changes in the
infiltration of immune cells to the heart post-MI.
d) Fate-mapping and cell-specific loss-of-function approaches: These
studies could be useful in examining whether AZM-induces repolarization of
macrophages from one state to another or whether its actions are due to
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downregulation of one activation state (M1) and/or upregulation of other activation
states (M2).
4.11 Repurposing AZM
The National Center for Advancing Translational Sciences defines the
repurposing process for drugs equates to discovering new clinical benefits of drugs
that are already approved to treat other diseases or conditions with proven safety
record in humans. It is estimated that 30% of new drugs and vaccines approved
by the US FDA in recent years are attributed to the process of drug repurposing,
repositioning, and rescuing (Agranat, Caner et al. 2002). This process offers many
advantages including cost and time saving from circumventing the extensive
testing typically required for newly developed drugs. Since these drugs are
approved for human use, the well-characterized properties (pharmacology,
toxicology, and formulation) of these candidates allow for a quick therapeutic
switch to novel clinical use. The estimated cost associated with the development
of a new drug is over $2 billion, and the timeline typically involves more than 12 16 years. In contrast, a repurposed drug can be approved in a shorter time frame,
3- 12 years, with an average cost of $300 million (DiMasi and Grabowski 2007).
Due to extensive financial and time commitments required for new drug
development, repurposing an old drug to a new market with a relatively low cost is
very attractive.

In addition, approval rates for new drugs are extremely low,

typically close to 10% while the approval of therapeutically repurposed drugs is
typically triple that figure. Finally, the process of repurposing drugs represents
substantial assistance for low-income patients. This increases the significance of
our work since AZM has a proven safety record in humans and could be beneficial
in the management of millions of patients with acute myocardial infarction
worldwide.
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4.12 Limitations in preclinical animal studies
In preclinical studies, enthusiasm for the role of inflammation in various
pathological conditions, and the large body of positive evidence of animal studies
could be misguided (Frangogiannis 2014). Negative experiments are often
unpublished, creating selection bias, which results in unrealistic expectations from
new therapies. Targeting the inflammatory pathways using animals with certain
genetic modifications or specific inhibitors has examined the role of inflammation
in the progression of myocyte death. However, there is still controversy since
positive studies are contradicted by others that fail to demonstrate reduction in
infarct expansion and disappointing clinical trials. These opposite observations
could be attributed to an overstated role for the inflammatory response in MI, or
methodological variability in study design and data analysis/interpretation. For
instance, MI in young mice is often associated with a profound inflammatory
response that is not particularly observed in older mice (Frangogiannis 2014).
Furthermore, variability in collateral blood flow and post-MI metabolic rate
significantly impacts scar size (Ito, Tate et al. 1987). It is also important to note that
the inconsistency observed in these studies is related to the different MI
experimental designs (permanent ligation vs. I/R). It is assumed that I/R provokes
a stronger inflammatory response (Moro, Jouan et al. 2007). Using large animals
like pigs or dogs could reduce this variability in experimental MI models compared
to rodents but one must consider the cost and logistic demands as well (Verdouw,
van den Doel et al. 1998).
Patients with MI are a heterogeneous population, adding another layer of
complexity for direct clinical translation of successful strategies in animal studies
(Frangogiannis 2014). Most MI patients suffer comorbidities (diabetes,
hypertension, and hyperlipidemia), are typically older and exhibit a wide range of
pre-existing pharmacological treatments. All these factors could markedly change
the inflammatory and reparative stages post-MI. These variable factors make the
clinical relevancy of animal models challenging and problematic (Frangogiannis
2014).
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However, experimental MI models in mice remain tremendously useful to
study cellular and molecular mechanisms controlling the pathophysiology of MI
(Frangogiannis 2014), and to explore new therapeutic interventions. This model
provides a way to assess both acute and long-term benefits of novel therapeutic
approaches after MI. Recent advancements in genetic and surgical interventions
of murine models of cardiovascular disease have significantly reduced variability
and provide a more complete understanding of cardiovascular response to
ischemic injury, making it a beneficial tool in predicting the influence of various
factors in human heart function. Furthermore, principal similarities of the immune
response initiated by MI between mice and humans (Tahto, Jadric et al. 2017)
make animal studies extremely helpful in appropriately determining the role of
inflammation in acute injury and its subsequent complications.
In this work, we used AZM in a murine MI model as a means to modulate
intense inflammation and improve cardiac recovery after infarction. The finding that
free/targeted liposomal AZM therapy is effective in moderating cardiac
immunopathology of ischemic cardiac injury may be very important to clinical
practice. Our work with AZM in mice allowed us to test multiple protocols, doses,
controls, and dosage forms to identify immunomodulatory and cardioprotective
effects of the drug in MI. To enhance clinical translation of our work, it would be
quite interesting to explore the cardioprotective effect of AZM in ApoE-/- mice that
show a prolonged inflammatory phase and a trend towards hyperlipidemia similar
to that of humans (Panizzi, Swirski et al. 2010). Additionally, we can treat these
mice with high fat diet, to represent the pathogenesis of human atherosclerotic
patients, and then subject them to MI injury. In another but rather complementary
direction, these initial results in small animals can be confirmed in a large animal
model that more closely resembles the human heart function, anatomy, and
genetic conservativeness (Heidt, Courties et al. 2014). Nevertheless, it is also
important to consider the economic, ethical and logistic limitations with large
animals as they are more expensive to buy and maintain compared to smaller
rodents (Chen and Frangogiannis 2017).
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4.13 Concluding remarks
The work of this dissertation reveals novel findings, which are summarized in the
following points:
a) We found that AZM (free and liposomal formulations) reduces cardiac
inflammation and improves adverse cardiac remodeling after infarction via shifting
immune cell response towards the reparative state.
b) This work is early evidence of a novel and clinically relevant immunotherapy

using AZM for ischemic heart disease, which could be applicable for other sterile
inflammatory diseases.
c) This is the first study to demonstrate the immune modulatory properties of
liposomal AZM, which are previously unexamined and have potential wide
therapeutic applications beyond the cardiovascular field.
d) This the first study to clearly demonstrate that the liposomal dosage form of
AZM is indeed protective against the drug adverse effects such as hemodynamic
modifications, which is a truly important consideration in clinical practices of high
risk patients.
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Figure 4.1 Illustration of the immunotherapeutic effects of AZM in MI.
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